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ABSTRACT 
Background: Salmonella bacteraemia is an important public health problem in children 
from sub Saharan Africa (SSA). Understanding what constitutes natural acquired 
immunity to Salmonella is crucial for the development of Salmonella vaccine. It was 
hypothesized that natural Salmonella exposure within the GIT and peripheral blood 
induces the generation of specific-antibodies and T cells and these might provide 
protection to subsequent Salmonella infection. 
Methods: Natural acquisition of antibody and T cell immunity to Salmonella was 
investigated in healthy and Salmonella infected Malawian children. Acquisition of 
typhoid vaccine induced T cell immunity in healthy adults from the United Kingdom 
(UK) was investigated to model natural immunizing events occurring within the gut 
associated lymphoid tissues (GALTs) following Salmonella infection. Acquisition of 
immunity was examined using immunological tools including the intra-cellular cytokine 
staining assay (ICS), serum bactericidal activity (SBA) assay, ELISA and ELISpot. 
Exposure to Salmonella was examined using microbiological tools including standard 
culture and real-time PCR. 
Principal findings: CD4+ T cells and IgG antibodies to Salmonella develops 
sequentially in under-five children. Acquisition of Salmonella-specific CD4+ T cells and 
antibodies coincides with the decline in S. Typhimurium bacteraemia cases in older 
children. As much as 47% of Malawian children (aged 6-18 months) are exposed to 
Salmonella at least once within the gastrointestinal tract (GIT). Natural Salmonella 
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exposure within the GIT is associated with development of potentially protective SBA in 
children. Invasive Salmonella infection elicits an increase in generation of Salmonella-
specific CD4+T cells, IgG and IgA antibody secreting cells (ASC). Oral Ty21a 
vaccination (model of natural Salmonella infection) did not elicit an increase in 
generation of both CD4+Cytokine+ and CD8+Cytokine+ T cells in the peripheral blood 
and gut mucosa  compartments at day 11, and day 18 post vaccination.  
Conclusion: Young children (<2 years of age) are more vulnerable to invasive 
Salmonella infection. Salmonella exposure within the GIT and peripheral blood 
compartments tissues facilitates acquisition of robust immunity (mediated by antibodies 
and T cells) in children and these might provide protection to subsequent Salmonella 
infection. Public health interventions are urgently required in SSA including vaccination 
with cross-protective Salmonella vaccine, improvements in sanitation, access to clean and 
safe water and food hygiene.  
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CHAPTER 1: INTRODUCTION  
1. THEME AND OVERVIEW 
This thesis focusses on a number of cross-cutting issues including natural and vaccine 
induced immunity to Salmonella in humans. Investigations into natural immunity aimed 
at characterizing the development of antibody and T cell immunity to Salmonella in 
healthy children and children with Salmonella bacteraemia during the acute and 
convalescent phases, and the relationship between Salmonella exposure events within the 
gastrointestinal tract (GIT) and the development of Salmonella-specific serum immunity 
in healthy children. Investigations into oral Ty21a vaccine induced immunity aimed 
modelling natural Salmonella infection immunizing events occurring within the gut 
associated lymphoid tissues (GALT) and secondary lymphoid tissues (SLTs) in healthy 
adults from the UK. 
 
1.1  THE SALMONELLA BACTERIUM 
Salmonella are Gram-negative, facultative and rod-shaped bacteria belonging to 
Enterobacteriaceae family. Members of Salmonella genus are mainly motile, aerogenic, 
non-lactose fermenting, oxidase negative, urease negative, citrate-utilizing and produce 
hydrogen sulphide. 
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1.2  NOMENCLATURE 
The genus name Salmonella was adopted in honour of an American scientist Dr Daniel 
Elmer Salmon whose assistant researcher Theobald Smith discovered Salmonella from 
the intestine of a pig in 1884 (Su & Chiu, 2007, Schultz, 2008). Salmonellae are widely 
distributed in nature and cause gastroenteritis and bacteraemia in both humans and 
animals. The nomenclature of Salmonella has been the subject of scientific debate for 
some time because historically the taxonomy of Salmonella genus was based on names 
according to epidemiology, clinical conditions, host range, biochemical reactions and 
surface antigenic patterns (Su & Chiu, 2007, Agbaje, et al., 2011). These early taxonomy 
approaches proved to be inconsistent in dividing the genus into species and serovars. The 
advent of nucleotide technology in early 1970s was the turning point for Salmonella 
genus nomenclature (Crosa, et al., 1973). Nucleotide sequence relatedness as 
demonstrated by DNA-DNA hybridization experiments uncovered that typical 
salmonellae were closely related and could be considered a single species with the 
exception of Salmonella bongori which was shown to have a distinct nucleotide sequence 
(Le Minor, et al., 1982, Reeves, et al., 1989). In 1986, a proposal to designate  
Salmonella enterica  as the only species was recommended by Le Minor and Popff  and 
received overwhelming acceptance by the subcommittee of Enterobacteriaceae of the  
International Committee on Systematic Bacteriology at the XIV International Congress of 
Microbiology (Su & Chiu, 2007). In 1989, Reeves and colleagues published and 
upgraded Salmonella enterica subsp. Bongori from subspecies to  Salmonella bongori 
species (Reeves, et al., 1989). The current nomenclature used by the Centre for Disease 
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Control and Prevention is borne out of recommendation from World Health 
Organization’s (WHO) collaborating centre based on the two-species Salmonella enterica 
and bongori  with each species containing multiple serovars (Agbaje, et al., 2011). 
Currently, more than 2,500 Salmonella serovars have been identified based on antibody 
reaction with surface antigens: O (somatic), H (flagellin) and Vi (Vi or capsular 
polysaccharide) as described by Kauffman and White. The Kauffman-White scheme is 
now re-designated as the White Kauffman-Le Minor Scheme and this document  has a 
list of all identified Salmonella serovars (Agbaje, et al., 2011).  The current nomenclature 
is summarized in the Figure 1.1.  
All salmonellae of direct relevance to human infection fall within the subspecies enterica. 
Note that, for example, the full written designation of Salmonella enterica, subsp. 
enterica Typhimurium is commonly shortened to Salmonella Typhimurium or S. 
Typhimurium, and this modification will be followed in this thesis. 
S. Typhi, S. Paratyphi A and B are all human host restricted Salmonella serovars while S. 
Typhimurium and S. Enteritidis have a wider host range and spread between humans and 
domestic animals such as chicken, goat and cattle. 
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Figure 1. 1:  Current Salmonella nomenclature 
 
In this introductory chapter we focus on S. Typhimurium and also provide comparative 
background with S. Typhi and S. Enteritidis.  
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1.3  BURDEN OF SALMONELLA INFECTIONS IN HUMANS  
1.3.1 Geographical distribution and epidemiology of S. Typhi 
Over the last century, cases of enteric fever (typhoid fever) caused by S. Typhi have 
tremendously reduced in the developed countries (Clark, et al., 2010). In the developing 
countries particularly in Eastern Asia, the sub-continent of India and Africa, where access 
to clean water is low and people live in poor sanitary conditions, enteric fever is still 
endemic (Figure 1.2) (Crump, et al., 2004, Crump & Mintz, 2010). It is estimated that 
21.7 million people worldwide contract typhoid infection annually and about 217,000 of 
these typhoid cases die (assuming a conservative case fatality rate of 1%) (Crump, et al., 
2004, Crump & Mintz, 2010). In the year 2004, in south Asia, southeast Asia and the 
Indian Subcontinent, the overall incidence rate of typhoid fever was as high as 
>100/100,000 cases per year (Crump, et al., 2004). Toddlers, preschool children, school 
going children and young adults are at risk of typhoid disease (Pasetti, et al., 2011) 
In sub-Saharan Africa (SSA), estimating the true burden of typhoid fever has been 
challenging because data is patchy and confined largely to sentinel facility-based 
surveillance (Crump & Heyderman, 2014). In Kenyan urban slums, the incidence of S. 
Typhi bacteraemia was 247 cases per 100,000 person-years of observation among 
children <10 years and this was similar to incidence of S. Typhi bacteraemia in Asian 
urban slums (Breiman, et al., 2012).   
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In SSA, multi-drug resistant (MDR) S. Typhi isolates have increased in the recent years 
(Kariuki, et al., 2010, Lutterloh, et al., 2012). In Kenya, MDR S. Typhi isolates appear to 
belong to a single haplotype H58. This haplotype H58 MDR S. Typhi was first identified 
in Southeast Asia suggesting intercontinental spread of a single MDR clone (Kariuki, et 
al., 2010). In Zambia, between 2010 and 2012 the outbreak of typhoid affected about 
2,000 with case fatality rate of 0.5% (Hendriksen, et al., 2014). A majority of S. Typhi 
isolates in Zambia are MDR (83%) and belong to MLST ST1 and haplotype H58B 
(Hendriksen, et al., 2014).  
In Malawi and Mozambique border MDR S. Typhi associated with neurological 
manifestation were reported in 2009 (Lutterloh, et al., 2012, Sejvar, et al., 2012). Out of 
214 suspected cases, 47 deaths were registered, representing case fatality rate of 5% 
(Lutterloh, et al., 2012). In Malawi, between 2011 and 2014, through blood stream 
infection surveillance that Malawi Liverpool Wellcome Trust (MLW) has undertaken at a 
referral hospital in Blantyre, approximately 2,000 S. Typhi were isolated in blood and 
95% of these isolates are MDR (unpublished data). MDR isolates from Blantyre, Malawi 
also belong to haplotype H58 (unpublished data).  
Since 2008, in Uganda outbreaks of typhoid associated with increased intestinal 
perforation in the districts of  Kasese (ranging 40-80%) and Bundibugyo (more than 
20%) were reported (Neil, et al., 2012, Walters, et al., 2014). Case fatality rate for S. 
Typhi bacteraemia was 8.1% (47 deaths/577 cases) in the district of Kasese (Neil, et al., 
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2012). Estimated S. Typhi incidence in the community survey is considerably high at 
8,092 cases/100,000 persons (Neil, et al., 2012).  
In Dzivaresekwa and Kuwadzana suburb of Harare City, Zimbabwe, typhoid outbreak 
involving approximately 2,600 confirmed and suspected-cases were reported in 2011 
(Muti, et al., 2014, Polonsky, et al., 2014). These outbreaks were attributed to 
environmental sources (Centers for Disease & Prevention, 2012). Taken together these 
reports demonstrate that the burden of typhoid fever in the developing countries is 
considerably high and requires public health interventions including vaccination and 
improvements in food hygiene and sanitation. 
 
Figure 1. 2: Geographical distribution of typhoid fever  
(Adapted from Bull World Health Org 2004:82:351) 
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1.3.2 Geographical distribution and epidemiology of nontyphoidal Salmonella 
Nontyphoidal Salmonella (NTS), principally Salmonella enterica serovars Typhimurium 
(S. Typhimurium) and Enteritidis (S. Enteritidis) causes gastroenteritis worldwide but 
commonly cause life-threatening bacteraemia in SSA (Figure 1.3) (Reddy, et al., 2010, 
Feasey, et al., 2012). NTS bacteraemia is particularly common in children below 3 years 
of age and HIV infected individuals (Gordon, et al., 2008). Other important NTS 
bacteraemia comorbidities in children from SSA include malaria, malnutrition, anaemia 
and sickle cell (Gordon, et al., 2008).   
A meta-analysis demonstrated that about 10% of all infections in Africa are blood stream 
infection (BSI) (Figure 1.3) (Reddy, et al., 2010). The important bacterial pathogens 
causing BSI in Africa include; Salmonella, Streptococcus pneumoniae, Staphylococcus 
aureus and E. coli. Approximately 90% of Salmonella BSI are caused by NTS (Reddy, et 
al., 2010). Fever surveillance in 11 sites located in 7 countries across SSA (Tanzania, 
Mozambique, Malawi, Kenya, Ghana, Gabon and Burkina Faso) during the RTS,S/AS01 
malaria vaccine phase 3 trials demonstrated NTS bacteraemia incidence of  478 
cases/100,000 patients per year in children aged 5 and 17 months (Agnandji, et al., 2011). 
NTS case fatality in children, exceed 20%, even with appropriate antimicrobial treatment 
(Gordon, et al., 2002, Gordon, et al., 2008).   
Over the past 6 years NTS bacteraemia  have been decreasing in SSA and this has been 
attributed in part to the decline in malaria cases (important risk factor in young children) 
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and introduction of antiretroviral therapy (ART) (HIV is an important risk factor) 
(Kariuki, et al., 2006, Mackenzie, et al., 2010, Feasey, et al., 2014). In Blantyre, Malawi, 
between  1997 and 2008 blood stream infections (BSI) declined from 16% of suspected 
cases to 10%  (a majority of these BSIs were caused by NTS) (Feasey, et al., 2014). Prior 
to the introduction of free antiretroviral therapy (ART) and cotrimoxazole prophylactic 
therapy (CPT) in Malawi public hospitals case fatality of NTS bacteraemia was more 
than 40% in HIV infected individuals. BSI case fatality rate has reduced from 40% to 
14% following the roll out of antiretroviral therapy (ART) and cotrimoxazole 
prophylactic therapy (CPT) (Feasey, et al., 2014).   
Taken together, although NTS bacteraemia cases has fallen in the recent years, the 
burden of remain considerably high (cases of NTS bacteraemia and related case fatality 
rate remain high). Public health interventions including vaccination and improvements in 
food hygiene and environmental sanitation are required.  
 
1.3.3  Invasive NTS molecular genetics 
Evidence from whole genome sequencing of S. Typhimurium strain D23580, the 
commonest NTS serovar isolated in Malawi and a representative invasive NTS strain in 
SSA, uncovered that it has a particular multilocus sequence type (MLST), ST313 which 
is distinct from the classical S. Typhimurium sequence type ST19 associated with 
gastroenteritis in other parts of the world  (Kingsley, et al., 2009, de Jong, et al., 2012). 
High throughput genome sequencing of S. Typhimurium strain D23580 has also revealed 
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loss of genes implicated in virulence such as ssel, ratB, and the accumulation of 44 novel 
pseudogenes or deletions relative to S. Typhimurium strain LT2 (Kingsley, et al., 2009, 
de Jong, et al., 2012). Taken together, ST313 appear to have undergone genomic 
degradation similar to S. Typhi which suggests possible loss of an enteric lifestyle and 
possible human-host adaptation (Msefula, et al., 2012, Okoro, et al., 2012) and this have 
not been thoroughly investigated. 
 
Figure 1. 3: Community acquired-blood stream infections in Africa  
 (Adapted from Reddy EA Lancet Infect Dis 2010:10:417-32) 
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1.3.4 Environmental risk factors 
1.3.4.1 Food and water 
Salmonella infection is contracted through oral-faecal route. In many developing 
countries (particularly in Eastern Asia, the sub-continent of India and Africa) food 
hygiene practices, sanitary conditions remain poor and access to clean water is still low 
(Crump & Mintz, 2010, Kariuki, et al., 2010, Breiman, et al., 2012). These inefficacies 
hugely contribute to the risk of contracting Salmonella infections. This is further 
supported by evidenced of seasonal peaks of NTS bacteraemia during the rainy season 
(Kariuki, et al., 2006, Gordon, et al., 2008, Morpeth, et al., 2009). In Africa, it  has been 
demonstrated that  enteric organisms such as Salmonella are found at highest 
concentrations in drinking water source at the onset of the wet season (Wright, 1986). In 
the developed countries food such as meat, eggs and daily products have all been 
implicated as the vehicles of NTS transmission (Crump, et al., 2002). Similarly NTS 
have also been isolated from cattle, goats, sheep and pigs in Africa (Morpeth, et al., 
2009). However in Africa, there is no proven link of invasive NTS isolates from animals 
and humans (Kariuki, et al., 2006, Feasey, et al., 2012). 
 
1.3.4.2 Transmission of Salmonella  
S. Typhi, S. Paratyphi A and B are all human host restricted while NTS have a wider host 
range and spread between humans and domestic animals. Children may excrete NTS in 
their stool for some weeks after recovering from enteric infection (Morpeth, et al., 2009). 
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Asymptomatic NTS carriers have previously been demonstrated in Africa (Nkuo-Akenji, 
et al., 2001). Duration of NTS excretion and carriage could form the basis of Salmonella 
transmission from human to humans and animals to humans. Contact with domestic 
animals, particularly chickens is a well-established risk factor of contracting NTS 
infection (Crump, et al., 2002). Kariuki et al in Kenya, demonstrated carriage of identical  
NTS strains in stool of children with invasive disease and human household contacts, 
while there was lack of identical NTS strains in children with invasive disease and  
isolates  from households  domestic animals and environment (Kariuki, et al., 2006). 
These findings suggested anthroponotic transmission (human-host restricted) and not 
zoonotic transmission (Kariuki, et al., 2006). S. Typhimurium strain D23580 has recently 
been shown to cause invasive disease in chickens (Parsons, et al., 2013), but whether 
chicken could be the vehicle for transmission of invasive NTS strain from animals to 
humans in Africa has not been shown. Taken together, at the moment it is not clear 
whether transmission of invasive NTS isolates in Africa occur from human to humans 
and also animal to humans. 
 
1.4  CLINICAL FEATURES AND MANAGEMENT OF INVASIVE 
SALMONELLA DISEASE  
1.4.1 Clinical features of typhoid fever  
Typhoid fever is an invasive, systemic clinical syndrome that is characterized by high 
fever. Typhoid patients also presents with bradycardia, malaise, headache, cough and 
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abdominal pains during the first week of infection. During the second week typhoid 
patients may present with rose spots, hepato-splenomegaly, diarrhoea and constipation. 
During the third week typhoid  patients may develop complications  including  sepsis and 
shock, gastrointestinal bleeding or perforation, encephalopathy, and focal metastatic 
complications such as cholecystitis or hepatitis (Weening, et al., 2005, Crump, et al., 
2008, Gordon, 2008, Nambiar, et al., 2009, Feasey, et al., 2012).  
 
1.4.2 Clinical presentation of invasive NTS disease (NTS bacteraemia) 
NTS bacteraemia clinical presentation is poorly defined especially in young children and 
exhibit clinical overlap with the presentations of both pneumonia and malaria (Graham, 
et al., 2000, Graham & English, 2009, Feasey, et al., 2012). Invasive NTS disease 
typically presents as a febrile systemic illness similar to enteric fever (Graham, et al., 
2000, Gordon, et al., 2002, Feasey, et al., 2012). Adults with Salmonella bacteraemia 
commonly presents with a combination of high fever and splenomegaly (Peters, et al., 
2004). NTS also causes meningitis in children and adults and this is associated with poor 
health outcomes (Molyneux, et al., 2009). Case fatality of NTS meningitis is 52% in 
young children and 80% in adults (Molyneux, et al., 2009).  
 
1.4.3 Treatment of typhoid fever 
Emergence of MDR S. Typhi resistant to ampicillin, chloramphenicol, trimethoprim-
sulfamethoxazole, amoxicillin and ciprofloxacin commonly used for typhoid  treatment 
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has been reported in Africa and Asia (Kariuki, et al., 2010, Zaki & Karande, 2011). 
Ciprofloxacin resistance is an increasing problem, especially in the Indian subcontinent 
and Southeast Asia (Rowe, et al., 1997, Kariuki, et al., 2010). In-case of ciprofloxacin 
resistance, azithromycin is the recommended first line treatment and it performs  better at 
treating uncomplicated enteric fever than both fluoroquinolone drugs and ceftriaxone 
(Crump & Mintz, 2010, Aggarwal, et al., 2011, Zaki & Karande, 2011). Azithromycin 
significantly reduces relapse rates compared to ceftriaxone (Effa & Bukirwa, 2011).  
 
Current treatment regime for typhoid fever is associated with better clinical outcomes 
compared to the past. For instance, during three episodes of S. Typhi outbreak between 
1948-1990, Van den Bergh et al demonstrated that typhoid patient’s treated with full dose 
of chloramphenicol cleared  high fever in  6 days, 13% of cases developed complications 
and mortality was 5% while typhoid patients that were not treated, fever cleared after 16 
days, 38% developed complications and mortality was 26% (van den Bergh, et al., 1999). 
A recent review by Parry and colleagues, reported that typhoid patients treated with 
fluoroquinolones on average fever-clearance time is less than four days, and the cure 
rates exceed 96 percent (Parry, et al., 2002). They also reported that less than 2 percent of 
treated patients become persistent faecal carriers or relapse occurs (positive faecal culture 
at the end of treatment or recurrence of symptoms with a positive blood or bone marrow 
culture after hospital discharge) (Parry, et al., 2002). These reports show that clinical 
outcome of treated typhoid patients are generally good.  
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1.4.4 Treatment of NTS bacteraemia 
In Malawi and SSA the epidemics of MDR invasive NTS have emerged (Gordon, et al., 
2008). MDR are defined as resistance to ampicillin, chloramphenicol, and co-trimoxazole 
(Gordon, et al., 2008). Currently NTS sepsis is treated with  the third generation 
cephalosporins and fluoroquinolones such as ciprofloxacin (Feasey, et al., 2012). 
Azithromycin is alternative antimicrobial drug while ceftriaxone is the preferred first line 
intravenous treatment for patients unable to take oral dugs (Feasey, et al., 2012). 
 
1.5  S. TYPHIMURIUM AND S. TYPHI AS PATHOGENS AND HOST 
ADAPTIVE DIFFERENCES  
This section provides a description of Salmonella bacterium structure to appreciate their 
importance in disease pathogenesis.   
1.5.1 Flagella 
Flagella are long helical filaments attached to rotary motors embedded with the 
membrane and are essential for motility during infection (Figure 1.4) (de Jong, et al., 
2012). The main subunit of Salmonella flagella is encoded by fliC or fljB and these 
correspond to H1 and H2 variants of the H antigen, respectively (Silverman & Simon, 
1980). Interestingly, only one type of flagellin can be expressed at a specific time through 
a phase variation mechanism (Simon, et al., 1980). In contrast to S. Typhimurium where 
variation of flagellin types has been observed, S. Typhi are mostly monophasic since they 
lack the fljB locus (Frankel, et al., 1989). Parkhill et al have demonstrated that fljB is a 
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pseudogene in S. Typhi which may explain this phenomenon (Parkhill, et al., 2001). 
During the early phase of S. Typhimurium infection within the intestine, flagellin has 
been implicated in up-regulation of pro-inflammatory cytokines (IFN-γ, TNF-α, IL-1β) 
and  the chemo-attractant (IL-8), and  results in the influx of neutrophils into the gut 
mucosal tissue (Zeng, et al., 2003). In-contrast, S. Typhi, through TviA (S. Typhi specific 
DNA region preventing the production of IL-8 during invasion of intestinal epithelial 
cells) repress flagellin, therefore avoiding toll like receptor 5 (TLR-5) signalling and 
subsequent migration of neutrophil  through IL-8 secretion (Raffatellu, et al., 2005, 
Winter, et al., 2008). 
 
SPI
flagellin
fimbriae
plasmid
outer cell membrane
inner cell membrane
peptidoglycan
LipopolysaccharideTSSS
 
Figure 1. 4: Structure of S. Typhimurium 
 
1.5.2 Vi capsule  
The Vi antigen is a polysaccharide capsule and is present in only three Salmonella 
serovars; S. Typhi, S. Paratyphi C and S. Dublin (Pickard, et al., 2003). Vi has important 
roles in S. Typhi virulence and is regulated by the two loci: viaA and viaB (Kolyva, et al., 
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1992). It is thought that Vi presence increases disease infectivity and severity (Wain, et 
al., 2005). Contradicting these thoughts, in human volunteers exposed to Vi capsule 
negative S. Typhi mutants exhibit a typhoid-like disease (Zhang, et al., 2008). These 
observations suggest that Vi is not absolutely required for S. Typhi disease infectivity and 
severity. In addition, Vi capsule is associated with resistance to serum bactericidal 
activity and intracellular survival (Looney & Steigbigel, 1986, Miyake, et al., 1998). Vi 
capsule prevents recognition of S. Typhi lipopolysaccharide (LPS) by the host TLR-4 and 
inflammation in the intestinal mucosa (Sharma & Qadri, 2004, Wilson, et al., 2008). 
Together these observations indicate that the Vi capsule facilitates immune-modulatory 
activities in the intestinal mucosa by limiting S. Typhi LPS and TLR-4 interaction (limits 
pro-inflammatory response and influx of neutrophils), while at the same time promoting 
dissemination of S. Typhi to distant tissues (escape serum bactericidal activity and 
promoting survival inside the phagocytes). 
 
1.5.3 Lipopolysaccharide 
Lipopolysaccharide (LPS) is the main cell wall component of all Gram negative bacteria 
and is comprised of three structural regions; O antigen, core and lipid A (Ernst, et al., 
2001) (Figure 1.4 and 1.5). Both O antigen and core are made up of polysaccharide 
chains while lipid A is made up of the fatty acid and phosphates substitutes bound to a 
central glucosamine dimer. In addition, lipid A comprises the outer leaflet made of the 
outer membrane lipid bilayer, while the inner leaflet is a phospholipid. Primarily LPS 
prevents bacteria from complement attack. Assembly of membrane attack complex 
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(MAC) is affected by the chemistry of the O polysaccharide, the length of O 
polysaccharide  chain and relative amounts of long chain smooth LPS (Rautemaa & Meri, 
1999, Murray, et al., 2006). MacLennan et al demonstrated previously that NTS strains 
causing invasive NTS disease in Malawi had long-chain lipopolysaccharide and rck gene 
(MacLennan, et al., 2008), features that resist direct complement-mediated killing 
(Heffernan, et al., 1992, Heffernan, et al., 1992). Lack of ex vivo NTS killing and 
complement deposition in serum from Malawian children (< 16 months of age) lacking 
anti-Salmonella antibody strongly suggest that long-chain lipopolysaccharide and rck  
confer protection against complement in the absence of specific IgG or IgM antibody in 
humans (MacLennan, et al., 2008). The O-specific chain is very variable even within the 
Gram-negative species and this form the chemical basis for serological classification of 
Salmonella. In addition, LPS components; O-antigen, core polysaccharide and lipid A 
activates cellular immune system through interactions with TLR-4 and its accessory 
protein termed MD-2 (Beutler, 2000, Kaisho & Akira, 2000). 
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Figure 1. 5: Chemical structure of Gram-negative lipopolysaccharide 
 
1.5.4  Salmonella Pathogenicity Island and Type Three Secretion System 
Salmonella Pathogenicity Islands (SPI) are genetic structures where virulence genes 
cluster in a localized region of the chromosome (Figure 1.4)  (Groisman & Ochman, 
1996). Salmonella acquire SPI virulence genes through horizontal gene transfer 
(Groisman & Ochman, 1996). There are up to 21 SPIs known to date, but only SPI-1 and 
SPI-2 have been extensively studied (Sabbagh, et al., 2010). For delivery of virulence 
proteins, SPIs utilize the type three secretion system (TTSS or T3SS). TTSS are 
specialized virulence devices capable of modifying host cell function (signal 
transduction, cytoskeletal architecture, membrane trafficking and cytokine gene 
expression) through the direct translocation of bacterial virulence proteins into the host 
cells cytoplasm (Hueck, 1998, Ohl & Miller, 2001). Unique sets of virulence proteins 
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contribute to the distinct virulence phenotype of each Salmonella serovar (Ohl & Miller, 
2001).  
Salmonella enterica contains two TTSS gene clusters encoding a secretion apparatus that 
functions like a molecular syringe (de Jong, et al., 2012). SPI-1 harbours the genes for 
TTSS-1 which are essential during the early phase of  Salmonella infection for invasion 
of non-phagocytic cell like intestinal epithelial cells (M cells) and induction of intestinal 
secretory and inflammatory responses (Watson, et al., 1995, Galan, 1999). In-vitro 
models uncovered that Salmonella mutants lacking a functional SPI-1 TSSS are unable to 
invade epithelial cells or trigger cytokine production (Watson, et al., 1995). These 
attributes permits Salmonella (typically S. Typhimurium) to invade the intestinal mucosa 
barriers, trigger pro-inflammatory responses, neutrophils influx and but may fail to 
establish system infection when overcome by host resistance at this early phase of 
infection.  
TTSS-2 encoded on SPI-2 is essential during the second phase of Salmonella infection, 
for replication inside the macrophages and establishment of systemic infection (Hensel, et 
al., 1998) (Forest, et al., 2010). TTSS-2 is activated in the phagosome and it translocate 
effector proteins from phagosome into macrophage cytosol and prevents co-localization 
of Salmonella containing vacuoles (SCV) with NADPH dependent oxidase that catalyses 
production of reactive oxygen species within the phagocyte (Uchiya, et al., 1999, Ohl & 
Miller, 2001). These attributes permit Salmonella enterica (typically S. Typhi) to survive 
and replicates within the host macrophage and establish systemic infection. 
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1.5.5 PhoP/PhoQ regulator 
PhoP/PhoQ regulators are two component regulators that regulate simple signal 
transduction systems of bacterial gene expression in response to environmental cues 
(Miller, et al., 1989, Ohl & Miller, 2001). PhoP/PhoQ regulators are found in many 
Gram-negative bacteria including Salmonella (Groisman, 2001). PhoP/PhoQ regulation 
involve triggering expression of the PhoP activated genes (pag) and repressing expression 
of genes termed PhoP-repressed genes (prg) (Miller, et al., 1989, Ohl & Miller, 2001). 
PhoP-activated genes are expressed (SPI-2 TSSS) for intra-cellular survival while PhoP 
regressed genes (SPI-1 TTSS) are switched off in the phagosome (Pegues, et al., 1995). 
Using PhoP null and PhoP mutant’s experiments, it has been shown that timely regulation 
of the PhoP/PhoQ regulator is essential for Salmonella survival (Miller & Mekalanos, 
1990). At least in part, PhoP- activated gene promotes resistance to antimicrobial 
peptides by catalysing covalent modification of the lipid A component of LPS (Guo, et 
al., 1998, Ohl & Miller, 2001). PhoP regulated lipid A modification also promotes a 
bacterium LPS molecule to avoid pro-inflammatory response (Guo, et al., 1997). These 
attributes allow Salmonella (typically S. Typhi) to survive and replicate within the host 
macrophage and establish systemic infection. 
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1.6  IMMUNITY TO SALMONELLA INFECTION  
In this section we discuss immunity to Salmonella. Human studies on immunity to 
Salmonella are generally lacking and much of what is known about immunity to 
Salmonella comes from murine studies. Since S. Typhi is human host restricted and 
cannot cause disease in mice, therefore immunity to S. Typhi is actually investigated in S. 
Typhimurium murine models. It therefore possible that what is true for immunity to S. 
Typhimurium could not be true for immunity to S. Typhi. 
 
1.6.1 Spread of ingested Salmonella to distant tissues via the GIT 
To fully understand the human host response to Salmonella infection it is important to 
appreciate the steps that lead to tissue invasion. Human beings ingest Salmonella from 
contaminated food, water and fomites (Kariuki, et al., 2006). Salmonella reaches the 
distal ileum or caecum, following the survival of host protective mechanisms that include 
competition with normal flora and gastric acid toxicity (Mastroeni, 2003, Tam, et al., 
2008). Murine models reveal that Peyer’s patches (PP) and epithelial covering villi are 
the key sites where Salmonella penetrates the gut epithelial barrier (Tam, et al., 2008)  
Salmonella invades the PP specialised epithelial cells known as Microfold cells (M cells) 
through SPI-1 (Monack, et al., 2004) (Figure 1.6). Salmonella are also transported from 
the gastrointestinal tract to the blood stream by CD18 expressing phagocytes (Vazquez-
Torres, et al., 1999). Salmonella also penetrates the gut epithelial barrier through 
dendritic cells (DC). DCs extend their dendrites between epithelial cells, overlying villi 
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and capture gut luminal Salmonella. DCs then translocate the captured Salmonella into 
the lamina propria (LP) by retracting its dendrites (Rescigno, et al., 2001). Salmonella 
that penetrate the PP, directly access the mesenteric lymph node (MLN) while LP 
Salmonella finds their way to the MLN through the lymphatic drainage system (Monack, 
et al., 2004). Resident macrophages ingest Salmonella in the PP and MLN, to control 
Salmonella infection. However, virulent Salmonella may evade macrophage immunity by 
inducing macrophage cell death through SPI-1 encoded Sip B protein which activates 
caspase 1 (Monack, et al., 2004). Depending on Salmonella virulence and host 
immunological factors, Salmonella can remain restricted to the  MLN or disseminate via 
the thoracic duct to systemic organs  including  peripheral blood, spleen, liver and bone 
marrow (Mastroeni, 2003, Sansonetti, 2004). 
 
Figure 1. 6:  Salmonella ingestion and invasion of the gut mucosal barrier 
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At the gut lumen Salmonella evade epithelial through direct invasion (depend on the 
virulence of Salmonella serovar) of the epithelial cells, through the M cells and DC 
capture of the Salmonella from the gut lumen. In the gut mucosal Salmonella can be 
killed by innate immune cells (neutrophils and macrophages) and adaptive immune cells 
(B cells and T cells) or survives and disseminate to distance tissues. 
1.6.2 Innate immunity in response to Salmonella infection  
In addition to gastric pH, innate immunity provides the first line of defence against 
Salmonella infection. It comprises the cellular components such as macrophages and 
neutrophils and the soluble components such as complement and cytokines.  
1.6.2.1 Activation of innate immune responses to Salmonella infection 
Innate cells (neutrophils and monocytes) are primarily  activated through pathogen 
recognition receptors (PRR) expressed on cell surfaces such as toll like receptor-4 (TLR-
4) when they recognise pathogen associated molecular patterns (PAMPS) such as 
lipopolysaccharide (LPS) expressed by infecting pathogens. Important specific PAMPs 
and TLRs interactions in Salmonella and innate cells involves; LPS and TLR-4, flagellin 
and TLR-5 and lipopeptide and TLR-2/6 (Srinivasan & McSorley, 2006, Tam, et al., 
2008). For instance, TLR-4 and LPS interactions result in signal transduction that 
culminates into activation of NFκB and leads to the transcription of pro-inflammatory 
cytokines such as TNF-α. The importance of macrophage TLR-4 has been shown in LPS 
d/d mice (TLR-4 defect mice). LPS d/d mice are hypo responsive to Salmonella LPS and 
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fail to control Salmonella growth compared to wild type mice that efficiently control 
Salmonella growth (Hormaeche, 1990, Mastroeni, 2002).   
 
1.6.2.2 Phagocytosis and intracellular killing by phagocytes 
Monocytes and neutrophils are important for controlling Salmonella during the early 
phase of infection (Fierer, 2001, Cheminay, et al., 2004, Tam, et al., 2008). Mice 
rendered neutropenic by administration of granulocyte depleting monoclonal antibodies, 
are more susceptible to Salmonella infection compared to wild type mice, indicating  
neutrophils importance in controlling early Salmonella infection (Conlan, 1997). 
Neutrophils and monocytes efficiently ingest Salmonella opsonised by complement 
factor C3b, through surface membrane complement receptor 3 (CR3) (van Bruggen, et 
al., 2007). However, non-opsonised Salmonella can also be ingested by macrophages and 
neutrophils through CD14 and LPS interactions (Heale, et al., 2001).  
Killing of engulfed Salmonella is achieved through metabolic reactions within the 
phagosome membrane and cytosol (Mastroeni, 2003). Phagocytes killing mechanisms 
include; acidification (pH ranging 5-4.5) through glucose consumption, generation of 
phagolysosomes, generation of reactive oxygen intermediates (ROI) and reactive nitrogen 
intermediates (RNI) termed respiratory burst (Mastroeni, 2003). In mice, Salmonella 
growth in the tissues is controlled by macrophage associated Nramp1 (natural resistance-
associated macrophage protein one) gene (also known as Slc11a1) during the first few 
days of infection (Hormaeche, 1990). Nramp1 encodes divalent metal (Fe
2+
, Zn
2+
 and 
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Mn
2+
) pump phosphoglycoproteins, which are recruited to Salmonella containing 
phagosome and these metals are required for efficient bactericidal functions (Vidal, et al., 
1993, Mastroeni, 2003). In humans, polymorphism of the Nramp1 gene has been 
associated with susceptibility to intracellular bacteria including Mycobacterium 
tuberculosis infection (Vidal, et al., 1993). Furthermore, importance of macrophages in 
controlling Salmonella infection is shown in chronic granulomatous disease (CGD) 
patients. CGD patient’s macrophages exhibit defective respiratory burst and this permits 
intracellular bacteria invasion (Mouy, et al., 1989).  
 
1.6.2.3  Phagocytes killing and the role of cytokines  
Innate immune cells such as macrophages, neutrophils and natural killer cells (NK) 
generate specific-cytokines that allow co-ordination of immune responses and subsequent 
Salmonella killing. To ensure efficient immune response, macrophages and neutrophils at 
the site of infection generate chemokines IL-8 and MIP-1 respectively (Tam, et al., 
2008). IL-8 and MIP-1 allow recruitment of more leukocytes to the site of infection. 
TNF-α generated by macrophages promotes transmigration of leukocytes to site of 
infection, in addition to generation of organised lesions at the infected tissues.  
Importance of TNF-α has been shown in mice treated with anti-TNF-α antibodies or 
TNFR 55 knockout mice prior to Salmonella oral challenge, these mice fail to restrict 
bacterial growth and exhibit poor organised lesions in the infected tissues (Mastroeni, 
2002). IFN-γ is also important for macrophages efficient killing of intracellular 
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Salmonella (Yrlid, et al., 2000, Tam, et al., 2008). NK cells and gamma-delta T cells 
provide the early source of IFN-γ, (Lalmanach & Lantier, 1999, MacLennan, et al., 2004, 
Nyirenda, et al., 2010). Early source of IFN-γ generated by NK cells has been shown in 
Rag 1 knockout mice (lack mature CD4+ T cells, CD8+ T cells and B cells). Rag 1 
knockout mice can produce IFN-γ in response to Salmonella infection, indicating that NK 
cells is the source of  this IFN-γ (Ramarathinam, et al., 1993).  
 
1.6.2.4 Complement mediated immunity to Salmonella  
Complement is comprised of more than 20 proteins present in plasma and on cell 
surfaces. Activation of complement leads to formation of a cascade and these proteins are 
essential for specific biological functions including pathogen killing through complement 
membrane attack (MAC), opsonisation of pathogen and recruitment of inflammatory 
cells (Krushkal, et al., 2000). Complement cascade can be activated in three pathways 
through C3; the classical pathways requires antibody and bacteria complexes for 
activation and these binds to C1 C4 C2 complexes, lectin binding pathway requires 
mannose binding protein (MBP) binding on bacteria surface for activation and this binds 
to C4 and the alternative pathway requires non-specific bacteria surface and factors B D 
P and these binds to C3 (Figure 1.7). Complement involvement in controlling Salmonella 
infection is shown in mice with C1q deficiency (Warren, et al., 2002). C1q deficient mice  
are more susceptible to infection with S. Typhimurium compared to strain-matched 
control mice, indicating  the importance of C1q complement classical pathway in 
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protection against Salmonella infection (Warren, et al., 2002). Sickle cell patients are also 
more susceptible to Salmonella bacteraemia compared to healthy controls (Calis, et al., 
2008). This susceptibility to Salmonella bacteraemia has been attributed to reduced serum 
bactericidal activity as a result of  defective function of  alternative complement pathway 
and low concentration of C3 (Hand & King, 1977) and also  impaired splenic function 
(Booth, et al., 2010).    
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Figure 1. 7: Complement pathways 
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1.6.3 Adaptive immunity to Salmonella  
1.6.3.1 Salmonella antigen processing and presentation by the APC 
Mature dendritic cells (DCs) and macrophages that ingest Salmonella at the site of 
infection migrate to lymph nodes, to prime Salmonella-specific T cells and B cells (Yrlid, 
et al., 2000). DC can either directly (upon uptake and processing of Salmonella) or 
indirectly (by bystander mechanisms, including cross-presentation) present Salmonella 
peptide antigens (Sundquist, et al., 2004). Salmonella antigens are mainly processed 
through exogenous pathway and peptides  are  presented by  antigen presenting  cell 
(APC) to CD4+ T cell through APC MHC-II  and  CD4+ TCR  interaction (Yrlid, et al., 
2000) (Figure 1.8). Salmonella antigens could also be presented by APC to CD8+ T cell 
through APC MHC-I and CD8+ TCR interaction, in a process referred to as cross-
presentation (Salerno-Goncalves & Sztein, 2009). In cross-presentation, APC take up 
antigens and process these antigens through MHC Class II pathway and later processed 
antigens  are directed to their own MHC I pathway and peptides are subsequently 
presented to naive CD8+ T-cells (Heath, et al., 2004, Rock & Shen, 2005, Salerno-
Goncalves & Sztein, 2009). Furthermore, Sztein reported that  CD8+ T cells play a role 
in controlling Salmonella infection and killing is mediated by both MHC-Ia restricted and 
non-classical HLA-E restricted cytotoxic T cell response in Ty21a vaccinated humans 
(Sztein, 2007). 
In MHC-II antigen presentation pathway, phagocytised Salmonella are delivered to 
specialised antigen processing endosome compartments (Wolf & Ploegh, 1995). The 
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endosome compartments contain MHC-II molecules in complex with the invariant chain 
inserted in its membrane (Wolf & Ploegh, 1995). Proteases are activated by acidic 
conditions within the endosome compartments, which allow the generation of 
Salmonella-specific peptides and degradation of invariant chain (Wolf & Ploegh, 1995, 
Jensen, et al., 1999). HDA-DM catalyses the removal of invariant chain and peptides 
loading into the MHC-II grooves (Wolf & Ploegh, 1995, Jensen, et al., 1999). The 
peptide MHC-II complex is then transported to the surface of antigen presenting cell 
(APC) for CD4+ T cell activation through peptide MHC-II complex and TCR interaction 
(Wolf & Ploegh, 1995, Jensen, et al., 1999).  
Efficient T cell activation however, requires co-stimulatory signals in additional to T cell 
TCR and APC peptides MHC complex interactions. Co-stimulatory signals involve 
interactions between APC via CD80 and CD86 (B7.1/B7.2) with T cell CD28 and 
CTLA-4 (Mittrucker, et al., 1999, McSorley, et al., 2002). CD28 mediates positive T cell 
co-stimulatory signal while CTL-4 mediates T cell inhibitory signal (Mittrucker, et al., 
1999, McSorley, et al., 2002). It has been demonstrated that CD28 knockout mice fail to 
mount efficient T cell immunity against S. Typhimurium, indicating the role of CD28 in 
providing T cell positive co-stimulatory signal (Mittrucker, et al., 1999). The recently 
activated Salmonella specific CD4 T cells leave the lymph nodes to the infected tissues, 
to mount Salmonella-specific immune response.  
Introduction and Literature review 
 
31 
 
Antigen Presenting Cell
Naïve CD4+ T cell
MHC-II
TCR
Antigen processingCD4
CD28/CTLA4 B7.1/B7.2
Antigen internalization
Antigen presentation &
T cell activation
 
Figure 1. 8:   APC antigen processing and presentation to CD4+ T cell  
  
Naïve CD4+ T cells are primed by the APCs in the lymphoid tissues (including GALT, 
PLN) through the interaction of MHC-II and specific-peptide complex (APC) and TCR 
(CD4+ T cell). Mature APC internalise Salmonella and processed Salmonella-specific 
peptides are presented to naïve CD4+ T cells through MHC-II. Primed CD4+ T cells 
migrate to the site of infection of effector functions.  
 
1.6.3.2  Polarisation of CD4+ T helper immunity to Salmonella  
Polarisation of activated CD4+ T cells towards CD4+ T helper 1 (Th1), CD4+ T helper 2 
(Th2) and CD4+ T helper 17 (Th17) are dictated by factors including infecting organisms 
and cytokines (Figure 1.9). CD4+ Th1 immunity to Salmonella is the dominant form of 
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immunity. CD4+ T cell production of  IFN-γ and TNF-α significantly increases during  
acute and convalescent phases, in Salmonella infected patients compared to healthy 
controls (Stoycheva & Murdjeva, 2004, Thompson, et al., 2009, Charles, et al., 2010, 
Khoo, et al., 2011). Salmonella infections stimulates macrophage to produce  cytokines; 
IL-12 and IL-23 and these cytokines drives the polarization of recently activated CD4+ T 
cells towards CD4+ T helper 1 cells (MacLennan, et al., 2004). In a feedback fashion 
CD4+ T cell generated IFN-γ and TNF-α provides help to macrophages effector 
functions. Patients with defects in IL-12/IFN-γ axis are more susceptible to Salmonella 
indicating the importance of CD4+ Th1 immunity in controlling Salmonella infection 
(Sharifi Mood, et al., 2004). Lin et al, demonstrated that human-host defence against 
Salmonella infection (during the acute phase) is associated with  these increase in CD4+ 
T helper 1 transcriptional factor Tbet and IL-2, while CD4 T helper 2 transcriptional 
factor Gata 3 and IL-4  are reduced, indicating the importance of CD4+ T helper 1 
response in controlling Salmonella infection (Lin, et al., 2008). 
Polarisation of CD4+ T cells towards CD4+ T helper 2 cells in Salmonella infection is 
dictated by IL-4 and IL-10 (Ramarathinam, et al., 1993). A study by Srinivasan  et al, 
showed that intestinal environment (immune regulatory) may also promote APCs to 
signal recently activated CD4+ T cells towards CD4+ T helper 2 cells (Srinivasan & 
McSorley, 2006). IL-4 and IL-10 play an inhibitory role of CD4+ T helper 1 mediated 
response against Salmonella (Ramarathinam, et al., 1993). IL-4 knockout mice efficiently 
control Salmonella infection compared to wild type following Salmonella oral challenge, 
suggesting that IL-4 promote salmonellosis progression (Ramarathinam, et al., 1993).  
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Emerging evidence from animal studies suggests that CD4+ T helper 17 (Th17) cells 
have a role in controlling Salmonella infection (Raffatellu, et al., 2008). In simian 
immunodeficiency virus (SIV) infected macaques (human HIV infected model), CD4+ 
Th17 cells in the ileal mucosa of rhesus macaques are depleted and this impairs mucosal 
barrier functions (blunted Th17 responses) resulting in increased systemic dissemination 
of S. Typhimurium from the gut (Raffatellu, et al., 2008). Furthermore, Th17 cells have 
been implicated in controlling extracellular bacterial infection in the gut thereby avoiding 
systemic dissemination of the pathogen (Raffatellu, et al., 2008, Blaschitz & Raffatellu, 
2010). Cytokines; IL1, IL-6, IL-23 and TGF-β1 and transcriptional factor Roγt are 
required for CD4+ T cell differentiation towards Th17 cells and their subsequent 
expansion (Chen & O'Shea, 2008). The contribution of Th17 immunity in controlling 
NTS bacteraemia in humans has not been investigated.   
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Figure 1. 9:  CD4+ T cell plasticity in response to Salmonella antigens 
The polarization of  Th1, Th2 and Th17 immunity is dictated by several factors including 
the infecting pathogen (Salmonella) or components (LPS, flagellin and OMP), cytokines 
profile generated by naïve cells including macrophage and natural killer cells (IL-12 
drive Th1 while IL-6, IL-1 and TNF-α drive Th2). In turn- CD4+ T cells generate pro-
inflammatory; IFN-γ and IL-2 (Th1 immunity) or anti-inflammatory; IL-4, IL-6 and IL-
10 (Th2 immunity) that up regulates and down regulates macrophages bactericidal 
machinery respectively. IL1, IL-6, IL-23 and TGF-β1 are required for CD4 T cell 
differentiation to Th17 cells and their subsequent expansion 
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1.6.3.3  B cell immunity to Salmonella infection 
B cells play an important role in protection against Salmonella. Antibody production is 
the dominant function of B cells, but they are also involved in antigen presentation to T 
cells. Salmonella are facultative intracellular organism and are capable of surviving in 
both the extracellular and intracellular space. It is thought that extracellular Salmonella 
are mainly controlled by antibody mediated immunity (MacLennan, et al., 2008). 
Salmonella in the extracellular space might have result from escaping neutrophil and 
macrophage mediated immunity. Opsonic IgG or IgM antibodies specific for S. 
Typhimurium control Salmonella bacteraemia by activating complement cascade through 
the classical pathway which are  ultimately killed through membrane attack complex 
(MacLennan, et al., 2008). Opsonic IgG or IgM antibodies specific for S. Typhimurium 
also control Salmonella bacteraemia by facilitating efficient neutrophils and monocytes 
phagocytosis through their surface membrane FcR (Uppington, et al., 2006) and the 
engulfed Salmonella are killed by respiratory burst (Gondwe, et al., 2010).  
MacLennan et al showed in Malawian children that antibody mediated serum killing of 
invasive NTS strain occurs in children >16 months of age and not in younger children 
(MacLennan, et al., 2008), indicating the requirement of mature NTS-specific antibodies 
(IgG and IgM) in this immunity (MacLennan, et al., 2008). Interestingly, a similar trend 
(age related development) of antibody mediated serum immunity to S. Typhi was 
reported in children from Nepal (Pulickal, et al., 2009). Furthermore, Xu and colleagues 
showed positive correlation  of Salmonella-specific antibody titres with resistance to 
lethal challenge with S. Typhimurium in  vaccinated genetically susceptible C57BL/BL 
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mice (Xu, et al., 1993). These findings support the exploration of an antibody-based 
vaccine for NTS bacteraemia. 
The production of Salmonella-specific IgG, IgM and IgA antibodies are increased during 
Salmonella disease. Anti-IgG titres to Salmonella LPS, flagellin and membrane proteins 
(MP) are higher in Salmonella infected patients compared to healthy controls (Lee, et al., 
Choo, et al., 1997, Strid, et al., 2007). Limited studies have explored the longevity of 
immune responses triggered naturally by Salmonella infection, to determine whether or 
not protection to subsequent infection is conferred. Longevity of IgG-antibodies targeting  
S. Typhi membrane protein (MP) in Malaysian children with typhoid fever (clinical 
typhoid fever, blood or stool culture positive or Widal test positive) 21 months into the 
recovery period was explored. At 6 months  into  the recovery period 50% of typhoid 
cases had detectable IgG antibody responses-specific for MP (positive dot enzyme 
immunosorbent assay [dot EIA]) and these responses declined to 30% at 12 months 
(Choo, et al., 1997). These findings suggest the longevity of these IgG-specific antibody 
responses triggered by natural Salmonella infection might mimics those induced by 
vaccination. Evidence on protection conferred by natural Salmonella exposure is elusive.  
 
1.6.3.4  B cell and T cell interactions in response to Salmonella infection 
Cellular interactions between B cells and T cells are important for development of robust 
immunity to Salmonella and other pathogens (Mastroeni & Menager, 2003). During 
secondary humoral response, B cells also function as APCs. This is evidenced by
 
reduced 
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ability to produce IFN-γ and IL-2 by CD4+ T cells isolated from B-cell-deficient Igh-
6
−/−
 mice immunized with live attenuated Salmonella (Mastroeni, et al., 2000). 
Immunized Igh-6
−/−
 mice also fail to control the growth of virulent Salmonella in 
secondary infection (Mastroeni, et al., 2000, McSorley & Jenkins, 2000, Mittrucker, et 
al., 2000). On the other hand, B cells generation of class switched and high affinity 
antibodies is dependent on T cells help (Figure 1.11) (Mittrucker, et al., 1999). This is 
proved in T cell deficient mice (athymic nu/nu mice), when vaccinated with live 
attenuated Salmonella fail to generate high affinity antibodies including  IgG1, IgG2A 
and IgG2B instead generate low affinity antibodies such as IgM and IgG3 against 
Salmonella LPS (Mastroeni & Menager, 2003). Essentially, interaction between CD4+ T 
cells and B cells is important for establishment long-term and robust  CD4+ T cells and 
antibody immunity to Salmonella infection (Mastroeni, 2002, Takemori, et al., 2014).     
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Figure 1. 10: Generation of high affinity and class-switched antibodies through B 
cell and T cells interaction 
Primed B cells also function as APC to CD4+ T cells. Primed CD4+ T cells provide help 
primed B cells to generate memory response, class-switch antibodies and high affinity 
antibodies specific for Salmonella. 
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1.6.4  Clinical features and immunity to Salmonella exposure within the GIT 
1.6.4.1 Normal  flora resistance to enteric pathogens 
Normal flora in the gastrointestinal tract (GIT) is present in large numbers particularly in 
the colon and lower intestine (Hooper & Gordon, 2001, Sekirov, et al., 2010). Normal 
flora provides colonisation resistance of the intestinal lumen to enteric pathogens 
including Salmonella (Endt, et al., 2010, Stecher & Hardt, 2011). Three mechanisms of 
intestinal microbiota-mediated colonisation resistance have been clearly defined 
including direct inhibition of the pathogen by antimicrobial effector molecules 
(bacteriocins, metabolic by-products), efficient competition for nutrients by shutting 
down all potentially available nutrient niches for the pathogen and  indirect inhibition by 
stimulating the host’s antimicrobial defence system (defensins, mucin and secretory IgA) 
(Stecher & Hardt, 2011). In the event that antibiotics (particularly broad-spectrum 
antibiotics) are administered the protective role of the normal flora is compromised 
(Miller, et al., 1954). Antibiotics can kill large numbers of commensal gut bacteria and 
thereby favouring an ecological niche of opportunistic pathogen such as Salmonella.   
 
1.6.4.2 Symptomatic Salmonella exposure: diarrhoea  
Enteric pathogen exposure within the GIT may be accompanied by gastrointestinal 
symptoms such as diarrhoea and this may be followed by carriage. The mechanisms 
underlying Salmonella diarrhoeal disease have not been clearly elucidated in humans.  
Generally the presence or absence of symptoms following Salmonella exposure within 
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the gut lumen may be dictated by the host immune response, pathogen virulence and the 
infecting dose. This has been demonstrated by modelling estimates of dose and  illness 
from  Salmonella outbreaks (Bollaerts, et al., 2008) and streptomycin mouse model for 
Salmonella diarrhoea (Kaiser, et al., 2012). Diarrhoea occurs when there is an altered 
movement of electrolytes and water that follows an osmotic gradient within the gut 
lumen, and this alterations is driven by enteric pathogens including Salmonella (Hodges 
& Gill, 2010). Salmonella are among the enteric pathogens that cause inflammatory 
diarrhoea and this primarily target the lower bowel, particularly the distal ileum and the 
colon (Navaneethan & Giannella, 2008). Salmonella causes inflammatory diarrhoea and 
is characterised by presence of neutrophils (Zeng, et al., 2003, Raffatellu, et al., 2005). 
Neutrophils regulate absorption through cytokine secretion and generation of precursors 
such as adenosine and secretagogue that activates the cystic fibrosis transmembrane 
receptor (CFTR), a Cl
-
 channel
 
(Navaneethan & Giannella, 2008, Hodges & Gill, 2010) 
(Figure 1: 11). Taken together Salmonella causes inflammatory diarrhoea and this is 
characterised by influx of neutrophils, increased secretion of Cl
-
 in the gut lumen 
following CFTR activation and the general reduced absorption.  
 
1.6.4.3 Duration of NTS shedding  
Evidence of Salmonella exposure to the GIT relies on stool cultures. Several factors are 
thought to govern the duration of Salmonella shedding including age, clinical 
presentation, antibiotic treatment and the anatomical site of carriage. In patients with 
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NTS  infection within the intestinal tract, Salmonella faecal shedding is usually short, 
ranging from 4 to 8 weeks in children and adults (Buchwald & Blaser, 1984). However 
the duration of NTS shedding is normally longer in children less than five years 
compared to older children and adults (Buchwald & Blaser, 1984). Antimicrobial 
treatment of acute Salmonellosis has been implicated to prolong the duration of faecal 
Salmonella shedding (Dixon, 1965, Levine, et al., 1982). Persistent NTS shedding for a 
period longer than 1 year (formal definition chronic carrier) is very rare (might occur in 
<1%) (Musher & Rubenstein, 1973, Buchwald & Blaser, 1984). The location of 
persistent foci in NTS infection is unknown, although cholelithiasis has been documented 
in about 40% of Salmonella carriers (Musher & Rubenstein, 1973). Taken together, these 
findings show that NTS chronic carriage is rare, but shedding of NTS even for shorter 
duration could be a way of transmitting NTS infection in animals and humans. 
 
1.6.4.4 Evidence of immunity to Salmonella disease within the GIT 
Exposure of Salmonella within the GIT is likely an immunizing event. Diarrhoea 
resulting for enteric pathogen exposure in naïve children is typically severe and faecal 
shedding lasts longer compared to subsequent diarrhoea episode  (Buchwald & Blaser, 
1984, Pitzinger, et al., 1991, Steffen, 2005). Similarly  travellers’ diarrhoea is usually 
severe with longer duration of faecal shedding in visitors from enteric pathogens non-
endemic countries compared to diarrhoea in native subjects from enteric pathogens 
endemic countries (Steffen, 2005). These observations support the notion that Salmonella 
exposure within the GIT does confer protection to subsequent specific infection within 
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the GIT. Whether this protection induced by Salmonella exposure within the GIT can 
provide protection against Salmonella blood stream infection (BSI) is a key question.  
Furthermore, it was demonstrated  in the mouse model of diarrhoea that perioral 
treatment with ciprofloxacin of S. Typhimurium  a  disrupts  adaptive immunity to S. 
Typhimurium while parenteral ceftriaxone does not disrupt development of  adaptive 
immunity (Endt, et al., 2012). Selection of antibiotics for intestinal localised Salmonella 
infections must take into account the impact on establishment of natural immunity and 
sensitivity of Salmonella to the antibiotics. This area has received limited attention and 
need further investigations to ascertain the impact of drug selection for treatment of 
Salmonella and subsequent establishment of natural immunity.  
 
 
Figure 1. 11: Protective immunity following Salmonella exposure within the GIT 
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Low dosage of NTS in the gut lumen and the balance between NTS and normal flora 
might dictate asymptomatic colonisation. This balance might however permit NTS to 
exist in the gut lumen for longer periods and faecal shedding could be detected. The 
imbalance between the NTS and normal flora dictate symptomatic colonisation of the gut 
lumen which is associated with the influx of the neutrophils and electrolyte imbalance. 
These processes result in diarrhoea with or without detectable faecal shedding. During 
the initial NTS attack the diarrhoea is usually severe and the duration of shedding and 
diarrhoea is longer. While during the second NTS attack the diarrhoea is less severe and 
the duration shedding and diarrhoea is shorter, perhaps due to the protective immunity 
induced during the previous attack. 
 
1.6.5 Immunological lessons drawn from humans that are vulnerable to iNTS 
1.6.5.1 Malnutrition is commonly associated with NTS bacteraemia 
NTS bacteraemia is commonly associated with malnutrition in SSA (Graham, et al., 
2000, Babirekere-Iriso, et al., 2006). The mechanism underlying susceptibility to NTS 
bacteraemia in malnourished children has not been elucidated in humans. Since 
malnourished children exhibit a leaky gut (Reynolds, et al., 1996), it is possible that 
impaired gut integrity in malnourished children permit the spread of Salmonella from the 
gut lumen through the gut mucosa and submucosa, and subsequently spread to systemic 
circulation (Reynolds, et al., 1996). Rehabilitation of malnourished children may restore 
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the gut mucosa barrier and restricts spread of enteric pathogens including Salmonella into 
systemic circulation, but this is unproven.  
 
1.6.5.2 Malaria and Salmonella bacteraemia co-infection infection (Neutrophils and 
monocytes)  
Both malaria and Salmonella bacteraemia remain important causes of death among 
under-five children in SSA (Guinovart, et al., 2006, Reddy, et al., 2010). NTS 
bacteraemia is commonly associated with malaria infection, particularly severe malarial 
anaemia (Bronzan, et al., 2007). Case fatality rate is higher in children presenting to 
hospital with severe malaria anaemia and bacteraemia co-infection compared to malaria 
infection alone (Bassat, et al., 2009). This is in part due to indistinguishable clinical 
presentation of NTS bacteraemia, and lack of diagnostics in poor resource settings. 
Children are diagnosed and treated for malaria infection while NTS bacteraemia is 
unattended. The association between malaria infection and NTS bacteraemia in Africa 
was first reported in the 1920s (Graham, 2010). Biggs et al recently demonstrated NTS 
bacteraemia and malaria infection co-infection was common among febrile paediatric 
inpatients (aged 2 months to 13 years) from low altitude  and high malaria transmission 
area compared to those from high altitude and low malaria transmission area in Tanzania 
(Biggs, et al., 2014). In contrast to NTS bacteraemia pattern, S. Typhi bacteraemia was 
uncommon in febrile paediatric inpatients from low altitude and high malaria 
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transmission  area (Biggs, et al., 2014). These findings underlie the differences in the 
burden and mode host susceptibility of S. Typhi and NTS among children from SSA. 
The mechanism underlying association between NTS bacteraemia and malaria co-
infection is not clear. It has been shown that the reduction in neutrophil oxidative burst 
activity, reduction in IL-12 levels and increased levels of IL-10 in malaria infected mice 
play a role in impairing  immunity to NTS (Roux, et al., 2010, Cunnington, et al., 2012, 
Maclennan, 2014). Together these studies suggest that compromised neutrophil immunity 
against malaria and increased inhibitory cytokines favours NTS growth and perhaps 
dissemination to systemic organs. These mechanisms have not been investigated 
thoroughly in humans.   
 
1.6.5.3 Cellular and humoral immune responses in HIV infected individuals 
NTS bacteraemia is common in HIV infected individuals worldwide. Impaired antibody 
and cellular immunity have been implicated. MacLennan et al demonstrated that HIV 
infected adults exhibit significantly high levels of anti-Salmonella IgG titres targeting S. 
Typhimurium-LPS O antigen compared to healthy adults and these antibodies were 
inhibitory as they block bactericidal anti-Salmonella IgG antibodies targeting S. 
Typhimurium-outer membrane protein (OMP) (MacLennan, et al., 2010). Whether or not 
S. Typhimurium-specific IgG antibodies in HIV infected individuals are class switched or 
high affinity antibodies is not clear.   
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Gordon et al  demonstrated that low absolute CD4+ T cells in HIV infected individuals 
correlate independently with viable NTS in peripheral blood, suggesting failure to clear 
intracellular infection in advanced HIV (Gordon, et al., 2010). In keeping with these 
observations, Raffatellu et al demonstrated that simian immunodeficiency virus (SIV) 
infection results in depletion of Th17 cells (subset of CD4+ T cells) in the ileal mucosa of 
rhesus macaques, thereby impairing mucosal barrier functions to S. Typhimurium and 
this subsequently promotes S. Typhimurium spread to distant tissues (Raffatellu, et al., 
2008).   
A recent transcriptome study in HIV infected adults with NTS bacteraemia showed 
attenuated NFќB inflammation while NFќB inflammation was normal in controls with 
other common extracellular bacteraemia (Schreiber, et al., 2011). NFκB signalling 
pathway plays a key role in signalling downstream activities including cell proliferation 
and pro-inflammatory cytokine generation (including IFN-γ). In keeping with these 
findings, Gordon et al demonstrated dysregulation of  pro-inflammatory cytokine 
(including IL-12) production by macrophages in adults with advanced HIV in responses 
to Salmonella (Gordon, et al., 2007) and also impaired  NTS internalisation and killing 
by the macrophages even in the presence of  exogenous IFN-γ (Gordon, et al., 2007).  
Furthermore, immunohistochemistry studies have revealed that the architecture of 
lymphoid tissues are disorganised in HIV infected subjects (Alos, et al., 2005), 
suggesting disorganisation of the lymphoid tissues underline compromised immunity to 
pathogens including Salmonella in HIV infected subjects, since mounting of effective 
adaptive immunity is dependent on proper machinery of the lymphoid tissue. There is 
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evidence that ARV therapy restores the loss of CD4+ T cells to relatively normal counts 
(Guadalupe, et al., 2003) and cases of BSI including Salmonella bacteraemia have 
reduced tremendously in HIV infected Malawian adults following the roll out of   
Antiretroviral therapy (ART) and Cotrimoxazole preventative therapy (CPT) (Feasey, et 
al., 2014). Whether or not ART therapy restores the organisation of lymphoid tissues and 
function of the adaptive immunity to Salmonella infection in HIV infected individuals is 
not clear. A study on Malawian children who were chronically infected with HIV 
receiving ART showed delayed restoration of memory B cells compared to CD4+ T cells 
and B cell function specific for pneumococcal protein antigen was also delayed 
(Iwajomo, et al., 2014). Another study on Malawian adults infected with HIV receiving 
ART showed that recovery of pneumococcal CD4+ T cells at 12 months following ART 
initiation  and incomplete recovery of CD4+ T cell function (CD154 expression  and 
production of antigen specific IFN-γ) (Sepako, et al., 2014). Together these findings 
suggest that ART therapy incompletely restores B cell and T cell immunity in HIV 
infected individuals. 
 
1.7  VACCINES 
In this section, discussion focusses on vaccine development status for both S. Typhi and 
NTS bacteraemia. Two currently licenced vaccines (Oral Ty21a and Vi CPS) for S. Typhi 
and also new generation vaccines are reviewed. No human vaccine is licenced for NTS 
and discussion dwells on progress made in exploring NTS vaccine candidates.  
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1.7.1 Oral Ty21a vaccine 
Oral Ty21a is a vaccine for  typhoid fever and was generated in the 1970s following 
chemical mutagenesis of the wild type strain S. Typhi Ty2 and does not express the Vi 
polysaccharide and galE gene (Germanier & Fuer, 1975, Guzman, et al., 2006). Ty21a 
(Vivotif) contains attenuated S. Typhi Ty2 in lyophised form, and each capsule contains 
no less than 2x10
9
 viable cells (Guzman, et al., 2006). Oral Ty21a vaccine is 
administered in children above 6 years and adults. Three doses of Ty21a vaccine are 
recommended worldwide, but  other countries including  Canada and  USA opt to 
provide four doses (Guzman, et al., 2006). One capsule is taken on days 1, 3 and 5 with 
lukewarm water at least 1 hour before meal (Pasetti, et al., 2011). Clinical trials for oral 
Ty21a vaccine showed that it is extremely safe and well tolerated (Olanratmanee, et al., 
1992). Common adverse effects (AEs) reported include mild gastrointestinal disturbances 
and fever (Guzman, et al., 2006). A meta-analysis showed overall three years cumulative 
protective efficacy of 51% (Fraser, et al., 2007). Furthermore, immunogenicity studies 
demonstrated that oral Ty21a vaccine induces both antibody and T cell mediated 
immunity. However oral Ty21a vaccine requires multiple doses to elicit a protective 
response, even after booster doses the vaccine confers incomplete protection. To address 
oral Ty21a vaccine shortfalls a number of novel live attenuated S. Typhi vaccine 
candidates have been developed including Ty800, CVD 908, CVD 908-htrA, CVD 909 
and M01ZH09 (Tacket, et al., 2000, Tacket & Levine, 2007, Wahid, et al., 2011). 
Unfortunately none of these new live attenuated vaccines are currently licensed as 
typhoid vaccines (Table 1-B).  
Introduction and Literature review 
 
49 
 
1.7.2 Vi capsular polysaccharide vaccine 
Vi capsular polysaccharide vaccine (Vi CPV) for typhoid fever was licenced in 1994. Vi 
CPV is now available in >90 countries and is administered as a single or multiple doses 
intramuscularly (Martin, 2012). The vaccine induces acquisition of serum anti-Vi IgG 
and these have been shown to correlate with efficacy (Hessel, et al., 1999). Vi CPV 
confers about 70% protection for up to 3 years in children aged >2 years  and adults 
(Tacket, et al., 1986). Interestingly, in populations where Vi CPV have been 
implemented, cases of typhoid fever have been reduced (Khan, et al., 2010). In Kolkata, 
among children aged 2 and 5 years, a cluster randomised trial of Vi CPV demonstrated a 
low transmission and herd immunity amongst controls (Sur, et al., 2009). The pitfalls of 
Vi CPV include; lack of immunogenicity in children below 2 years, shorter duration of 
protection and the need for repeated doses (Robbins & Robbins, 1984, Tacket, et al., 
1988, Hessel, et al., 1999). Furthermore, Vi CPV lack memory response and even with 
repeated doses, immune responses are not boosted (Kantele, et al., 2012). In pursuit of 
better vaccine for typhoid fever, glycoconjugates vaccines appear to be promising. 
Glycoconjugate vaccines induces T cell immune responses that provides help to  
antibodies against Vi and O-antigens through covalent linkage to protein carrier 
molecules (Maclennan, et al., 2014). The glycoconjugate strategy for generation of new 
Salmonella vaccines is principally an antibody approach and to date a number of the 
vaccine have been generated including Vi-TT, Vi-rEPA, Vi-CRM and Vi-DT 
(Maclennan, et al., 2014). Importantly, the Vi-TT and Vi-rEPA are already licenced for 
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in-country use in India and China respectively (Maclennan, et al., 2014) (Table 1-A and 
Table 1-B).   
 
1.7.3 Vaccine candidates for Salmonella bacteraemia 
No human vaccine is currently available for S. Typhimurium, S. Enteritidis, and S. 
Paratyphi A and B. Efficacy for two licenced vaccines for S. Typhi (Vi CPV and Ty21a) 
are poor and it is not known whether they could provide cross-protection to NTS. 
Antibodies to Salmonella targeting moieties on the outer surface including Vi, O and H 
antigens of Salmonella are thought to mediate protection (Maclennan, et al., 2014). These 
antigens (Vi, O and H antigens) are highly immunogenic and have been proposed as 
vaccine candidates (Brenner, et al., 2000, Maclennan, et al., 2014).  
S. Typhimurium LPS has considerable potential as a vaccine target and is being develop 
as a conjugate vaccine to  overcome  short-lived T cell independent immunity elicited by 
LPS alone (MacLennan, 2013). In mice OMP and FliC induce both T cell and antibody 
immunity and are also being investigated as vaccine candidates (Simon, et al., 2011, 
Simon & Levine, 2012). Whether or not OMP or FliC co-administered or incorporated 
into conjugate vaccine would consolidate the protective efficacy is not known.    
A number of challenges have been noted in developing vaccines for NTS. For instance, 
flagellin is not constitutively expressed by S. Typhimurium during infection due to its 
phase variable expression and this might cause problems as a vaccine candidate 
(Maclennan, et al., 2014) . Immunisation with OmpC and OmpF and OmpD confers  
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protection in mice challenge studies (Cunningham, et al., 2007, Gat, et al., 2011) but the 
production of  purified Omp antigens is  complicated by multiple spanning domains 
(Maclennan, et al., 2014).  
Generalized Modules from Membrane Antigens (GMMA) technology provide an 
innovative strategy (purification is straight forward and economical) to maintain the 
conformation integrity of Salmonella antigen (Maclennan, et al., 2014). GMMA vaccines 
can deliver both surface polysaccharides and outer membrane proteins to the immune 
system and are more immunogenic compared to the glycoconjugate vaccine in mice 
(Maclennan, et al., 2014). GMMA reactogenicity and immunogenicity in humans are not 
known. 
In the recent years protein arrays have enabled the screening of sera for antibodies 
targeting thousands of Salmonella proteins. Lee et al recently identified  potential vaccine 
candidates including SseB  by uncovering overlapping antibodies targeting  protein 
antigens in serum from mice immunised with live attenuated  Salmonella and  children 
convalescing from invasive NTS disease (Lee, et al., 2012). Furthermore, important 
Salmonella protein antigens including PagC, OmpA, Hly-E and GroEL that are targeted 
by the host immunity were uncovered in a study of  Bangladeshi patients with acute 
typhoid and those with febrile illness due to other causes (Charles, et al., 2010). These 
antigens are now being explored to evaluate their potential to induce protection, 
particularly as subunit vaccine in pre-clinical phase (Lee, et al., 2012). Protein arrays 
approach in the discovery of candidate vaccine targets will help in refining the current 
vaccines and generation of better novel vaccines for Salmonella.   
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As part of vaccine broader strategy in development of Salmonella vaccines, it will be 
important to ensure that the immunity generated by a candidate vaccine is cross-
protective (targeting S. Typhi, S. Paratyphi, S. Typhimurium, and S. Enteritidis, S. Dublin 
and S. Stanleyville). O-antigen based conjugated vaccines might offer cross-protection 
against other non-encapsulated serovars within the same group. Other groups have 
proposed to generate a multivalent vaccine made of 5-6 conjugates covering all invasive 
Salmonella disease (Simon & Levine, 2012, Maclennan, et al., 2014) 
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Table 1-A: Licensed vaccine for S. Typhi 
Vaccine 
type 
Vaccine  Description   Advantage  Disadvantage  
Live 
attenuated 
Ty21a  
(Licenced  for 
adults and 
children > 5 yrs) 
(Germanier & 
Fuer, 1975, 
Guzman, et al., 
2006) 
S. Typhi Ty2 
mutation in Vi 
polysaccharide 
and galE gene 
Some cross 
protection 
against S. 
paratyphi B 
Not licenced for 
infants  and low 
efficacy  
Vi Vi CPV 
(Licenced  for 
adults and 
children > 2 yrs) 
(Khan, et al., 
2010) 
 
S. Typhi purified 
Vi 
Single dose 
and low 
reactogenicity  
Not licenced for 
infants. Low 
efficacy. Lack of 
memory and 
affinity 
maturation. Only 
protects against 
S. Typhi 
Vi 
conjugate 
Vi-EPA 
(Licenced in 
China) (Szu, 
2013) 
 
S. Typhi Vi 
conjugated to 
recombinant P. 
aeruginosa 
exoprotein A 
T dependent 
antibody 
response for 
memory 
induction and 
affinity 
maturation. 
Low 
reactogenicity  
Only protects 
against S. Typhi 
Vi-tetanus toxoid 
(Licenced in  India) 
(Szu, 2013) 
S. Typhi Vi 
conjugated to 
tetanus toxoid 
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Table 1-B: Vaccines under development targeting Salmonella serovars 
Type Vaccine  Description   Advantage  Disadvantage 
New live 
attenuated oral 
M01ZH09 (Hindle, et 
al., 2002, Kirkpatrick, 
et al., 2006) 
Mutation in 
phoP/phoQ 
 
B and T cell 
immunity 
 
Reduced need for 
multiple dosing 
Breadth of coverage 
may be limited by 
insufficient 
expression of key 
antigens 
Ty800 (Hohmann, et 
al., 1996) 
Mutation in aroC, 
ssaV 
CVD 908-htrA 
(Tacket, et al., 2004) 
Mutation in aroC, 
aroD, htrA 
CVD 909 (Wahid, et 
al., 2007) 
Mutation in aroC, 
aroD and htrA, 
constitutively 
expresses Vi 
Vi  conjugate Vi-diphtheria toxoid 
(Szu, 2013) 
Vi conjugated to 
diphtheria toxoid 
T dependent 
antibody 
response.  Low 
reactogenicity  
Only protects 
against S. Typhi 
Vi-CRM (van 
Damme, et al., 2011, 
Bhutta, et al., 2014) 
Citrobacter Vi 
conjugated to 
diphtheria toxoid  
Combination 
conjugate 
O-polysaccharide 
conjugate plus Vi-
conjugate (Simon & 
Levine, 2012) 
Paratyphi A O-
polysaccharide 
conjugate to carrier 
protein formulated 
with Vi-conjugated 
Broader coverage 
with a single 
vaccine 
 
Recombinant 
proteins 
OmpC, OmpF and 
OmpA(Toobak, et al., 
2013) 
 B and T cell 
immunity  
Antigen 
conformation may 
limit ability to 
induce B cell 
immunity 
Proteins 
purified from 
whole 
Salmonella 
OmpC and OmpF 
(Salazar-Gonzalez, et 
al., 2004, Secundino, 
et al., 2006), OmpD 
(Cunningham, et al., 
2007) 
 B and T cell 
immunity. 
Potential for pan 
immunity 
Purification of  
integral  membrane 
proteins difficult 
GMMA S. Typhimurium and 
S. Enteritidis GMMA 
(MacLennan, 2013) 
S. Typhimurium 
and S. Enteritidis 
GMMA 
Potential for pan 
immunity.  Easy 
to manufacture 
and at low cost 
Reactogenicity and 
immunogenicity in 
man not known 
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1.8  RATIONALE 
NTS and S. Typhi bacteraemia remain important public health problem in Malawi and 
elsewhere in Africa and Asia. Currently, there’s no vaccine for NTS bacteraemia and the 
vaccines available for S. Typhi cannot be used in children in under 2 years. There’s is a 
knowledge gap as to what naturally constitutes protective immunity to invasive 
Salmonella disease and how this develops in children from Salmonella endemic regions 
to inform the development of an effective vaccine. This thesis investigates the following;  
1. Development of antibody and T cell immunity to Salmonella in healthy and 
invasive Salmonella infected Malawian children. 
2. Relationship between Salmonella exposure within the GIT and development of 
Salmonella-specific serum immunity in healthy Malawian children. 
3. Model natural Salmonella infection immunizing events within the gut mucosa by 
oral Ty21a typhoid vaccination in healthy adults from UK. 
The hypotheses investigated in this thesis are;  
1. Gut localized or systemic Salmonella exposure induces the development of 
antibody and T cell immunity that has the potential to protect against subsequent 
Salmonella infection and particularly invasive Salmonella disease. 
2. Oral Ty21a vaccination induces the development of Salmonella-specific T cells 
and these might provide insight into natural immunizing events occurring within 
the gut mucosal compartment.  
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CHAPTER 2: STUDY DESIGNS, PARTICIPANTS, MATERIALS AND 
METHODS 
 
2.1 DEVELOPMENT OF ADAPTIVE IMMUNITY TO NONTYPHOIDAL 
SALMONELLA IN MALAWIAN CHILDREN 
2.1.1 Study design and participants 
A prospective cross-sectional study was conducted among healthy Malawian children 
aged 0 to 60 months to characterise the acquisition of S. Typhimurium-specific T cell and 
antibody immunity with age. Study participants were children attending vaccination 
clinic, health check clinics and newborns in the maternity ward at Ndirande Health 
Centre (NHC). Furthermore adults were recruited in this study as controls. Following 
study approval by the College of Medicine  Ethics Committee (COMREC) (section 
2.1.6), the study team (including myself as the study investigator, research nurse and the 
MLW science communication team) conducted the study specific sensitization meetings 
with NHC healthy workers (Clinicians, Nurses and Healthy Surveillance Assistants) and 
Ndirande community leaders (headmen and religious leaders). These sensitization 
meetings were aimed at bringing awareness of the research study at NHC and focussed 
on discussing information contained in the study information sheets. Study specific 
sensitization meetings are useful as they help to eliminate misinformation about the 
research study objectives, rationale and specific procedures. The recruitment process was 
conducted by the study research nurse. Recruitment process began with group 
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sensitisation talk given to parents and guardians attending NHC. Children’s parents and 
guardians who were keen to participate in the study were sensitised individually and their 
child recruited into the study provided they consented. Study participants were recruited 
consecutively provided they were meeting entry criteria including the specific age group 
(Figure 2.1 and section 2.1.3). Study specific samples were collected by the research 
nurse and transported to the laboratory for immunological investigations (section 2.1.7). 
 
Figure 2. 1: Study design; Development of adaptive immunity to NTS  
Eighty healthy Malawian children of varying ages (0-60 months) as indicated in figure 
2.1, were recruited. Twenty healthy adults were also recruited in the study as controls. 
5ml venous blood was collected from all children except for 0 month group (newborns), 
where blood was collected from the umbilical cord of the placenta post-delivery. Blood 
samples were collected and processed as described in methods section 2.1.7. 
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2.1.2 Sample size 
When this study was being conducted there were no data on how variable the responses 
would be, and how they might vary with age. To illustrate the power of the study to 
detect an effect the situation that the relationship of immune response (Salmonella-
specific T cells producing cytokines) to age is linear was considered. With 80 subjects 
whose ages ranged from  0 to 60 months (resulting in a standard deviation for age (years) 
of about 1.4) there is  80% power to detect that the slope of the line differs from zero at 
the 5% significance level if the slope is at least 0.21 standard deviation / year of age.  
 
2.1.3 Inclusion and exclusion criteria  
Children aged between 0 and 60 months were recruited provided they were medically 
well. Study exclusion included; children presenting to NHC with fever >38°C, severe 
malnutrition (weight-for-age<60% or weight-for-height<80%), malaria parasitaemia, date 
of birth (exact age) not known, known HIV-positive (documented in child health 
passport) or clinical HIV/AIDS and those that tested positive using rapid HIV tests 
(children aged <18 months) (who tested positive  were referred to early infant diagnosis 
(EID) clinic  for HIV-DNA confirmatory test). HIV exposed children (born from HIV 
infected mothers), either uninfected or infected were also excluded from the study. 
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2.1.4 Study location  
Participants were recruited at NHC (vaccination clinic, under-five clinic and maternity 
ward) in Blantyre district. NHC provide primary health care within the Blantyre city. 
According to Blantyre district health office (DHO) and QECH 2010/2011 annual report, 
it was projected that NHC to have catchment population (those receiving service from the 
health facility) of about 221,217 in the year 2012 (MCI, 2013). Blood was collected from 
study participants at NHC and   transported at room temperature (RT) to Malawi 
Liverpool Wellcome Trust Laboratories (MLW) located at Queen Elizabeth Central 
Hospital (QECH), Blantyre for immunological investigations. 
 
2.1.5 Blood stream infection surveillance   
Queen Elizabeth Central Hospital (QECH) is a 1,250 bed teaching hospital and the 
largest government hospital in Malawi, providing free health care to Blantyre district 
(population approximately 1 million). QECH is the only inpatient paediatric facility for 
non-fee paying patients in Blantyre. MLW has been conducting routine blood stream 
infection (BSI) surveillance of febrile children presenting to QECH since 1997. MLW 
team (including laboratory technicians, research nurses and clinicians) performed these 
experiments. Blood-cultures are obtained from febrile children who are thick-film-
negative for malaria parasites or critically ill, irrespective of malaria infection. Blood-
culture is undertaken using a paediatric bottle BacT/Alert® PF (BioMerieux, UK) and 
isolates identified using standard techniques (Gordon, et al., 2002). 
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2.1.6 Ethical consideration 
The study was compliant with Good Clinical Practice (GCP) regulations and conducted 
in accordance with the 1996 ICH GCP guidelines and the 2000 Declaration of Helsinki. 
Ethical approval (protocol number P.08/09/815) was granted by the College of Medicine 
Ethics Committee (COMREC). Informed consent was obtained from a parent or guardian 
of each participating child. 
2.1.7 Laboratory methods 
2.1.7.1 Collection of peripheral blood sample 
Venous blood samples were collected by an experienced study research nurse. A 
tourniquet was applied and the site for venipuncture sterilized with alcohol prep. The 
needle was inserted into the selected vein and a total of 5 ml of blood was drawn from 
each child. Blood was transferred into appropriate tubes i.e. 1ml BD vacutainer® serum 
tube, 3ml BD vacutainer® sodium heparin and 1ml BD microtainer® 
ethylenediaminetetraacetic acid (EDTA) (all Becton Dickinson, USA) and transported to 
the laboratory for testing. 
 
2.1.7.2 Collection of umbilical cord blood samples 
The umbilical cord blood specimen was collected by experience study nurse ex-utero as 
previously described (Pafumi, et al., 2011) with minor modifications. The placenta was 
placed on a sterile cloth and the umbilical cord was allowed to hang down over the side. 
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The umbilical cord and the blood vessel were cleaned and disinfected with betadine 
solution and alcohol. 5ml of cord blood was drawn from several places where necessary 
using a sterile needle and syringe. Blood was transferred into appropriate tubes i.e. 1ml 
BD vacutainer® serum tube, 3ml BD vacutainer® sodium heparin and 1ml BD 
microtainer® EDTA (all Becton Dickinson, USA) and transported to the laboratory for 
testing. 
 
2.1.7.3 HIV testing  
Children with unknown HIV status were tested using HIV rapid test kits, according to 
national guidelines. Finger prick blood was collected using an EDTA coagulated 
capillary tube (Becton Dickinson, USA). Two rapid HIV test kits were used in parallel; 
Determine
TM
 HIV1/HIV2 (Abbott Laboratories, Japan) and Unigold
TM
 (Trinity Brotch, 
Dublin). A third test SD
TM
 Bioline HIV1/2 3.0 (Standard Diagnostics, Korea) was used as 
a tie-breaker in case of discrepant results. Testing was performed, according to the 
manufacturer’s instructions.  
 
2.1.7.4 Malaria testing  
Research study nurse collected blood from the finger prick using EDTA coagulated 
capillary tube (Becton Dickinson, USA) and prepared a thick smear for malaria parasite 
slides (MPS) by transferring a drop of blood from the capillary tube onto a clean labelled 
slide. A drop of blood on the slide was spread and air dried for 10 minutes at room 
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temperature. These slides were transported to Blantyre Malaria Project (BMP) 
Laboratory at NHC for malaria testing. The BMP laboratory team (Laboratory 
Technicians)  stained air dried slides with field stain A and B, air dried for 10 minutes at 
room temperature and examined on high power field (HPF) microscope as previously 
described (Bailey, et al., 2013), with minor modifications. Parasite examination was 
verified by another laboratory technician before results were released. 
 
2.1.7.5 Preparation and storage of serum  
A total of 1ml blood was collected in BD vacutainer® serum tube and transported to the 
laboratory within 4 hours. Cloated whole blood was centrifuged at 500g for 10 min and 
serum isolated. 200µl aliquots of serum were stored at -70°C until the day of testing.  
 
2.1.7.6 Preparation of live S. Typhimurium for SBA  
A well characterised S. Typhimurium strain D23580 (MacLennan, et al., 2008, Kingsley, 
et al., 2009) was grown on a Luria Bertani (LB) agar (Sigma Aldrich, USA) plate 
overnight and a single colony was selected and inoculated into 10ml Luria Bertani (LB) 
broth (Sigma Aldrich, USA). This is a clinical strain isolated from a HIV negative child 
in 2004, at the peak of a Blantyre multidrug-resistant (MDR), invasive NTS epidemic 
(MacLennan, et al., 2008, Kingsley, et al., 2009). The inoculated broth container was 
loosely capped to permit gas exchange and incubated at 37⁰C for 18-24 hours to achieve 
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stationary growth phase. The culture suspension was briefly vortexed and 100µl 
transferred into pre-warmed fresh 10ml LB broth, tightly-capped (to avoid spillage) and 
incubated at 37⁰C on a rocker plate (Stuart Scientific, Belgium) at 20 rpm for 2 hours, to 
achieve a log growth phase. Two 1.5ml aliquots of S. Typhimurium strain D23580 in log 
growth phase were made in 2ml micro tubes (Eppendorf, Hamburg, Germany) and 
centrifuged at 6000rpm for 5 minutes and the supernatants were discarded. S. 
Typhimurium strain D23580 pellets were washed thrice with 1ml sterile phosphate 
buffered saline (PBS) at 6000 rpm. S. Typhimurium strain D23580 pellets were re-
suspended in 500μl of PBS, and pooled to achieve approximately 1x108 cfu/ml (Miles, et 
al., 1938). Viable S. Typhimurium strain D23580 colony forming units  were confirmed 
using the Miles and Misra as described before (Miles, et al., 1938). S. Typhimurium 
D23580 was diluted with PBS in 96 micro-well plates (Sarstedt, Germany), in 10-fold 
dilutions. LB agar plates were divided into 8 sections and in each section triplicates of 
10μl (S. Typhimurium strain D23580 preparation) from 96 micro-well plate were 
inoculated to the corresponding sections and aerobically incubated at 37⁰C for 24 hours. 
S. Typhimurium strain D23580 colony forming units (CFU) per ml were calculated as 
follows: CFU per ml = average number of colonies at each dilution x 100 (volume factor) 
x dilution factor. 
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2.1.7.7 Preparation of S. Typhimurium homogenate for T cell stimulation  
A single colony of S. Typhimurium strain D23580, from an LB agar plate, was inoculated 
into 10ml LB broth and incubated at 37⁰C for 18-24 hours. Two 5ml aliquots were 
centrifuged at 4,000rpm for 5 minutes and the supernatants were discarded. S. 
Typhimurium strain D23580 pellets from both tubes were re-suspended in 2.5ml of PBS 
and pooled in a single tube. Two 1ml aliquots were transferred in 2ml screw cap micro 
tube (Sarstedt, Germany) and topped up with 100μm beads (Biospec products, USA). S. 
Typhimurium strain D23580 aliquots were bead beaten using the Mini-Bead beater
TM
 
(Biospec products, USA) thrice, on high setting, for 120 seconds. The sample was 
inverted several times between each bead beating, to allow cooling. Samples were 
allowed to separate for 5 minutes and the bead-free supernatant portions were transferred 
into fresh 2ml screw cap micro tubes (Sarstedt, Germany). Protein concentration of S. 
Typhimurium strain D23580 homogenate and protein standards were determined using 
Thermo Scientific™ Bicinchoninic Acid (BCA) Protein assay (Thermo Scientific, UK). 
A standard curve was used to compute the S. Typhimurium strain D23580 homogenate 
protein concentration. The protein concentration was adjusted using sterile PBS, and S. 
Typhimurium strain D23580 homogenate aliquots at 100μg/ml were stored -20⁰C.  
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2.1.7.8 Intracellular cytokine staining for detection  cytokine producing T cells  
Intra-cellular cytokine staining (ICS) is an immunological technique that allows 
simultaneous detection and quantification of cytokine producing cytokine cells (T cells) 
at single cell level and detection of cellular phenotype (memory T cell subsets, CD4+ T 
cells). In addition this assay can detect cell viability and also proliferation. ICS for 
antigen specific T cells has been used as a marker of immune memory following natural 
infection and also in vaccine studies (De Rosa, 2012, Saade, et al., 2012, Freer & Rindi, 
2013). Taken together ICS for antigen specific T cells is both a functional and phenotype 
assay and can be used to evaluate immunogenicity, poly-functionality and memory 
profile.  
 
Whole blood (WB)  T cell ICS assay was performed as previously described (Nyirenda, 
et al., 2010)  with minor modifications. WB for ICS assay was collected in 3ml BD 
vacutainer® sodium heparin (Beckon Dickson, UK). 450μl aliquots of fresh WB were 
stimulated, on the day of collection with 50μl of bead-beaten S. Typhimurium strain 
D23580 at a final protein concentration of 1μg/ml, or with both phorbol myristate acetate 
(PMA) 1µg/ml and ionomycin (ION) at 10µg/ml (all Sigma Aldrich, USA). Furthermore, 
all conditions were co-stimulated with anti-CD28/49d (Becton Dickinson, USA), for 6 
hours at 37∘C in aerobic incubator. At 2 hours, intra-cellular cytokine release was 
inhibited with 1µl of BD GolgiStop™ (Becton Dickinson, USA) at 106 cells/mL. At 6 
hours, cells from 200μl of each sample were lysed with 2ml of 1X FACs lysing solution 
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(Becton Dickinson, USA) then permeabilised with 500μl of 1X permeabilising solution 
(Becton Dickinson, USA). Cells were washed with PBS/0.5% bovine serum albumin 
(BSA) buffer (Sigma Aldrich, USA) and stained with 3μl each of surface antibodies: 
CD3-APC Cy7, CD4-PB (all Becton Dickinson, USA) and 5μl each of intra-cellular 
cytokine antibodies: IFN-γ-PE, TNF-α-FITC, and IL-2-APC (all Becton Dickinson, 
USA). Cells were fixed in 200μl 1% formaldehyde/PBS and 20,000 events on CD4+ T 
lymphocyte gate were acquired immediately using a CyAN ADP
TM
 flow cytometer 
(Beckman Coulter, USA). CD3+CD4+ T cells producing IFN-γ, TNF-α and IL-2 were 
defined as CD3+CD4+IFNγ+, CD3+CD4+TNFα+, and CD3+CD4+IL2+ (Figure 2.2). 
Further analysis for polyfunctional CD4+ T cells producing single, double and triple 
cytokines were further analysed by Boolean gates using Flow Jo
TM
 version 7.6.5 software 
(Tree star, USA).  
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Figure 2. 2: Gating strategy for CD4+ T cell producing cytokines 
Lymphocytes were gated using side scatter (SSC) and forward scatter (FSC) 
characteristics (Figure 2.2A). Lymphocytes expressing CD3 were gated from the 
lymphocytes gate (Figure 2.2A, 2.2B). CD3+CD4+ T cells were gated from the CD3+ 
lymphocyte gate (Figure 2.2B, 2.2C). CD3+CD4+ T cells producing IFN-γ were gated 
from CD3+CD4+ T cell gate (Figure 2.2C-F). Representative un-stimulated, S. 
Typhimurium strain D23580 and PMA/ION stimulated plots are shown (Figure 2.2D-F). 
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2.1.7.9 Immunopheno-typing for quantification of CD4+ memory  T cell subsets  
Immuno-phenotyping (IPT) is an immunological technique used to detect and quantify 
cellular proteins (such as CD3) which are bound by flourochrome conjugated antibodies 
or marker (such as CD3-APC) and these are read out by flow cytometry. IPT is  
commonly  used to detect and quantify memory CD4+ T cell subsets including effector 
memory (CD45RO+CCR7-), central memory (CD45RO+CCR7+)  and naïve (CD45RO-
CCR7+) (Mackay, et al., 1990, Bunce & Bell, 1997). Whole blood (WB) for immuno-
phenotyping was collected in 1ml BD microtainer® ethylenediaminetetraacetic acid 
(EDTA) (all Becton Dickinson, USA). 200µl of WB was stained with antibodies: CD3-
APC, CD4-PB, CD45RO-FITC and CCR7-PE (all Becton Dickinson, USA) and RBCs 
lysed with 2ml of 1X FACS lysing solution (Becton Dickinson, USA). Cells were 
washed with PBS (Sigma Aldrich, USA) and fixed in 200μl (1% formaldehyde/PBS). Up 
to 20,000 events on CD4+ T lymphocyte gate were acquired immediately on CyAN 
ADP
TM
 flow cytometer (Beckman Coulter, USA) and analysed using FlowJo
TM
 version 
7.6.5. Lymphocytes were gated by their forward scatter (FSC) and side scatter (SSC) 
characteristics. Naïve T cells were defined as CD4+CD45RO-CCR7+, effector memory 
(EM) T cells as CD4+CD45RO+CCR7- and central memory (CM) T cells as 
CD4+CD45RO+CCR7+ (Figure 2.3) (Mackay, et al., 1990, Bunce & Bell, 1997). 
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Figure 2. 3: Gating strategy for CD4+ memory T cells 
From the CD3+CD4+ T cell gate (Figure 2.3A) CD4+ memory T cells were defined by 
the expression of CD45RO and CCR7 as shown (Figure 2.3B). We defined naïve T cells 
as CD4+CD45RO-CCR7+, effector memory (EM) T cells as CD4+CD45RO+CCR7- and 
central memory (CM) T cells as CD4+CD45RO+CCR7+.   
 
2.1.7.10  Serum bactericidal assay for quantification of  antibody immunity  
Serum bactericidal activity (SBA) assays were performed as previously described 
(MacLennan, et al., 2008). Serum or PBS was mixed with S. Typhimurium strain D23580 
at 1.0x10
6
 cfu/ml (10µl of the prepared viable bacteria at 1 x10
7
 cfu/ml were added to 
90µl of undiluted freshly-thawed serum), prepared as described in section 2.1.7.6. Test 
samples were placed in a 37°C aerobic incubator for 180 minutes. Test samples were 
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serially diluted and plated in triplicate on Luria Bertani (LB) agar. Viable colony count of 
Salmonella was done after 24 hours of incubation as described in section 2.1.7.6. Log10 
change in S. Typhimurium cfu/ml from the baseline (PBS condition) was reported. As 
previously described (MacLennan, et al., 2008). 
 
2.1.7.11 Serum ELISA for quantification of anti-S. Typhimurium-IgG 
antibody 
Enzyme-linked immunosorbent assay (ELISA) is an immunological technique that has 
been applied for detection of memory B cell secreted antibodies to a specific antigen 
including Salmonella in serum or plasma. ELISA for detection of antibodies to specific 
pathogen has been used to evaluate immune responses elicited by a vaccine or natural 
infection, longevity of antibody responses, diagnosis of infection and surveillance 
(Carlsson, et al., 1975, Beasley, et al., 1981, Strid, et al., 2007). ELISA for detection of 
Salmonella specific antibodies were performed as previously described (Cunningham, et 
al., 2007) with minor modifications. Nunc-Immuno
™
 MicroWell
™
 96 well solid plates 
(Sigma Aldrich, USA)  were coated overnight using 100µl of carbonate-bicarbonate 
buffer (Sigma Aldrich, USA) per well containing antigens adjusted to 5µg/ml: S. 
Typhimurium O;4,5-LPS (ALEXIS Biochemicals), S. Typhimurium-OMP, S. 
Typhimurium-FliC (MacLennan, et al., 2010) (S. Typhimurium-OMP and S. 
Typhimurium-FliC were generated and kindly donated by Adam Cunningham laboratory 
[University of Birmingham]) and E. coli- LPS 0127:B8 (Sigma Aldrich, USA). Further 
description of these antigens is provided in Table 2-A below. Plates were washed with 
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wash buffer (PBS plus 0.05% Tween 20) and blocked with 200µl/well blocking buffer 
(PBS plus 1% BSA) for 1 hour at 37°C. Test serum at 1:20 in dilution buffer (PBS plus 
0.05% Tween 20 plus 1% BSA) was serially diluted 3-fold and incubated at 37°C in 
aerobic incubator for 1 hour. After washing, 100µl of 1:2000 secondary Goat Anti-human 
IgG-AP antibodies (Southern Biotech, USA) were added and incubated for 1 hour at 
37°C in aerobic incubator. Finally, after washing, 100µl of SIGMAFAST
™
 p-Nitrophenyl 
phosphate substrate (Sigma Aldrich, USA)  was added to each plate and the plate was 
read after 30 minutes, using a Bio Tek
TM
 reader ELx800 (Bio Tek Instruments, USA) at 
405nm. Specific antibodies were determined using arbitrary measurements (Figure 2.4). 
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Figure 2. 4: Quantifying anti-S. Typhimurium O; 4,5 LPS IgG antibody in serum 
Antibody titres targeting S. Typhimurium LPS in serum were determined by arbitrary 
measurements; 1 (cut off absorbance) was divided by the dilution factor for each sample.   
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Table 2- A: S. Typhimurium antigens used in antibody ELISA experiments  
S. Typhimurium antigens  Description of antigens 
1. S. Typhimurim LPS 
Commercial S. Typhimurium 0;4,5 antigen 
(ALEXIS Biochemicals) 
2. S. Typhimurim OMP 
Crude outer membrane protein generated from S. 
Typhimurium 
3. S. Typhimurim FliC 
FliC filament protein of flagellin generated from 
S. Typhimurium 
4. E. coli-LPS 127:B8 
Commercial E. coli-LPS 127:B8 (Sigma Aldrich, 
USA) was used as control 
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2.2  SALMONELLA EXPOSURE AND DEVELOPMENT OF SPECIFIC 
IMMUNITY IN MALAWIAN CHILDREN 
2.2.1 Study design and participants  
A prospective longitudinal cohort study was conducted among healthy children and their 
mothers to determine the relationship between Salmonella exposure within the 
gastrointestinal tract (GIT) or oropharynx and development of serum immunity to 
Salmonella. Mothers were recruited to determine whether maternal breast milk 
bactericidal activity is associated with prevention of Salmonella colonization of the GIT 
among breastfed children (Figure 2.5). Children were recruited from 6 months of age and 
not from birth because there was limited time to recruits and follow study participants for 
a period longer than 18 months. However, Chapter 3 describes that at 6 months children 
exhibit poor SBA to Salmonella as passively acquired maternal antibodies decline in 
blood circulation hence limiting this immunity as the confounder at baseline (study 
entry).   
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Figure 2. 5: Study design; Salmonella exposure and development of immunity 
 
A total of 60 healthy children and their mothers were recruited when children were aged 
6 months and followed up to until when they were 18 months old. Study participants 
were followed at monthly intervals (children) and six-month intervals (mother) for study 
specific procedures as in indicated. Stool, serum and oropharynx swab were collected 
from each children while serum and breast milk were collected from mothers during 
follow-up (Figure 2.5). All samples collected and processed as described in laboratory 
methods section 2.2.8. 
 
Following the study approval by COMREC (see below), the study team (including 
myself as the study investigator, research nurse and the MLW science communication 
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team) conducted the study specific sensitization meetings with ZHC healthy workers 
(Clinicians, Nurses and Healthy Surveillance Assistants) and Zingwangwa community 
leaders (village headmen and religious leaders). These sensitization meetings aimed at 
bringing awareness of the research study at ZHC and focussed on discussing information 
contained in the study information sheets. The recruitment process was conducted by the 
study research nurse. Study recruitment began with group sensitisation talk that was 
given to the parents and guardians attending ZHC. Children’s mothers who were keen to 
participate in the study were sensitised individually and their child recruited into the 
study provided they consented. Study participants were recruited consecutively provided 
they were meeting entry criteria including the specific age group (section 2.2.3). Study 
specific samples were collected by the research study nurse and transported to the 
laboratory for microbiological and immunological investigation (section 2.2.8). 
 
2.2.2 Sample size 
When this study was being conducted, the incidence of Salmonella exposure in healthy 
children for our study population was not known. However, a study with a similar design 
in Mexico showed that 40% of children were colonized or had minimally symptomatic 
infection with Salmonella during the first year of life (Cravioto, et al., 1990). A ratio of 
1.5 (60% unexposed/40% exposed) was assumed, percentage of unexposed with outcome 
10% (serum bactericidal activity) and percentage of exposed with outcome 50%. To 
detect 40% difference in serum bactericidal activity between Salmonella exposed and 
unexposed among children aged between 6 and 18 months with 80% power at the 0.05 
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significance level and allowing for 20% loss to follow up, a total  60 children aged 6 
months were recruited.   
 
2.2.3 Inclusion and exclusion criteria  
Study participants were only recruited as pairs (child and mother). Healthy children 
attending Zingwangwa Health Centre (ZHC) vaccination clinic aged 6 months were 
recruited. Mothers to these children were also recruited provided they were medically 
well. Children exclusion criteria included: children born preterm (before 38 weeks), 
known HIV-positive (documented in child health passport) or clinical HIV/AIDS and 
those that tested positive using rapid HIV tests (aged < 18 months were referred to early 
infant diagnosis (EID) clinic for HIV-DNA confirmatory test). HIV infected mothers and 
HIV exposed children were also excluded from the study. Children presenting with acute 
illness including fever >38°C, and residence outside the geographical wards that are 
situated within 5 km from ZHC were also excluded from the study.   
 
2.2.4 Study location 
Participants were recruited into the study at ZHC (under-five clinic) in Blantyre district. 
ZHC provide primary health care within the Blantyre city. According to Blantyre district 
health office (DHO) and QECH 2010/2011 annual report, it was projected that ZHC to 
have catchment population (those receiving service from the health facility) of about 147, 
676 in the year 2012 (MCI, 2013). Study specific samples were collected at ZHC and 
Participants, Materials and Methods 
 
77 
 
transported to MLW for microbiological and immunological investigations as described 
in laboratory methods section 2.2.8. 
 
2.2.5 Tracing and mapping of study participants homes (Follow up)  
During the first study specific visit, the research study nurse or study field worker 
obtained sketch maps and contact details from each study participant mother to locate 
their home. Study field worker, used these sketch maps and contact details to visit each 
study participant home and obtain exact location GPS co-ordinates. This information was 
used to trace study participants in case of missing their scheduled visit, and the GPS co-
ordinates were used to investigate Salmonella epidemiology (i.e. Salmonella transmission 
pattern). 
 
2.2.6 Study participants feeding practices and medical history  
At each study specific visit, a questionnaire was administered to mothers to explore child 
feeding practices. Mothers were also asked to provide medical history for their child. 
 
2.2.7 Ethical consideration  
The study was compliant with Good Clinical Practice (GCP) regulations and conducted 
in accordance with the 1996 ICH GCP guidelines and the 2000 Declaration of Helsinki. 
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Ethical approval (P.01/13/1327) was granted by COMREC. Informed consent was 
obtained from a parent or guardian of each participating child and mothers. 
 
2.2.8 Laboratory methods  
2.2.8.1 Collection of peripheral blood sample  
Blood samples were collected as described in section 2.1.7.1 at all scheduled visits 
(Figure 2.6). 
 
2.2.8.2  Preparation and storage of serum  
Serum samples were prepared and stored as described in section 2.1.7.5. 
 
2.2.8.3 Serum Bactericidal Assay for quantification of S. Typhimurium specific 
antibody mediated immunity 
Quantification of serum bactericidal activity (SBA) were performed as described in 
section 2.1.7.10 
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2.2.8.4 Collection of breast milk and storage  
Breast milk from mothers was collected to investigate whether breast milk kills S. 
Typhimurium ex vivo and speculate whether breast feeding prevents colonisation of 
Salmonella in the GIT of breast fed babies. To ensure that breast milk was properly 
collected by study participating mothers. At the clinic mothers were asked to wash their 
hands with soap and running water before expressing milk. Mothers were asked to sit 
somewhere comfortable, relax, have their baby close by and if necessary warm their 
breasts to express milk. Breast milk was self-expressed by mothers. A total of 5ml breast 
milk was collected in a sterile universal container, and transported to the laboratory 
within 4 hours of collection. At the laboratory, milk samples were stored at 4º C until 
processing on the same day of collection. Milk was centrifuged at 400g for 20 minutes 
and the fatty layer was discarded. Breast milk fluid (supernatant) was aspirated and 
aliquoted in 2ml volumes and stored at -70º C until when required for testing (Shapiro, et 
al., 2007). 
 
2.2.8.5 Breast milk bactericidal assay for quantification of antibody immunity  
A milk bactericidal assay was developed by optimizing the previously described SBA 
(MacLennan, et al., 2008). S. Typhimurium strain D23580 was adjusted to 1.0x10
6 
cfu/ml 
and incubated at 37°C for 180 minutes with 3 test samples: milk which was non-heated, 
milk which had been heated at 72°C for 30 minutes (preliminary experiments showed 
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that breast milk has factors that promoted Salmonella growth, therefore heated condition 
was considered as a baseline condition) and PBS (Table 2-B).  
 
Table 2- B : Experimental conditions used for evaluation milk bactericidal activity 
Experimental condition  Objective 
1. PBS plus Salmonella Confirm baseline concentration of Salmonella 
2. Milk plus Salmonella  Determine milk bactericidal activity 
3. Heated milk at 72°C plus 
Salmonella 
Inactivate complement and other bactericidal peptides 
 
Test samples were then serially diluted and plated in triplicate on Luria Bertani (LB) 
agar. A colony count of Salmonella was also done after 24 hours of incubation as 
described in 2.1.7.6. Log10 change in Salmonella cfu/ml from the baseline (heated at 
72°C for 30 minutes) was reported. 
 
2.2.8.6  Collection of stool specimens  
Mothers were provided in advance with stool collection containers (Sarstedt, Germany), 
and advised how to collect stool specimens from their children in sterile containers on the 
day they were due to attend study clinic. The spoon in the lid of the container was used to 
collect stool. Stool was collected up to a marked line on the tube and transported to the 
clinic within 8 hours of sample collection. 
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2.2.8.7 Stool processing storage and culture for selective Salmonella  
Stool specimens were stored in the refrigerator at 4ºC and processed for isolation of 
Salmonella on the same day. Stool specimens for DNA extraction were stored as whole 
stool for long term at -70
o
C. Matchstick head-size stool specimen was inoculated directly 
on selective media xylose lysine deoxycholate (XLD) agar plate (Oxoid, UK) and into 
10ml Selenite F broth (Oxoid, UK) and incubated aerobically at 37
o
C for 18-24 hours 
(Figure 2.6).  
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Figure 2. 6: Overview, isolation and identification of Salmonella from stool sample 
The process of isolation and identification of Salmonella from stool is shown. 
Representative images Salmonella colonies on differential culture media are shown. 
 
Selenite F Broth was used to enrich Salmonella from stool which may be in small 
numbers while reducing the growth of faecal coliform, particularly E. coli (Leifson, 1939, 
Wain & Hosoglu, 2008). The mechanism of how selenite F broth inhibit faecal coliforms 
Participants, Materials and Methods 
 
82 
 
is not clear but  selenium toxicity has been implicated that it reacts with sulphur and 
sulphydral groups in critical bacteria cell components (Weiss, 1965). The inoculated 
Selenite F broth was sub-cultured onto an XLD agar plate, and incubated aerobically at 
37
o
C for 18-24 hours, and 1ml of inoculated Selenite F broth was transferred into 2ml 
micro tube (Eppendorf, Hamburg, Germany) and this was stored at -70
o
C for Salmonella 
detection using real time PCR (rt-PCR). Presumptive Salmonella colonies on XLD agar 
(selective and differential media allows preferential growth of  Salmonella and Shigella) 
appear  pink, with or without a black centre (Park, et al., 2012). However other enteric 
bacteria including Citrobacter, Proteus  and Serretia  also grow on XLD and these may 
resemble Salmonella as they also appear pinkish and exhibit black centre due to hydrogen 
sulphide (H2S) production (Park, et al., 2012). Presumptive Salmonella colonies were 
then sub-cultured onto sheep blood agar (SBA) and MacConkey (MAC) agar plates (both 
Oxoid, UK) (spreading both plates for single colonies) and incubated aerobically at 37
o
C 
for 18-24 hours. Suspected Salmonella colonies on MAC agar plate are non-lactose 
fermenters (NLF), and these appear colourless. Proteus species swarm on SBA agar plate 
and is distinguished from Salmonella and other enteric bacteria such as Citrobacter and 
Serretia that do not swarm on SBA. Presumptive Salmonella were then distinguished 
from other enteric bacteria (i.e Citrobacter and Serretia) using biochemical tests 
including triple sugar iron (TSI) agar (Oxoid, UK) and Urea agar (Oxoid, UK). TSI agar 
is used for the determination of carbohydrate fermentation and hydrogen sulphide (H2S) 
production in the identification of Gram-negative bacilli (Hajna, 1945). Salmonella are 
urea negative and TSI acid but with or without gas, and alkaline slope with or without 
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H2S production (Yong, et al., 1985). Further Salmonella identification was determined 
using API® 10S (bio Merieux, France) according to the manufacturer’s instructions. 
Salmonella serovar identification was then determined using standard serological 
grouping (Kauffman-White scheme). This allows identification of Salmonella serovars 
using antisera reactions according to their antigenic properties O (somatic antigen), H 
(flagellin antigen) and Vi (capsular polysaccharide antigen). Salmonella isolates with 
incomplete serological identification (Table 2-C) were archived for molecular 
identification and characterization. All Salmonella isolates were stored at -70 
o
C in 
microbank™ (Pro-lab Diagnostic, UK).  
 
Table 2- C: Salmonella serological tests 
 S. Enteritidis S. Typhimurium S. Typhi 
Salmonella 
species 
PSO + + + + 
PSH + + + + 
O9 antigen + - + - 
O4 antigen - + - - 
Vi antigen - - + - 
HG,m 
antigen 
+ - - - 
Hi antigen - + - - 
Hd antigen - - + - 
H1,2 
antigen 
- + - - 
O5 Antigen  - + - - 
 
Participants, Materials and Methods 
 
84 
 
2.2.8.8 Development of real time PCR for Salmonella detection in stool specimen 
and other fluids  
To determine the pattern of Salmonella exposure within the GIT and the oropharynx both 
stool and oropharyngeal swabs were collected from each child at 1 month intervals. 
Currently, stool culture remain gold standard test for the detection of Salmonella within 
the GIT (WHO, 2003). However, stool culture is less sensitive (< 50%) (Hoffman, et al., 
1984, Matheson, et al., 2010) and time consuming (take no less than 3 days)(Wain, et al., 
2001). This study therefore also aimed to develop real-time PCR (rt-PCR) for Salmonella 
detection in faecal specimens. In Malawi and elsewhere in SSA the commonly isolated 
Salmonella serovars in blood include S. Typhimurium, S. Enteriditis and S. Typhi. To 
begin with, this study aimed at detecting the frequency of S. Typhimurium and S. Typhi 
using rt-PCR, therefore DNA primers sequences for the following genes: invaA 
(targeting all Salmonella serovars), FliC (targeting S. Typhimurim), LPXO (targeting S. 
Typhimurium ST313 strain) and fimbriae (targeting S. Typhi) were generated.   
 
DNA primers were generated using NCBI tool Primer Blast. Table 2-D describes design 
properties of DNA primers generated. Specificity of primers was checked using a 
BLAST search and primer secondary structures with the potential to hinder annealing 
were identified using mfold software version 3.6 (Washington University). Furthermore, 
melting temperature matches and checking for any hairpins was performed using the 
online tool (www.basic.northwestern.edu). Table 2-E and 2-F provides the list of DNA 
primers and probes generated.  
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Table 2- D: Primer design properties 
1. Product size ranging from 80-150bp. 
2. Having a GG, CC, GC or CG (‘G/C-clamp’) at the 3’end is preferable: 2 Gs or Cs 
in the last 5 bases, 1 G or C in the last 3 bases, and an A or T at the 3’end. 
3. Melting temperature 55-60°C, only 1-2°Cs difference between forward and 
reverse primers. 
4. GC content of 50-60%. 
5. Runs of same bases were avoided, especially stretches of >3 Gs or Cs at 3’ end. 
These results in polymerase slippage. 
6. Self-complementarity at 3’ end was avoided. 
7. Any 3’dimer formed by primer annealing to itself or partner must be non-existent 
or very weak (deltaG should be > -2 kcal). Any primer with both terminal delta 
G> -2 and an extendable 3’end (5’overlap) should be avoided. The strongest 
overall dimer should be unstable as well, delta G> -6. 
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Table 2- E: List of primers   
Primer name           Primer 
direction  
 
   Primer code 
Flic-STm 1                 Forward TGCTGATTTGACAGAGGCTAAA 
 
Flic-STm 1                 Reverse  
 
TCGCCTACCTTAACTGCTAAAC 
 
Flic-STm 2                 Forward 
 
GGGAACTGGTAAAGATGGCTATTA 
 
Flic-STm 2                 Reverse 
 
TTCACATCCTCAGTTGCTGTC 
 
LPXO-ST313 1          Forward 
 
TAGTCGAAGATGACGGCTTTG 
 
LPXO-ST313 1          Reverse 
 
CGGTTCAGTACGTTACCATCTT 
 
LPXO-ST313 2          Forward 
 
ACCTCCTATTTCCAGCGAGA 
 
LPXO-ST313 2          Reverse 
 
CTCGCCGTGGAATGGTTT 
 
INVA 1                      Forward 
 
AGCGTACTGGAAAGGGAAAG 
 
INVA 1                      Reverse 
 
CACCGAAATACCGCCAATAAAG 
 
INVA 2                      Forward 
 
TCATCGCACCGTCAAARGA 
 
INVA 2                      Reserve 
 
CGATTTGAARGCCGGTATTATT 
 
Fimbriae-ST  1           Forward 
 
CCGACCAAGTTCCAGATCAA 
 
Fimbriae-ST  1           Reverse 
 
GTTGGTTAGTAGCGAGGTGTT 
 
Fimbriae-ST 2            Forward  
 
CGCGAAGTCAGAGTCGACATAG 
 
Fimbriae-ST 2            Reverse AAGACCTCAACGCCGATCAC 
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Table 2- F: List of probes 
Probe name                                                               Probe description
Flic-STm 1 
 
Fam-TGTTACCGGCACAGCATCTGTTGT-BHQ1 
 
Flic-STm 2 
 
Fam-CCAGCAAGAGTCACCTCACCGTTC-BHQ1 
 
LPXO-ST313 1 
 
Vic-AGCTATGGCGCTGTCGATCAACTT-BHQ1 
 
LPXO-ST313 2 
 
Vic-ACTGCCGTCGCTAAGAAACTGCTT-BHQ1 
 
INVA-1 
 
Fam-TTACGGTTCCTTTGACGGTGCGAT-BHQ1 
 
INVA-2 
 
Fam-ACGCTTCGCCGTTCRCGYGC-BHQ1 
 
Fimbriae-ST 1 
 
Vic-TGGCCAGTAATAATGTCGGGACGA-BHQ1 
 
Fimbriae ST 2 
 
Vic-CATTTGTTCTGGAGCAGGCTGACGG-BHQ1 
 
 
2.2.8.9 Extraction of DNA from stool for PCR testing and sequencing 
To extract DNA for detection of Salmonella and other enteric bacteria in stool using real 
time PCR and sequencing of gut microbial communities, DNA extraction methods that 
allow optimum detection of both Gram positive and Gram negative bacteria were 
adopted.  Approximately 200mg of stool was suspended in 500µl of PBS. Freshly 
prepared, 50ul lysozyme (10mg/ml) (Sigma Aldrich, USA) was added to each sample and 
incubated aerobically at 37 °C for 1 hour. Approximately 300 mg of 0.1mm diameter 
silicon beads (Biospec products, USA) were added to samples to disrupt bacteria at 
2100rpm for 1 minute.  Both the bead beating step and addition of lysozyme steps were 
aimed at enhancing the extraction of DNA from Gram positive and Gram negative 
bacteria. 1.2 ml lysis buffer ASL (Qiagen, Netherlands) was added to each sample and 
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thoroughly homogenized by vortexing. Samples were heated for 5 minutes at 70°C, 
vortexed for 15 seconds and centrifuged at 16,000rpm for 1 min to pellet stool particles. 
An InhibitEX
 
tablet (Qiagen, Netherlands) was added to 1.2 ml supernatant to remove 
PCR inhibitors from DNA extraction preparations, vortexed continuously for 1 minute 
then incubated for 1 minute at room temperature. Samples were centrifuged twice at 
16,000rpm for 3 minutes to pellet inhibitors bound to InhibitEX matrix. 15µl QIAGEN 
Proteinase K (Qiagen, Netherlands), 200μl supernatant and 200μl Buffer AL (Qiagen, 
Netherlands) were mixed and incubated at 70°C for 10 minutes. 200μl of ethanol (96–
100%) was added to the lysate and the mixture was transferred into QIAamp spin column 
(Qiagen, Netherlands)  placed in a 2 ml collection tube and centrifuged at 16,000rpm for 
1 minute. QIAamp spin column was placed on new 2ml collection tube, and tube 
containing the filtrate was discarded. 500μl Buffer AW1 (Qiagen, Netherlands) was 
added to the QIAamp spin column and centrifuged at 16,000rpm for 1 minute. 500μl 
Buffer AW2 (Qiagen, Netherlands) added to QIAamp spin column and centrifuged twice 
at 16,000rpm for 3 minutes. 200μl Buffer AE (Qiagen, Netherlands) was added directly 
onto the QIAamp membrane incubated for 1 minute at room temperature, then samples 
were centrifuged at 16,000rpm for 1 minute to elute DNA. Eluted DNA was stored at –
20°C. 
 
2.1.1.1  Real time PCR for detection of  Salmonella in stool specimens 
Previously optimised PCR protocol at MLW molecular laboratory was adopted. Master-
mix for rt-PCR was prepared using pre-defined quantities. A total of 20µl master-mix 
Participants, Materials and Methods 
 
89 
 
was comprised of the following:12.5µl Platinum® Quantitative PCR Super Mix-UDG 
(Life Technologies, USA), 0.10µl specific forward primer, 0.10 specific reverse primer, 
0.10 specific probe (all primers and probes at 200nM), 0.05µl ROX reference dye (Life 
Technologies, USA) at 50nM final concentration, and 7.15µl nuclease-free water. This 
mixture was transferred to appropriate 96-well plate PCR wells. Five µl of test DNA, 
controls DNA, negative control (UV treated water) were added to appropriate well (with 
master-mix). Rt-PCR was run using Applied Biosystems® 7500 Real-Time PCR Systems 
(Life Technologies, USA) under appropriate reporter dye settings. The threshold was set 
in the lag phase, controls were checked for correctness, and then test samples CT values 
were registered (Figure 2.7).   
 
 
Figure 2. 7: Representative real time PCR read out 
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2.2.8.10 Limit of detecting  of Salmonella using  real time PCR 
The level of yielding positive Salmonella result using stool culture is low (< 50% true 
positive stool samples are detected) (Hoffman, et al., 1984, Matheson, et al., 2010). To 
determine a method that would yield superior limit of detecting Salmonella in stool 
samples, a number of methods were compared; standard stool culture method (selenite 
broth and XLD) with rt-PCR on spiked stool and rt-PCR on spiked stool (PCR method 3) 
and treated with selenite broth (PCR method 4) (Figure 2.8). Salmonella was adjusted to 
10
4 – 101 cfu/ml using Miles and Misra technique and DNA extracted using method 3 or 
method 4 (Figure 2.8). DNA extraction was performed as described section 2.2.8.9, but 
without treatment with lysozyme and bead beating step.  
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MILES MISRA: Bacteria at 104 – 10-1 cfu/ml
Sub-culture 
10µl Selenite
Spike 
(Loose stool)
(1) DIRECT
(PBS) 
DNA EXTRACTION (0.5ml)
(2) INDIRECT 
Spike 
(Loose stool)
Sub-culture 
10µl Selenite
(3) INDIRECT
MINUS SELENITE 
(4) INDIRECT 
PLUS  SELENITE
rt-PCR
STEP  ONE
STEP  TWO
STEP  THREE
STEP  FOUR
 
Figure 2.8: Methods of detecting Salmonella in stool using PCR 
 
Limit of detecting (LOD) S. Typhimurium in stool using the standard stool culture ranged 
between 10
3  
and 10
4
cfu/ml, while LOD S. Typhimurium in stool ranged between 10
1
 and  
10
3
 cfu/ml using PCR method 3 (Figure 2.9A). Observations were made that addition of 
Selenite F broth (PCR method 4) improved the LOD Salmonella in stool using rt-PCR 
(from LOD ranging 10
1
-10
3
 cfu/ml, [CT 30-35] using PCR method 3 to LOD ranging 
<10
1
-10
1
 cfu/ml, [CT <25] using PCR method 4) (Figure 2.9B). 
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Figure 2. 9: Development of real time PCR for detection of Salmonella exposure in 
stool 
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Representative diagram showing direct rt-PCR results (Figure 2.9A) and indirect (selenite 
enriched) rt-PCR results (Figure 2.9B). DNA was prepared at varying concentration as 
indicated. 
 
2.2.8.11 Specificity and sensitivity of PCR for Salmonella  
Stool samples harbours a huge amount of closely related (genetically) enteric 
bacteria(Fanaro, et al., 2003). These possess a challenge as regards to generation of 
highly specific and sensitive primers for rt-PCR assay. Newly generated DNA primers 
specificity was tested against a panel of Gram negative including Proteus, E. coli, 
Citrobacter and Klebssiella and Gram positives including Staphylococus aureus and 
Streptococcus pneumoniae. Both InvaA DNA primer and LPXO DNA primer were not 
specific for Salmonella (Proteus and E. coli DNA tested positive) (Table 2-E and 2-F). 
FliC and Fimbriae DNA primers were therefore considered for use in successive 
experiments. It’s possible that these DNA primers could be specific against enteric 
bacteria but fail to distinguish DNA from Salmonella serovars. Intra-Salmonella 
specificity and sensitivity of the DNA primers were investigated. Fimbriae DNA primer 
sensitivity was 100%, 95% CI (19.2-100) and specificity was 100%, 95% CI (75.1-100) 
(Table 2-G). FliC-1 DNA primer sensitivity was 100%, 95% CI (58.3-100), while its 
specificity was 37.5%, 95% CI (8.7-75.3) (Table 2-G). FliC-2 DNA primer sensitivity 
was 83%, 95% CI (36 -97.2) and sensitivity 100%, 95% CI (58.9-100) (Table 2-H and I).  
Taken together sensitivity and specificity for fimbriae DNA primer was excellent while 
specificity and sensitivity were poor for FliC-1 DNA primer and moderately good for 
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FliC-2 DNA primer. Fimbriae DNA primer was used for detection of S. Typhi in stool 
specimens. FliC-1 and FliC-2 DNA primers were used for screening and confirmation of 
S. Typhimurium detection in stool specimens.  
 
 
Table 2- G: Specificity and sensitivity for Fimbriae DNA primer (S. Typhi) 
 
 
 
 
Present 
 
 
n 
 
 
Absent 
 
 
n 
 
 
Total 
 
Positive 
 
TP 
 
2 
 
FP 
 
0 
 
2 
 
Negative 
 
FN 
 
0 
 
TN 
 
13 
 
13 
 
Total 
 
 
2 
 
 
13 
 
15 
 
Sensitivity= 100%, 95% CI (19.2-100) 
 
Specificity =  100%, 95% CI (75-100) 
TP refers to true positive 
FN refers to false negative 
FP refers to false positive 
TN refers to true negative 
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Table 2- H: Specificity and sensitivity for FliC-1 DNA primer (S. Typhimurium) 
 
 
 
 
Present 
 
 
n 
 
 
Absent 
 
 
n 
 
 
Total 
 
Positive 
 
TP 
 
7 
 
FP 
 
5 
 
12 
 
Negative 
 
FN 
 
0 
 
TN 
 
3 
 
3 
 
Total 
 
 
7 
 
 
8 
 
15 
 
Sensitivity= 100%, 95% CI (58-100) 
 
Specificity =  37.5%, 95% CI (8.7-75.3) 
TP refers to true positive 
FN refers to false negative 
FP refers to false positive 
TN refers to true negative 
 
Table 2- I: Specificity and sensitivity for FliC-2 DNA primer (S. Typhimurium) 
 
 
 
 
Present 
 
 
n 
 
 
Absent 
 
 
n 
 
 
Total 
 
Positive 
 
TP 
 
5 
 
FP 
 
0 
 
5 
 
Negative 
 
FN 
 
1 
 
TN 
 
7 
 
8 
 
Total 
 
 
6 
 
 
7 
 
13 
 
Sensitivity= 83.3%, 95% CI (36-97.2) 
 
Specificity =  100%, 95% CI (58.9-100) 
TP refers to true positive 
FN refers to false negative 
FP refers to false positive 
TN refers to true negative 
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2.3   DEVELOPMENT OF T CELL AND ANTIBODY MEDIATED IMMUNITY 
IN RESPONSE TO INVASIVE SALMONELLA INFECTION 
 
2.3.1 Study design and participants  
A prospective longitudinal cohort study was conducted comprising of children presenting 
to hospital with invasive Salmonella (index cases). To evaluate T cells and antibodies 
immune response, index cases were recruited when S. Typhimurium or S.Typhi was 
isolated in blood cultures as part of routine surveillance at Queen Elizabeth Central 
Hospital (section 2.1.5). Family members of index cases were also recruited to evaluate T 
cells and antibodies immune response and further explore Salmonella immune-
epidemiology. Blood samples were collected from study participants for immunological 
investigations (Figure 2.10). 
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(sample collection)
1 month
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Figure 2. 10: Salmonella bacteraemia and development of cellular and immunity 
A total of 20 children with Salmonella bacteraemia and their family members were 
recruited. Only index cases were prospectively followed at 1 month into the recovery 
period. A blood sample was collected from study participant as indicated (Figure 2.10). 
All blood samples were processed as described in section 2.3.6. 
 
2.3.2 Sample size  
A total of 20 children (less than 15 years of age) were recruited presenting to hospital 
with Salmonella bacteraemia and their family members. This was a pilot study and power 
calculations were not undertaken. 
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2.3.3 Inclusion and exclusion criteria  
Children recruited were only those that had microbiologically confirmed Salmonella 
bacteraemia, among febrile paediatric admissions to Queen Elizabeth Central Hospital 
(QECH) and who were domiciled in Blantyre district. Family members of these children 
were also recruited. Children with conditions that could potentially interfere with the 
evaluation of the study objectives were excluded such as terminally illness and upper GI 
surgery. Children with HIV infection and severe malnutrition were not included. 
 
2.3.4 Study location  
Children and family members participating in the study were recruited and blood samples 
collected at QECH (paediatrics and child health ward and outpatient department). QECH 
has been described in section 2.1.5. Blood samples were transported to MLW for 
immunological investigations within 4 hours of collection. 
 
2.3.5 Ethical consideration  
The study was compliant with Good Clinical Practice (GCP) regulations and conducted 
in accordance with the 1996 ICH GCP guidelines and the 2000 Declaration of Helsinki. 
Ethical approval (P.02/11/1040 and P.08/12/1265) was granted by COMREC. Informed 
consent was obtained from a parent or guardian of each participating child and adult 
family members. 
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2.3.6 Laboratory methods  
2.3.6.1 Collection of peripheral blood sample  
Blood samples were collected as described in section 2.1.7.1 at all study specific 
scheduled visits (Figure 2.10). 
 
2.3.6.2 Preparation and storage of serum  
Serum samples were prepared and stored as described in section 2.1.7.5 
 
2.3.6.3 Intracellular cytokine staining for detection of CD4+ IFN-γ+ T  cells  
Whole blood (WB) for intra-cellular cytokine staining (ICS) assay was collected in 1ml 
BD vacutainer® sodium heparin and the assay was performed as described in section 
2.1.7.8 with minor modifications. Briefly 450μl blood was stimulated with (Salmonella 
enterica Generalized Modules for Membrane Antigens expressing O antigen), GMMA- 
(Salmonella enterica Generalized Modules for Membrane Antigens not expressing O 
antigen), FliC (S. Typhimurium flagellin protein) and OMP (S. Typhimurium outer 
membrane protein) [all adjusted to 10µg/ml] were all generated and kindly donated by 
Calman MacLennan laboratory (Novartis Vaccine Institute for Global Health) and all 
samples were co-stimulated with anti-CD28/49d antibody (Becton Dickinson, USA) for 6 
hours at 37
º
C. At 2 hours, intra-cellular cytokine release was inhibited with 1µl of BD 
GolgiStop™ (Becton Dickinson, USA) at 106 cells/mL. Cells from 200μl of blood 
sample were lysed with 2ml of 1X FACs lysing solution then permeabilised with 500μl 
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of 1X permeabilising solution (Becton Dickinson, USA). Cells were washed with 
PBS/0.5% BSA buffer (Sigma Aldrich, USA), and stained with 3μl each of the surface 
antibodies: CD3-PercP, CD4-APC and 5μl of the intra-cellular cytokine antibody: IFN-γ-
PE (all Becton Dickinson, USA). Cells were fixed and events acquired and analysed 
using FlowJo as described in section 2.1.7.8 (Figure 2.11). 
Un-stimulated GMMA O+ GMMA O-
OMP FliC
C
D
4
 P
er
C
P
IFN-γ PE
CD4+IFN-γ+
0.06%
CD4+IFN-γ+
0.10%
CD4+IFN-γ+
0.04%
CD4+IFN-γ+
0.30%
CD4+IFN-γ+
0.30%
INDEX
 
Figure 2. 11: Detection of T cells producing cytokines 
A representative figure of antigen-specific CD4+ T cells producing IFN-γ.  T cells 
were stimulated by various Salmonella antigens as indicated.  
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Representative plots of CD4+ T cells producing IFN-γ in unstimulated condition or 
stimulated with GMMA O+, GMMA O-, OMP, and FliC antigens. Index T cell responses 
at the point of diagnosis are shown (Figure 2.11). 
 
2.3.6.4 B-cell ELISPOT for detection of Salmonella specific ASC 
B cell immunity to specific pathogens including Salmonella are commonly evaluated 
using antigen specific ELISA in serum or plasma (Carlsson, et al., 1975, Beasley, et al., 
1981, Strid, et al., 2007). However, evaluation of B cell immunity using ELISA alone 
does not provide the whole picture of B cell immunity as this excludes the examination of 
memory B cells pool. It has therefore being argued that evaluation of B cell immunity by 
using both ELISA and B cell ELISpot give the complete picture of B cell immunity 
(Jahnmatz, et al., 2013). B cell ELISpot is used to detect antigen specific secreting cells 
(ASC) and memory B cells. Active plasma blast (ASC) stimulated in vivo by either 
natural infection or vaccination can be examined directly by B cell ELISpot without ex 
vivo stimulation as is the case with memory B cells which require ex vivo stimulation to 
reach detectable levels (Jahnmatz, et al., 2013). In this study IgG or IgA ASC were 
quantified by B cell ELISpot (without re-stimulation) as previously described (Kantele, et 
al., 2012) with minor modifications. Millipore multiscreen 96-well ELISpot plates (EMD 
Millipore, USA) with a 0.45µm surfactant free mixed with cellulose ester membrane 
were coated with Salmonella O:4,5-LPS (ALEXIS Biochemicals), Salmonella O:9-LPS 
(ALEXIS Biochemicals), GMMA+ (Salmonella enterica Generalized Modules for 
Membrane Antigens expressing O antigen), GMMA- (Salmonella enterica Generalized 
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Modules for Membrane Antigens not expressing O antigen), S. Tymphimurim -FliC (S. 
Typhimurium flagellin protein) and S. Tymphimurim -OMP (S. Typhimurium outer 
membrane protein) [all adjusted to 5µg/ml] diluted in carbonate-bicarbonate buffer 
(Sigma Aldrich, USA) pH 9.6 (filtered through a 0.2µm syringe filter). Plates layout is 
shown in Figure 2.12. Coated plates were incubated at 4°C overnight. On day 2, plates 
were washed 6 times with 200µl/well of PBS then soaked in 200µl/well of PBS for 5 
minutes. Plates were blocked with R10 medium (RPMI plus 10% Gibco® newborn calf 
serum (NBCS) [Life Technologies, USA]) (200µl/well) and incubated at 37°C in 5% 
CO2 for 1 hour. PBMCs were isolated from heparinized blood and processed within 4 
hours after collection. PBMC pellets were re-suspended in R10 medium and cells 
counted and adjusted to 2.5x10
6
cells/ml. A cell suspension of 100µl was added to the 
blocked ELISpot plate to achieve 2.5x10
5 
cells/well and incubated at 37°C in 5% CO2 for 
24 hours. Cells and supernatants were discarded and plates washed 5 times with PBS-
Tween then soaked for 5 minutes. Alkaline-phosphatase goat anti-Human IgG and IgA 
antibodies were diluted 1:5000 in 0.2µm filtered PBS/10% NBBS and added 100µl/well 
to the appropriate wells and incubated at RT for 4 hours. Plates were washed five times 
with PBS-Tween, and four times with 200µl/well of distilled water. Alkaline phosphatase 
(AP) colour development buffer concentrate (Bio Rad, Switzerland) was diluted 1:25 
with distilled water. 1:100 5-Bromo-4-chloro-3-indolyl-phosphate solution/nitro blue 
tetrazolium (BCIP/NBT) were diluted with 1:25 colour development butter. 200µl of 
newly prepared alkaline phosphates solution (BCIP/NBT) was added to appropriate well 
and incubated until spots were developed. Further colour development was stopped with 
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distilled water (200µ/well) without allowing background to become too dark. Lastly 
plates were washed twice with 200µl/well distilled water. Plates were air dried and read 
using AID ELISpot Reader version 4.0 (AID GmbH, Germany) (Figure 2.13).  
 
1 2 3 4 5 6 7 8 9 10 11 12
IgG 04 LPS 04 LPS 04 LPS
NC
04 LPS
NC
09 LPS 09 LPS 09 LPS
NC
09 LPS
NC
FliC FliC FliC
NC
FliC
NC
IgA 04 LPS 04 LPS 04 LPS
NC
04 LPS
NC
09 LPS 09 LPS 09 LPS
NC
09 LPS
NC
FliC FliC FliC
NC
FliC
NC
IgG OMP OMP OMP
NC
OMP
NC
GMMA+ GMMA+ GMMA+
NC
GMMA+
NC
GMMA- GMMA- GMMA-
NC
GMMA-
NC
IgA OMP OMP OMP
NC
OMP
NC
GMMA+ GMMA+ GMMA+
NC
GMMA+
NC
GMMA- GMMA- GMMA-
NC
GMMA-
NC
Index
Index
2.5x105 cells/well 2.5x105 cells/well 2.5x105 cells/well
 
Figure 2. 12: IgG and IgA antibody secreting cells ELISPOT plate layout 
A representative plate lay out for detection of IgG and IgA ASC using ELISPOT 
 
 
Participants, Materials and Methods 
 
104 
 
A
B
IgA ASC per 2.5x105 cellsIgG ASC per 2.5x105 cells
GMMA O-
O;9 LPS
O;4,5 LPS
GMMA O+
OMP
FliC
Index    Family
GMMA O+
O;9 LPS
O;4,5 LPS
GMMA O-
OMP
FliC
Index    Family
 
Figure 2. 13: IgG and IgA ASC per 2.5X10
5
cells/ml  
Representative images showing antigen-specific IgG antibody secreting cells (ASC) 
(Figure 2.13A) and IgA ASC (Figure 2.13B). Antigen-specific IgG and IgA ASC to 04-
LPS, 09-LPS, GMMA O+, GMMA O-, OMP and FliC for both index and family member 
are indicated (Figure 2.13A, B).  
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2.4  Ty21a ORAL TYPHOID  VACCINE INDUCED IMMUNITY IN THE 
PERIPHERAL  BLOOD AND GUT MUCOSA OF HEALTHY ADULTS 
 
2.4.1 Study design and participants  
An interventional study was conducted to model natural Salmonella immunizing events 
in the gut mucosa and peripheral blood in healthy adults from the UK vaccinated with 
Ty21a Oral Typhoid vaccine. Participants were given three oral doses of the vaccine.  
One capsule was taken on each of days 0, 2 and 4, approximately one hour before a meal, 
with a cold or lukewarm drink, as recommended by the manufacturer and as licensed for 
use in the UK (Figure 2.14).  
 
2.4.2 Sample size  
This study aimed at recruiting 10 healthy adults in the vaccine group and 10 healthy 
adults in the control group in Liverpool. This was a pilot study and so power calculations 
were not done. 
 
2.4.3 Inclusion and exclusion criteria  
Healthy adults aged between 18 and 60 years, fluent in spoken English and those capable 
of giving informed consent were included in the study. Participants that were pregnant, 
had chronic illness or immune-compromised, anaemia, platelet count below 30,000 and 
those that had previous GI surgery were excluded. Individuals who had received the 
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parenteral typhoid vaccine within the past three years or the oral typhoid vaccine within 
the past twelve months, those who had previously travelled in countries endemic for 
typhoid (outside Europe, Australia or North America) and those with previous adverse 
reaction to vaccination were also excluded.  
 
Figure 2. 14: Ty21a oral typhoid vaccine induced immunity in the peripheral blood 
and gut mucosa 
A total of 9 vaccines and 8 controls (healthy adults age 18-65) were recruited in this 
intervention study to compare immune responses induced by oral Ty21 a Typhoid 
vaccine within the gastrointestinal tract (GIT) and peripheral blood. Three doses of oral 
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Ty21a vaccine were administered in the vaccine group only, and blood and gastroscopy 
specimens were collected as indicated (Figure 2.14).  
 
2.4.4 Study location  
This study was conducted in Liverpool and was sponsored by the Royal Liverpool 
University Hospital and the Liverpool School of Tropical Medicine (LSTM). The clinical 
work was carried out at the Royal Liverpool University Hospital and blood samples 
investigations were performed at LSTM. 
 
2.4.5 Ethical consideration  
Ethical approval for this study was obtained from the National Research Ethics Service 
(10/H1005/20). Informed consent was obtained from all study participants.  
 
2.4.6 Laboratory methods  
2.4.6.1 Collection of peripheral blood sample  
A total of 30ml venous blood in 5ml BD sodium heparin tube (totalling 20ml)  and 10ml 
BD serum tube (all Becton Dickinson, USA) was collected from both study groups on 
day 0 (pre-immunization sample), day 11 and day 18 follow up (Figure 2.15). Blood 
samples were collected by research study nurse.  
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2.4.6.2 Isolation of peripheral blood mononuclear cells for ICS and IPT 
At total of 20ml of whole blood (WB) was collected in BD sodium heparin tubes (Becton 
Dickinson, USA) and was diluted with an equal volume of sterile PBS (Invitrogen, USA). 
Mixed blood/PBS was layered over half the volume of Lymphoprep
TM
 (Axis-Shield, 
Scotland) and centrifuged at 800g for 20 minutes, with the brakes off at room 
temperature (RT). PBMCs were aspirated using a sterile Pasteur pipette into a separate 
50ml BD Falcon™ Conical Centrifuge Tubes (Becton Dickinson, USA) and washed with 
40ml sterile PBS (Invitrogen, USA) at 500g for 10 minutes. Cell pellets were next 
washed with 10ml of complete medium (50ml FBS [Invitrogen, USA] and 10ml 200mM 
L-glutamine [Sigma Aldrich, USA] were added to a 500ml bottle of RPMI-1640 [Sigma 
Aldrich, USA]) at 500g for 5 minutes. Pelleted cells were suspended in 2ml of complete 
medium and counted using a Neubauer Haemocytometer (Hausser Scientific, USA). Over 
100 cells were counted if possible from 4 large squares to obtain a cell count per ml 
which was computed as follows: the product of cell count multiplied by 10
4
 and divided 
by the number of large squares. Each sample cell concentration was adjusted to 5x10
6
 per 
ml and used for immuno-phenotyping and intra-cellular cytokine staining as described in 
section 2.4.6.5 and 2.4.6.6. 
 
2.4.6.3 Collection of duodenum biopsy 
Duodenum biopsy collection was performed by a Consultant Gastroenterologist. D2-D3 
duodenal pinch biopsies were collected on day 18 from vaccinees and controls (Figure 
2.15). Study participants fasted at home for 8 hours from midnight prior to the 
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endoscopic procedure. Sedation was optional; study participants were given up to 5mg 
maximum of midazolam intravenously. Nasal oxygen was administered during the 
procedure, and pulse oximetry monitoring was conducted throughout the procedure.  
Between 12 and 15, D2-D3 duodenal single-bite cold biopsies at 20-25cm insertion were 
collected using Boston Scientific large capacity ‘jumbo’ forceps (Boston Scientific, 
USA) which passed through a standard 2.8mm endoscopic biopsy channel. Biopsies were 
placed in MR15 medium (Mixture of 50ml Fetal Bovine Serum [Sigma Aldrich, USA], 
10ml at 200mM L-glutamine [Sigma Aldrich, USA], 1ml Tazocin [piperacillin at 
250mg/ml, tazobactam at 31.25mg/ml] [Wyeth Pharmaceuticals, USA] and 2.5ml 
amphotericin B at 250µg/ml (Sigma Aldrich, USA) and 500ml RPMI-1640 [Sigma 
Aldrich, USA)]), and transported on ice to the laboratory for processing. Study 
participants were observed for two hours post-procedure, given a drink and snack before 
being discharged home.  
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Figure 2. 15: Gastroscopy of the duodenum 
 
2.4.6.4 Isolation of  gut mucosal mononuclear cells  
Gut mononuclear cells were isolated using a modification of the method previously 
described by Kaltsidis et al (Kaltsidis, et al., 2011). Biopsies were placed in 10ml MR15 
medium on ice and were transported to the laboratory within 1 hour of collection. 
Samples were centrifuged at 400g for 10 minutes at room temperature, with the brake 
disabled. Biopsy pellets were re-suspended in 12.5ml CII-S medium (50mg Collagenase 
II-S [Sigma Aldrich, USA] plus 100ml MR15) and incubated at a 45° angle in a 37˚C 
shaking incubator at 220 rpm for 30 minutes. The tissue suspension was transferred into 
an open 50ml BD Falcon™ Conical Centrifuge Tubes (Becton Dickinson, USA). The 
tissue suspension was introduced by force through the syringe attached to a 16-gauge 
blunt-ended needle (Miltenyi Biotec, Germany) and then plunged and aspirated 4-5 
Participants, Materials and Methods 
 
111 
 
times. Large aggregates were removed by passing the suspension through a 70µm cell 
strainer (Becton Dickinson, USA). Tissue fragments and clumps left were transferred 
from the cell strainer into the original tube by rinsing the cell strainer with 12.5ml of CII-
S medium, ensuring that all remaining CII-S medium also entered the original tube. The 
original tube was placed back into the shaking incubator and the digestion and disruption 
procedure was repeated twice. Free cells from all three passages were pooled and 
centrifuged for 7 minutes at 500g. Pellets were re-suspended in 30ml MR15, and then 
centrifuged at 500g for 7 minutes. Pellets were re-suspended in 1ml MR15. Mononuclear 
cells were then adjusted to 1.0 x10
6
/ml and seeded in Greiner CELLSTAR® 24-well 
plates (Greiner bio one, USA) at 1.0x10
6
/ml and rested overnight by incubating the plate 
at 37°C, 5% CO2. Cells were harvested, re-counted and adjusted to 5.0x10
6
/ml. 
Mononuclear cells were then used for intracellular cytokine producing T cells, as 
described in section 2.4.6.6. 
 
2.4.6.5 Immuno-phenotyping for quantification of homing markers 
This study aimed at characterizing homing properties of T cell subsets. The β7 integrin 
forms heterodimers with both the α4 and αE integrins (Stefanich, et al., 2011). Since 
commercial anti-α4β7 antibody conjugated to a flourochrome of interest was not 
available, alternatively employed anti-β7 PE Cy7 antibody for T cell immunophenotying.  
PBMCs were isolated from whole blood (WB) as described in section 2.4.6.2 and 
adjusted to 5.0x10
6
/ml. Test tubes were labelled as: fluorochrome Minus One (FMO) and 
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test for T cell surface phenotyping. A cell suspension of 200µl at 1.0 x10
6
/ml was 
transferred to appropriate tubes, pelleted at 500g for 5 minutes and 100μl supernatant was 
removed. PBMCs were stained for T cell FMO condition with a pre-determined cocktail 
of surface staining antibodies: 5µl CD3-APC, CD4-APC H7, 2µl CD8-PE Cy7, 5µl 
CD19-PB (all Becton Dickinson, USA), and 5µl PBS (Invitrogen, USA). PBMCs were 
stained for the T cell test condition with a pre-determined cocktail of surface staining 
antibodies: 5µl CD3-APC, 5µl CD4-APC H7, 2µl CD8-PE Cy7, 2μl  Integrin β7-PE Cy5 
(all Becton Dickinson, USA), 2μl CCR9-PerCP Cy5.5 (BioLegend, USA), 3μl CD62L-
AF700 (BioLegend, USA), 10μl CD45RA-FITC (Beckon Dickinson, USA), 5μl CCR7-
PB  (BioLegend, USA), and 5µl PBS (Invitrogen, USA). Stained PBMCs were incubated 
at 4°C in the dark for 20 minutes. Stained PBMCs were washed with 1ml PBS 
(Invitrogen, USA), centrifuged at 500g for 5 minutes. PBMCs were fixed in 1:10 diluted 
300µl FIX solution (Becton Dickinson, USA) then acquired on BD FACSDIVA version 
8 (Becton Dickinson, USA) within 24 hours. Memory T cells were gated and analysed 
using Flow Jo
TM
 version 7.6.5 software (Tree star, USA). 
 
2.4.6.6 Intracellular cytokine staining for detection of  T cell producing cytokines   
PBMCs isolated from whole blood (WB) and MMCs isolated from gut mucosal tissue 
were adjusted to 5x10
6
/ml for antigen stimulation experiments. These antigen stimulation 
conditions were prepared: un-stimulated fluorochrome Minus One (US-FMO), un-
stimulated stained (USS), Ty21a, influenza, and Staphylococcal enterotoxin B (SEB). 
200µl PBMC or MMCs at 1.0 x10
6
/ml were transferred appropriate micro-well (Greiner 
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bio one, USA). PBMCs or MMCs were stimulated as follows: US-FMO (no antigen 
stimulation), USS (no antigen stimulation), heat-inactivated Ty21a at 0.0632µg/ml 
(Berna Biotech, Switzerland), influenza (Influenza virus vaccine) at 0.225µg/ml (Solvay 
Biologicals B.V., Netherlands) and SEB at 100µg/ml (Sigma Aldrich, USA). Stimulated 
PBMCs or MMCs were incubated at 37 °C for 2 hours and treated with 1µl of BD Golgi-
Plug (Becton Dickson, USA). Stimulated PBMCs or MMCs were incubated at 37˚C for a 
further 16 hours before harvesting. Non-adherent MMCs were removed by adding 200µl 
of RPMI-1640 medium and pipetting up and down. Harvested PBMCs or MMCs were 
pelleted at 500g for 5 minutes at 4˚C and the supernatant poured off. PBMCs or MMCs 
were re-suspended in 1ml PBS (Invitrogen, USA) containing 1µl ViViD (violet 
fluorescent reactive dye) (Invitrogen, USA) and incubated at 4˚C in the dark for 20 
minutes. PBMCs or MMCs were suspended in 1ml PBS (Invitrogen, USA) and 
centrifuged at 500g at 4°C for 5 minutes.  Supernatants were poured off and cells were 
stained with pre-determined cocktails of surface staining antibodies, as follows: Pre-
determined cocktail of T cell FMO antibodies: 5µl CD3-APC, 5µl CD4-APC H7, 2µl 
CD8-PE Cy7, and 5µl CD19-Pacific Blue (all Becton Dickinson, USA). Pre-determined 
cocktail of surface antibodies for T cells: 5µl CD3-APC, 5µl CD4-APC H7, 2µl CD8-PE 
Cy7, 5µl CD19-Pacific Blue, 2µl β7-PE Cy5 (all Becton Dickinson, USA), 2µl CCR9-
PerCP Cy5.5 (BioLegend, USA), and 5µl PBS (Invitrogen, USA). Stained cells were 
incubated at 4°C in the dark for 15 minutes and washed with 1ml PBS (Invitrogen, USA) 
for 5 minutes at 500g. Cells were treated with 250µl of Cytofix/Cytoperm (Becton 
Dickinson, USA), incubated at 4°C in the dark for 20 minutes. Cells were then washed 
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with 1ml Perm/Wash (Becton Dickinson, USA) centrifuged at 500g for 5 minutes. 
Permeabilised cells were stained with pre-determined cocktail of intracellular cytokine 
staining antibodies: 1µl IFNγ-AF700, 2.5µl TNFα-AF488, 10µl IL2-PE (all Becton 
Dickinson, USA), and 1.5µl Perm/Wash. These were incubated at 4°C in the dark for 30 
minutes and washed with 1ml Perm/Wash for 5 minutes at 500g. Finally were fixed in 
1:10 diluted 300µl FIX solution (Becton Dickinson, USA) then acquired on BD™ LSR 
II flow cytometer (Becton Dickinson, USA). CD3+CD4+ T cells producing IFN-γ, TNF-
α and IL-2 were analysed for polyfunctional CD4+ T cells producing single, double and 
triple cytokines were further analysed by Boolean gates using Flow Jo
TM
 version 7.6.5 
software (Tree star, USA).  
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CHAPTER 3: DEVELOPMENT OF ADAPTIVE IMMUNITY TO 
NONTYPHOIDAL SALMONELLA IN MALAWIAN CHILDREN 
Some of the work in this chapter has been published in the Journal of Infectious Diseases. 
The full manuscript is included in the appendix. 
 
3.1 INTRODUCTION 
NTS bacteraemia remains an important health problem in sub Saharan Africa particularly 
in young children and HIV infected individuals (Reddy, et al., 2010, Feasey, et al., 2012). 
To effectively control NTS bacteraemia in humans, public health interventions, such as 
vaccination alongside improvements in sanitation and hygiene in endemic regions, are 
required. Well characterized immune components that constitute immunity to NTS will 
help to inform the design of an effective vaccine for Salmonella. Immunity to Salmonella 
has been extensively studied in animal models compared to humans. For instance, mouse 
models of invasive Salmonella disease implicate innate immune cells (phagocytes), T cell  
and antibody-mediated immunity (Mastroeni, et al., 1993, Tam, et al., 2008).  It is known 
that immunity to pathogens in mouse models is not always replicated in humans. 
Therefore, it is important to understand the similarities and differences between the 
immune response to Salmonella in animals and humans.   
As discussed in chapter 1 (introduction chapter), NTS bacteraemia is particularly 
common among African children under two years of age suggesting that immaturity of 
the immune response may contribute towards susceptibility to invasive Salmonella 
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infection in this group. Immunity to Salmonella is complex and involves both humoral 
and cell-mediated mechanisms (Mastroeni, 2002, Mastroeni, 2003). Most Malawian 
children acquire anti-Salmonella IgG and IgM antibodies and bactericidal activity against 
NTS by the age of 2 years (MacLennan, et al., 2008). Antibodies targeting NTS can 
effect bacterial killing through activation of complement cascade and assembly of the 
membrane attack complex (MacLennan, et al., 2008). Antibodies opsonize NTS and, 
together with C3b deposition, facilitate internalization by phagocytes and subsequent 
killing of NTS through oxidative burst (Gondwe, et al., 2010). These immune processes 
are thought to be critical for preventing extracellular growth and dissemination of NTS 
(MacLennan, et al., 2008). However, salmonellae are facultative intracellular bacteria 
and individuals with primary immune-deficiencies affecting the IL12/23-IFN-γ axis (T 
helper 1 pathway) are particularly susceptible to NTS (Jouanguy, et al., 1999, 
MacLennan, et al., 2004), indicating an important role for cellular immune mechanisms 
and T cells, in particular, in immunity to Salmonella. This is supported by the close 
association between HIV/AIDS and NTS bacteraemia among adults in Africa, Europe 
and the USA (Gilks, et al., 1990, Gordon, et al., 2002), particularly those with CD4+ T 
cell counts of less than 200 cells/ul (Gordon, et al., 2002). Prior to commencing ART, 
recrudescence of NTS bacteraemia is a common finding in this group, again indicating an 
important role for T cell immunity in clearing NTS infection and preventing chronic 
intracellular infection (Gordon, et al., 2002). Adoptive transfer studies in mouse model of 
salmonellosis indicate that a combination of Salmonella-specific T cell and antibody is 
required for optimal protection against Salmonella infection (Mastroeni, et al., 1993, 
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McSorley & Jenkins, 2000). T cells are particularly necessary to clear Salmonella from 
mice and prevent the development of chronic carrier states that could lead to relapse of 
infection (Mastroeni, 2003). Athymic mice and CD28
-/-
 mice both show increased 
susceptibility to Salmonella infection suggesting that in the mouse model, clearance of 
Salmonella requires CD28-dependent activation of T cells (O'Brien & Metcalf, 1982, 
Mittrucker, et al., 1999). Mice studies indicate that the T helper cell response to 
Salmonella is broad and is directed to protein antigens such as flagellin, porins and pilin 
(Mastroeni, 2002). Although it is known that CD4+ T cells orchestrate macrophage 
effector functions through IFN-γ and TNFα (Janssen, et al., 2002, Gordon, et al., 2005) 
and HIV-infected individuals with low CD4 counts are particularly susceptible to NTS 
bacteraemia (Gordon, et al., 2010), the contribution of CD4+ T cell-mediated control of 
NTS in humans has not been well studied.  
Class-switched (IgG isotype) and non-switched (IgM isotype) Salmonella-specific 
antibody levels have been shown to increase with age in young African children 
(MacLennan, et al., 2008). The study hypothesis was that in the first two years of life, 
CD4+ T cell immunity  to S. Typhimurium develop in parallel with the development of S. 
Typhimurium antibody immunity. Eighty healthy Malawian children aged 0-60 months 
were recruited in a cross-sectional study. S. Typhimurium-specific CD4+ T cells 
producing IFN-γ, TNFα and IL2 were quantified using intra-cellular cytokine staining. 
Antibodies to S. Typhimurium were measured by serum bactericidal activity assay 
(SBA), and anti- S. Typhimurium IgG antibodies by ELISA.  
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Hypothesis: In the first two years of life, CD4+ T cell immune responses to S. 
Typhimurium develop in parallel with the development of anti-S. Typhimurium 
antibodies. 
 
Study objectives: 
a) Characterize how T cell and antibody immune responses to S. Typhimurium develop 
in the first five years of life.   
b) Examine the development of T cells and antibodies to S. Typhimurium in relation to 
S. Typhimurium bacteraemia epidemiology in children from Blantyre.  
 
3.2 PARTICIPANTS RECRUITMENT AND METHODS  
The methods for this chapter have been described in Chapter 2: study designs, materials, 
and methods, section 2.1. 
In brief, 80 healthy Malawian children aged 0 to 60 months attending vaccination clinic, 
health check clinics and newborns in the maternity ward at Ndirande Health Centre 
(NHC) were recruited. A total of 20 adult participants were also recruited. NHC provide 
primary health care within the Blantyre city. According to Blantyre district health office 
(DHO) and QECH 2010/2011 annual report, it was projected that NHC to have 
catchment population (those receiving service from the health facility) of about 221,217 
in the year 2012 (MCI, 2013). Child and adult participants were sampled blood at NHC. 
To characterise the acquisition of T cell immunity to NTS whole blood was quantified for 
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memory T cells and Salmonella specific-CD4+ T cells producing cytokines; IFN-γ, TNF-
α and IL-2 by immuno-phenotyping and intracellular cytokine staining respectively. To 
characterise the acquisition of antibody mediated immunity to NTS, serum was quantified 
for complement fixing antibody by serum bactericidal assay and ELISA. These T cell and 
antibody responses to NTS were then examined in relation to age distribution of S. 
Typhimurium bacteraemia in under-five children. 
 
3.3 STATISTICAL ANALYSES 
GraphPad Prism version 5.0 (GraphPad Software, Inc, USA) was used to generate graphs 
and analyse the data. End-point response variables (antigen specific T cells producing 
cytokines, serum bactericidal activity and antibody titres) were examined for normality of 
distribution. The median was used as the measure of central tendency for non-normal 
distributed end points. Phases of the immune response were distinguished so as to further 
understand the evolution of immunity. Nonlinear regression models were used to fit to 
data relating S. Typhimurium-specific T cells and SBA responses with age. The inflection 
points of the resultant curves were taken to represent the boundaries of qualitatively 
different phases of immune response. The first period before the boundary was termed 
the early response and the subsequent period was termed the late response. The immune 
responses within these early and late periods were then modelled by linear regression. P-
value of <0.05 was considered significant. 
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3.4 RESULTS 
3.4.1 Healthy study participants 
A total of 80 healthy children (Table 3-A), in 8 predefined age categories ranging from 0 
to 60 months, were prospectively recruited at a large community health centre in 
Blantyre, Malawi, from March 2009 to January 2011. Children with malaria parasitemia, 
a positive HIV antibody test, severe anaemia (haemoglobin <7 g/dL), malnutrition 
(weight-for-height z score ≤2), or any other chronic illness were excluded from the study. 
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Table 3- A: General Characteristics, Nutritional and Haematological Profile 
Gender  
Parameter Female Male  All  
Median participants (%) 35 (43.7) 45 (56.3) 80 (100) 
Median age in months (range) 13.2 (0-52.5) 10 (0-47) 10.2 (0-52.5) 
Median weight in kgs (range) 9.5(3.5-17)ᵃ  10(6-16.9)ᵇ ND 
Median height cm (range) 73.5(48-97)ᵃ 74(52-95)ᵇ ND 
Median weight for height z-score (range) 0.89(-1.9-4.6)ᵃ 1.4(-2-4)ᵇ ND 
Median lymphs x10ᶺ3/μl (range) 6.3(2.9-13.46) 5.3(2.2-10.4) 5.4(2.2-13.6) 
Median Hgb in g/dl (range) 11.5(7.6-18.1) 11.2(8.0-17.7) 11.4(7.6-18.1) 
Abbreviations: ND, Not done   
ᵃ Twenty-five children aged 1-60 months were included. 
ᵇ Thirty-five children aged 1-60 months were included. 
 
 
 
Development of adaptive immunity in children  
 
122 
 
3.4.2 Age distribution of S. Typhimurium bacteraemia in under-five children in 
Malawi 
Between January 2006 and December 2011 S. Typhimurium bacteraemia was detected in 
449 children <5 years of age presenting to QECH, of whom 359/449 (80%) were <2 
years. The median age of S. Typhimurium bacteraemia was 13 months (range 0-60) 
(Figure 3.1). It was noted that age distribution for S. Typhimurium bacteraemia had not 
changed as previously reported (MacLennan, et al., 2008).  
 
Figure 3. 1: Age distribution of S. Typhimurium bacteraemia in the first 5 years of 
life 
Number of S. Typhimurium blood culture isolates was plotted against age in months. N= 
449, the dashed line represents the median age = 13 months. 
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3.4.3 Development of memory CD4+ T cell subsets in children under-five years 
To provide a context for the subsequent assessment of functional T cell memory, overall 
development of T cell subsets in Malawian children was assessed. Newborns are 
pathogen inexperienced (Ygberg & Nilsson, 2012) and therefore CD4+ T cells develop 
memory with age, enabling them to mount rapid immune responses to previously 
encountered pathogens. Naïve, effector and central memory CD4+ T cells can be 
differentiated by their extra-cellular expression of CD45RO and CCR7 (Mackay, et al., 
1990, Bunce & Bell, 1997). CD4+ T cell subsets were gated as described in Chapter 2: 
section 2.1.7.9. As expected (Chipeta, et al., 1998), the proportion of CD4+CD45RO-
CCR7+ naïve T cells decreased with age (r²=0.246, slope -0.58, 95% CI [-0.83, -0.34] 
p=<0.01) (Figure 3.2A). The proportion of CD4+CD45RO+CCR7- EM T cells (r²=0.119, 
slope 0.035, 95% CI [0.012, 0.057] p=<0.01) and CD4+CD45RO+CCR7+ CM T cells 
increased with age (r²=0.455, slope 0.43, 95% CI [0.32, 0.55] p=<0.01) (Figure 3.2B and 
3.2C). As expected the proportion of CD4+CD45RO-CCR7+ naïve T cells were lower in 
adults compared to children under-five (Figure 3.2A and 3.2D), while the proportion of 
CD4+CD45RO+CCR7- EM T cells and CD4+CD45RO+CCR7+ CM T cells were higher 
in adults compared to children under-five (Figure 3.2B-D). 
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Figure 3. 2: Development of memory CD4+ T cell subsets in the first 5 years of life 
Percentage of naïve CD4+ T cells: CD4+CD45RO-CCR7- (Figure 3.2A, n=73), 
effector memory CD4+ T cells: CD4+CD45RO+CCR7- (Figure 3.2B, n=73) 
and central memory CD4+ T cells: CD4+CD45RO+CCR7+) (Figure 3.2C, 
n=73) were plotted against age. Memory CD4+ T cells were determined by 
linear regression, represented by solid central line, and 95% CI represented by 
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dashed lines. Percentage of CD4+ T cell subsets in adults (Figure 3.2D, n=16). 
The mean, and 95% CI represented are shown. 
 
3.4.4 Development of S. Typhimurium-specific intracellular cytokine staining 
assay 
To determine the optimum concentration for stimulating whole blood (WB) for the 
detection of CD4+ and CD8+ T cells producing IFN-γ, WB was stimulated with varying 
concentrations of S. Typhimurium strain D23580 homogenate. Whole blood (WB) 
stimulation with  S. Typhimurium homogenate at 100 µg/ml resulted in lowest magnitude 
of CD4+ T cells producing IFN-γ while stimulation at 1 µg/ml triggered the highest 
magnitude of CD4+ T cells producing IFN-γ (Figure 3.3A). WB stimulation with S. 
Typhimurium homogenate at 0.1µg/ml triggered lowest magnitude of CD8+ T cells 
producing IFN-γ. Similar to CD4+ T cells responses; WB stimulation at 1 µg/ml 
triggered the highest magnitude of CD8+ T cells producing IFN-γ (Figure 3.3B).  It was 
resolved to use S. Typhimurium homogenate at 1µg/ml for WB stimulation in successive 
experiments. Optimum blood stimulation time, for the detection of cytokine producing T 
cells was investigated. WB stimulated with PMA/ION stimulated at varying time 
intervals was examined for CD4+ and CD8 T cells producing IFN-γ. Highest magnitude 
of CD4+ cells producing IFN-γ was detected at 8 hours of stimulation while for CD8+ T 
cells producing IFN-γ, it was detected at 6 hours of stimulation (Figure 3.3C-D). It  was 
observed that the magnitude T cell responses (producing IFN-γ) increased progressively 
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at 2 to 6 hours (Figure 3.3C-D). Although, WB stimulation with PMA/ION was highest 
at 8 hours in CD4+ T cells, 6 hours stimulation was chosen in successive experiments. 
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Figure 3. 3: Optimization of S. Typhimurium-specific intracellular cytokine staining 
assay 
WB was stimulated S. Typhimurium homogenate at varying concentrations as indicated 
(Figure 3.3A-B). Percentage of CD4+ and CD8+ T cells producing IFN-γ are shown 
(Figure 3.3A-B). WB was stimulated with at varying time intervals as indicated (Figure 
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3.3C-D). Percentage of CD4+ and CD8+ T cells producing IFN-γ are shown (Figure 
3.3A-B). For all experiments n=1 
 
3.4.5 Early acquisition of S. Typhimurium-specific CD4+ T cell immune responses 
To explore the hypothesis that CD4+ T cell immune responses to S. Typhimurium 
develop in parallel with acquisition of antibody-mediated immunity. CD4+ T cells were 
defined as described in Chapter 2, section 2.1.7.7 and 2.1.7.8. Contrary to this study 
hypothesis, S. Typhimurium-specific CD4+ T cells producing cytokine were detected 
early in life, peaked at 14 months and then decreased with age (Figure 3.4A).  
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Figure 3. 4: Early acquisition of S. Typhimurium-specific CD4+T cell immune 
responses  
Percentage of S. Typhimurium-specific CD4+ T cells producing total cytokine (Figure 
3.4A, n=68) early (Figure 3.4B, n=36), late (Figure 3.4C, n=32), PMA/ION stimulated 
CD4+ T cells producing total cytokine (Figure 3.4E, n=62), Percentage of S. 
Typhimurium-specific CD8+ T cell producing cytokine (Figure 3.4D, n=62). Nonlinear 
polynomial regression models of third order were fit to data relating specific T cell 
cytokine response with age. S. Typhimurium-specific T cells response within  early and 
late periods was determined by linear regression, represented by solid central line, and 
95% CI  represented by dashed lines. 
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This was further analysed by using the non-linear model peak points as defining early and 
late S. Typhimurium -specific CD4+ T cells. This showed early acquisition of S. 
Typhimurium -specific CD4+ T cell immunity (r²=0.129, slope 0.021, 95% CI [0.002, 
0.041], p=0.031), followed by a decrease in older children (r²=0.157, slope -0.005, 95% 
CI [-0.009, -0.0006], p=0.024) (Figure 3.4A and 3.4C). These changes in intra-cellular 
cytokine profiles mirrored changes in IFN-γ- and TNF-α-, rather than IL-2-secreting cells 
(Figure 3.5). Unexpectedly, S. Typhimurium-specific CD4+ T cell responses were 
generally lower in adults compared to children under-five (Figure 3.5A-D). 
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Figure 3. 5: Early acquisition of S. Typhimurium-specific CD4+T cell immune 
responses 
Blood samples were analysed for S. Typhimurium-specific CD4+ T cells producing 
cytokines using ICS assay. Percentage of S. Typhimurium-specific CD4+ T cells 
producing IFN-γ (Figure 3.5A, n=68), IL-2 (Figure 3.5B, n=68), TNF-α (Figure 3.5C, 
n=67). The immune response with age was determined by nonlinear regression 
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polynomial models represented by solid line. The immune responses in adults (Figure 
3.5D, n=20). Bars represent median. 
 
S. Typhimurium-specific CD4+ cytokine responses did not correlate with PMA/ION 
stimulated CD4+ T cell cytokine responses (r=0.109, 95% CI[-0.128, 0.371] p=0.426) 
(Table 3-B), indicating that these responses to S. Typhimurium antigens were not simply 
due to a general maturation of the immune system (Figure 3.4E and Figure 3.6). 
Interestingly, the trend of S. Typhimurium -specific CD4+ cytokine responses were 
similar to S. Typhimurium-specific CD8 cytokine responses (Figure 3.4A and 3.4D). 
Similar trend of specific CD4+ and CD8+ responses re-affirms the pattern of S. 
Typhimurium-specific T cell immune responses. 
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Table 3- B: Association between immune variables 
Parameter (s) XY Pairs Spearman r 95% Cl P value  
NTS vs PMA CD4+Cytokine+ 55 0.109 -0.128, 0.371 0.426 
SBA vs anti- S. Typhimurium -LPS IgG 
antibody titers 55 0.329 0.552, 0.062 0.01 
SBA vs anti- S. Typhimurium -OMP IgG 
antibody titers 57 0.044 -0.226, 0.308 0.741 
SBA vs anti- S. Typhimurium -FliC IgG 
antibody titers 58 -0.001 -0.266, 0.264 0.992 
SBA vs anti-E. coli-LPS IgG antibody 
titers 50 0.031 -0.257, 0.314 0.830 
CD4+ Cytokine+ vs anti- S. 
Typhimurium -OMP IgG antibody titers 65 0.137 -0.117, 0.375 0.275 
CD4+ Cytokine+ vs anti- S. 
Typhimurium -FliC IgG antibody titers 67 0.174 -0.075, 0.404 0.157 
CD4+ Cytokine+ vs anti- S. 
Typhimurium -OMP IgG antibody titers 
(early)ᵃ 39 0.405 0.088, 0.647 0.01 
CD4+ Cytokine+ vs anti- S. 
Typhimurium -FliC IgG antibody titers 
(early)ᵃ 38 0.394 0.080, 0.637 0.01 
CD4+ Cytokine+ vs anti- S. 
Typhimurium -LPS IgG antibody titers 
(early)ᵃ 36 -0.257 -0.547, 0.087 0.129 
Abbreviations: Cl, confidence interval 
 ᵃ Early refers to parameters of participants aged less than 14  months 
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Figure 3. 6: Acquisition of PMA/ION-specific CD4+T cell immune responses 
Blood samples were analysed for PMA/ION specific CD4+ T cells producing cytokines 
using ICS assay. Percentage of PMA/ION-specific CD4+ T cells IFN-γ (Figure 3.6A, 
n=62), IL-2 (Figure 3.6B, n=62), TNF-α (Figure 3.6C, n=62). The immune response with 
age was determined by nonlinear regression polynomial models represented by solid line.  
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Generation of antigen-specific multiple cytokine-producing cells is widely thought to 
indicate maturation of antigen-specific CD4+ T cell responses (Kannanganat, et al., 
2007). Maturation of S. Typhimurium -specific T cell responses in these healthy children 
(either double or triple cytokine producers) peaked mostly between 13-24 months and 
subsequently declined, while for IL2+TNFα+CD4 T cells, the response was sustained 
(Figure 3.7).  
 
 
Figure 3. 7: S. Typhimurium-specific CD4+ T cell cytokine profiles in children 
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S. Typhimurium-specific CD4+ T cells producing IFN-γ, TNF-α and IL-2 were detected 
using ICS assay. CD4+ T cells producing multiple cytokines were analysed using FlowJo 
version 7.6.5 and graphs generated by Prism version 5.0. S. Typhimurium -specific CD4+ 
T cells producing single cytokine, double cytokines and triple cytokines were shown with 
age (Figure 3.7).  
 
3.4.6 Delayed acquisition of S. Typhimurium -specific SBA  
To confirm previous observations made in Blantyre by MacLennan et al, the same SBA 
assay and clinical S. Typhimurium strain D23580 (MacLennan, et al., 2008) were used 
and described in Chapter 2, section 2.17.10. In line with the previous findings, S. 
Typhimurium-specific SBA declined in the first 8 months of life and then increased to a 
peak at 35 months (Figure 3.8A).  
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Figure 3. 8: Acquisition of S. Typhimurium-specific serum bactericidal activity 
among children 
Log 10 change in S. Typhimurium cfu/ml from the control condition was plotted against 
age. The y-axis was inverted. Nonlinear regression polynomial model was represented by 
solid line (Figure 3.8A, n=65). SBA responses within early (Figure 3.8B, n=29), and late 
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periods (Figure 3.8C, n=27) was determined by linear regression, represented by solid 
central line and 95% CI represented by dashed lines. 
 
To further analyse these trends in S. Typhimurium-specific SBA, periods were divided 
into early and late phases according to peak and nadir points, as before. S. Typhimurium -
specific SBA declined in the first 8 months of life (r²=0.323, slope 0.292, 95% CI [0.125, 
0.459], p=<0.01), and then increased between 8-35 months (r²=0.319, slope -0.121, 95% 
CI [-0.193, -0.048], p=<0.01), (Figure 3.8A and 3.8C). This S. Typhimurium-specific 
increase in SBA occurred later than that seen in T cell immunity to S. Typhimurium 
(Figure 3.4 and 3.8). 
 
3.4.7 S. Typhimurium -specific SBA correlates with presence of antibodies 
targeting S. Typhimurium -LPS 
Previous work in HIV-infected Malawian adults showed that excess anti-LPS IgG 
antibodies can inhibit complement-mediated killing of NTS in vivo while antibodies to 
outer membrane proteins (OMP) can mediate bactericidal activity (MacLennan, et al., 
2010). To clarify the antigenic targets of the S. Typhimurium-specific antibody in 
children, serum antibodies to S. Typhimurium LPS, OMP and FliC and E. coli 0127:B8 
LPS were measured  as described in Chapter 2, section 2.1.7.11. Anti- S. Typhimurium-
LPS IgG antibody titers mirrored the pattern seen with SBA assay (Figure 3.8A and 
Figure 3.9A).  
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Figure 3. 9: Age dependent acquisition of specific anti- S. Typhimurium-IgG 
antibodies 
Serum from children was tested for anti-S. Typhimurium-specific IgG antibodies by 
ELISA. Anti-S. Typhimurium-LPS IgG (Figure 3.9A, n=63), anti- S. Typhimurium OMP 
IgG (Figure 3.9B, n=66), anti-S. Typhimurium-FliC IgG (Figure 3.9C, n=67) and anti-
E.coli-LPS IgG antibody titers (Figure 3.9D, n=63) were plotted against age. SBA with 
age was determined by nonlinear regression polynomial models represented by solid line. 
The immune responses in adults (Figure 3.9E, n=12). Bars represent median. 
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Anti- S. Typhimurium -OMP, were lowest at birth increasing with age while anti- S. 
Typhimurium -FliC IgG and anti-E. coli-LPS IgG antibody titers showed no particular 
trend with age (Figure 3.9B-D). The correlation between SBA and anti- S. Typhimurium-
LPS IgG titers (r=0.329, 95% CI [0.552, 0.062] p=0.01) and the lack of correlation 
between SBA and anti-E. coli-LPS titers suggest that SBA is due to S. Typhimurium -
specific rather than non-specific LPS antibodies (Table 3-B). A lack of a correlation with 
anti- S. Typhimurium -OMP and anti- S. Typhimurium-FliC suggest that these targets do 
not substantially contribute to SBA in these children. 
 
3.4.8 S. Typhimurium -specific CD4+ T cell immune responses in early childhood 
are associated with generation of anti- S. Typhimurium protein antibodies 
Having shown that S. Typhimurium -specific CD4+ T cells peak in early life (Figure 
3.10), whether this immune memory was linked to the generation of anti- S. 
Typhimurium -OMP and anti- S. Typhimurium -FliC IgG antibodies was then 
investigated.  
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Figure 3. 10: Sequential acquisition of T cells and antibodies to S. Typhimurium in 
children 
Age distribution of S. Typhimurium BSI in under-five children at QECH Blantyre, 
Malawi 2006-2011 was superimposed with kinetics of S. Typhimurium -specific CD4+T 
cell immune responses and S. Typhimurium -specific serum bactericidal activity (y-axis 
was inverted) in children (0-60 months age).  
 
S. Typhimurium -specific CD4+ T cell immune responses correlate with anti- S. 
Typhimurium -OMP and anti- S. Typhimurium -FliC IgG antibodies in early childhood 
(r=0.405, 95% CI[0.088, 0.647] p=0.01  and  r=0.394, 95% CI[0.080, 0.637]  p=0.01 
respectively) and not anti- S. Typhimurium -LPS IgG antibodies (r=-0.257, 95% CI[-
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0.547, 0.087]   p=0.129) (Table 3-B). This contemporaneous development of antibodies 
to S. Typhimurium OMP and T-cell immunity is in line with the conventional paradigm 
of the T cell dependent immune response to a protein antigen (Sinha, et al., 1997, Mohr, 
et al., 2010).  
 
3.5 DISCUSSION 
NTS bacteraemia remains an important cause of death among children in SSA. This study 
extend previous observations that complement-fixing antibodies to NTS are considered to 
be ‘protective’ and develop by 24 months of age (MacLennan, et al., 2008). S. 
Typhimurium specific CD4+ immunity peaked in early life (14 months of age), 
suggesting exposure to S. Typhimurium or to cross reactive antigens. It is likely that this 
exposure occurs within the gut associated lymphoid tissues (GALTs) and primed  T cells 
traffic into the peripheral circulation (Dougan, et al., 2011). Surprisingly, in older 
children (>14 months) specific T cells declined in the peripheral blood, probably due to a 
decline in S. Typhimurium specific exposure within the GALT. Together these findings 
suggest unique phases of S. Typhimurium exposure and T cell priming (early phase) and 
this perhaps permits antigen-specific to CD4+ T cells spilling into the peripheral blood.  
It is possible that the late phase is characterized by limited S. Typhimurium exposure and 
pathogen clearance by the CM T cells. Some confirmation of these findings is noted in 
the correlation of S. Typhimurium -specific T cell immune responses in early life and the 
antibody titers to S. Typhimurium protein antigens and not S. Typhimurium LPS. 
Furthermore the trends of S. Typhimurium - specific CD4+ and CD8+ cytokine producers 
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were similar suggesting the maturation of both CD4+ and CD8+ T cells following 
Salmonella exposure. 
 
Distribution of NTS within the gastrointestinal tract (GIT) by age in this population is not 
known. As previous demonstrated, this study has shown that S. Typhimurium 
bacteraemia peaks at 13 months of age and 80% of cases occur in children under-two 
among under-five children (MacLennan, et al., 2008). Whether this age distribution in S. 
Typhimurium bacteraemia indicates asymptomatic S. Typhimurium colonization within 
the gut is not clear. Contracting Salmonella infection occurs through ingestion of 
contaminated food or fomites (Kariuki, et al., 2006). In this population exclusive breast 
feeding is practiced mainly in the first 3 months of age and thereafter mixed feeding in 
commonly practiced (Kalanda, et al., 2006, Kerr, et al., 2007). It appears that the 
introduction of supplementary feeding coincides with the age group of S. Typhimurium 
bacteraemia. Risk factors of S. Typhimurium bacteraemia include malnutrition and HIV. 
The leaky gut mucosa in malnourished and HIV infected children (Reynolds, et al., 1996, 
Papasavvas, et al., 2011) might contribute to spread of S. Typhimurium normally 
localized in the GIT into the peripheral blood. The emergence of MDR and more virulent 
S. Typhimurium strain D23580 (driven by genetic degradation) (Kingsley, et al., 2009), 
might explain changes in life style of an organism that causes localized gastroenteritis 
worldwide but predominately causes invasive disease in otherwise healthy children in 
SSA. 
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Serum killing of an invasive S. Typhimurium strain D23580 that is predominant in the 
SSA region requires IgM or IgM S. Typhimurium specific-antibodies (MacLennan, et al., 
2008). In the absence of the S. Typhimurium-specific IgG antibody, the SBA is abrogated 
(Heffernan, et al., 1992, MacLennan, et al., 2008). As previously demonstrated 
(MacLennan, et al., 2008), this study demonstrates that passively acquired S. 
Typhimurium specific SBA from the mother gradually declines from birth to about 8 
months of age. This is consistent with the observation that  transfer of both immune 
serum and immune cells were necessary for protection to mouse-virulent strain S. 
Typhimurium C5 in innately susceptible BALB/c (ltys) mice (Mastroeni, et al., 1993). 
After 8 months of age, presumably following exposure to Salmonella, antigen-specific 
SBA develops with age and peaks at 36 months. Interestingly, this study shows that this 
specific SBA correlates with S. Typhimurium specific antibodies targeting LPS and not 
OMP and FliC. MacLennan et al previously demonstrated that in HIV infected Malawian 
adults S. Typhimurium-specific antibodies targeting LPS were SBA inhibitory and not S. 
Typhimurium specific antibodies targeting OMP. This was due to the high concentration 
of S. Typhimurium-specific IgG antibodies targeting LPS, which is not the case in 
healthy Malawian children examined in this study. High concentration of S. 
Typhimurium specific IgG antibodies in HIV infected individuals are likely due to leaky 
gut that might permits transfer of LPS molecules into the peripheral blood (Papasavvas, 
et al., 2011). 
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Taking into account age related acquisition of S. Typhimurium-specific T cell immune 
responses, it appears that acquisition of SBA is delayed. Perhaps not surprising, naturally 
acquired antibody responses to pneumococcal specific protein antigens appear early 
compared to antibodies to pneumococcal-specific-polysaccharide antigens in children 
(Rapola, et al., 2000, Soininen, et al., 2001). Furthermore, the process of generation of 
highly efficient isotype-switched IgG antibodies is dependent on CD4+ T cells and B cell 
cross talk (Cunningham, et al., 2007), suggesting that mature complement-fixing 
antibodies to S. Typhimurium are expected to follow the emergence of specific T cells.   
 
Immunity to Salmonella is considered complex due Salmonella facultative intracellular 
lifestyle and its strategies to escape even the competent host immune system. It has been 
hypothesized previously that high level of resistance to Salmonella is established in a 
step-wise fashion; innate immunity (innate cells and humoral immunity) preceding the  
adaptive immunity (beginning with the CD4+ T cell followed by the B cells and CD8+ T 
cells) (Mastroeni, 2002). In this study, the kinetics of S. Typhimurium -specific immunity 
(antibodies and T cells) and age distribution of S. Typhimurium bacteraemia were 
explored. Importantly cases of S. Typhimurium bacteraemia declines in parallel with 
decline in specific-CD4+ T cell immune responses and increase in SBA. Furthermore, 
cases of S. Typhimurium bacteraemia were more at the peak of CD4+ T cells responses, 
suggesting that CD4+ cells alone are not sufficient to clear S. Typhimurium infection and 
sequential acquisition of specific-SBA results in establishment of high level of resistance 
and decline in cases of S. Typhimurium bacteraemia.  
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Since salmonellae are facultative intracellular organism, complement-fixing antibodies 
are implicated in killing S. Typhimurium in the extracellular space and supports 
intracellular killing (Gondwe, et al., 2010). CD4+ T cells helps macrophages intracellular 
killing of S. Typhimurium and importantly clears reside S. Typhimurium that can 
potentially cause relapse of S. Typhimurium bacteraemia (Mastroeni, 2003). Taken 
together these findings are in agreement with the hypothesis that S. Typhimurium 
immunity is acquired in a step-wise fashion and high level of resistant is only established 
when both the T cell and antibody immunity are fully mature. 
 
Given the burden of iNTS in SSA (Reddy, et al., 2010), a vaccine is urgently required. S. 
Typhimurium LPS O-antigen has considerable potential as a vaccine target and there are 
currently several groups developing conjugate vaccines for this purpose to overcome the 
short-lived T-independent antibody response generated by polysaccharide alone 
(MacLennan, 2013). Immunization with S. Typhimurium -OMP and S. Typhimurium-
FliC induce both T cells response and production of antibodies in animal models, and 
these Salmonella derived proteins are therefore also being investigated as vaccine 
candidates, either separately (Gil-Cruz, et al., 2009) or covalently linked to O-antigen as 
glycoconjugates (Simon & Levine, 2012). 
 
Summary  
In Malawian children T cell and antibody immunity to S. Typhimurium are acquired 
sequentially.  Acquisition of both T cell mediated immunity and antibodies are required 
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for robust resistance to invasive Salmonella disease. Children below 2 years of age are 
more vulnerable to invasive Salmonella disease and public health intervention inform of 
vaccination is required. A vaccine that elicits both T cell and antibody immunity and also 
provide cross protection to common Salmonella serovars is required particularly in young 
children. 
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CHAPTER 4: SALMONELLA EXPOSURE AND DEVELOPMENT OF SPECIFIC 
IMMUNITY IN MALAWIAN CHILDREN 
 
4.1  INTRODUCTION 
As reviewed previously (chapter 1), Nontyphoidal Salmonella (NTS), principally S. 
Typhimurium and S. Enteritidis are among the commonest causes of bacteraemia in sub-
Saharan Africa (SSA)(Gordon, et al., 2008, Morpeth, et al., 2009). NTS infections are 
most common in children below 3 years of age and HIV-infected individuals (Gordon, et 
al., 2008, MacLennan, et al., 2008, Graham & English, 2009). Understanding what 
constitutes naturally acquired protective immunity to Salmonella and defining the age 
group when this acquisition occurs is important for understanding the pathogenesis of the 
disease and for the development of an effective vaccine. Opsonic IgG antibodies to 
Salmonella facilitate efficient killing of Salmonella in the extracellular space, primarily 
the blood, by fixing-complement (MacLennan, et al., 2008) and intracellular space of 
phagocytes by respiratory burst (Gondwe, et al., 2010). Acquisition of serum bactericidal 
activity (SBA) to S. Typhimurium has been described in Chapter 3, as peaking at 36 
months of age, which coincides with the decline in incidence of S. Typhimurium 
bacteraemia. Furthermore, Chapter 3 describes that CD4+ and CD8+ T cell immunity to 
S. Typhimurium are acquired early in life in Malawian children, peaking at 14 months of 
age, suggesting that the gut associated lymphoid tissues (GALTs) are exposed to S. 
Typhimurium or cross-reactive bacteria during this period.  
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Age distribution of Salmonella bacteraemia in Malawian children has been described in 
Chapter 3 and previously by MacLennan et al (MacLennan, et al., 2008), as peaking at 
13 months of age in under-five children but the age distribution of Salmonella exposure 
within the gastrointestinal tract (GIT) in this population is not known. Salmonella 
infection is thought to result from ingestion of contaminated food, water or contact with 
contaminated fomites (Kariuki, et al., 2006). A cohort study of Mexican children from 
birth to 12 months of age, demonstrated that 40% of children were initially exposed to 
Salmonella (detected by culture) within the GIT (Cravioto, et al., 1990). Under-five 
children have been shown to shed Salmonella in their stools for as long as 7 weeks 
(Buchwald & Blaser, 1984). In Malawi, in a study of children presenting to hospital with 
NTS bacteraemia, 40% (66/167) had Salmonella also isolated from the oropharynx, and 
52% (73/141) had Salmonella also isolated from stool at the point of diagnosis (Msefula, 
2009). Salmonella exposure within the oropharynx and/ or GIT might help to explain the 
natural immunizing events in children from SSA, and neither the acquisition of humoral 
immunity, following gut or oropharyngeal mucosal exposure, have previously been 
studied longitudinally in Malawian children. It is uncertain whether this Salmonella 
exposure within the GIT is asymptomatic or accompanied by an episode of diarrhoeal 
disease, which could be mild and transient or severe (Cravioto, et al., 1990). This study 
therefore aimed to explore the hypothesis that in the first 18 months of life, the 
gastrointestinal tract is exposed to Salmonella serovars or other cross-reactive enteric 
pathogens with minimal symptoms which induce the development Salmonella-specific 
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serum immunity. This immunity might have the potential to protect against subsequent 
Salmonella infection and particularly invasive NTS disease.  
 
Maternal breast milk antibodies (principally IgA) and trans-placental maternal IgG are 
thought to have a role in defence against pathogens in infancy. The protective role of 
breast milk against enteric pathogens has been recognized for a long time (France, et al., 
1980, Cravioto, 1990, Thomas, et al., 2004, Shapiro, et al., 2007); and has been shown to 
be critically important for Malawian infants (Kafulafula, et al., 2010). Chapter 3 shows 
that NTS bacteraemia is most frequent as maternally acquired (trans-placental) serum 
antibody wanes and following discontinuation of breast feeding or following introduction 
of supplementary food. This suggests that either or both trans-placental IgG and breast 
milk IgA might play a role in preventing Salmonella colonisation of the gastrointestinal 
tract in the early months of life.   
From this background, a prospective longitudinal cohort study of 60 healthy infants at 
Zingwangwa health centre (ZHC) in Blantyre, Malawi was conducted. These children 
and their mothers were recruited at 6 months of age and followed up until 18 months of 
age, to determine the association of Salmonella exposure within the GIT and oropharynx 
(examined at monthly intervals using stool and oropharyngeal samples, analysed by 
culture and real-time PCR) and the development of serum immunity to Salmonella 
(examined at 3 month intervals using serum killing assay). Furthermore, maternal breast 
milk bactericidal activities were quantified to explore their role in preventing Salmonella 
colonisation of the GIT. 
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Hypothesis: In the first 18 months of life, the gastrointestinal tract and / or oropharynx 
are exposed to Salmonella serovars which induce the development of Salmonella-specific 
serum immunity. 
 
Study objectives: 
c) To determine the pattern of Salmonella exposure events within the GIT and 
oropharynx in Malawian children over a period of 1 year from 6 to 18 months of age.  
d) To determine whether Salmonella exposure events in children are associated with 
acquisition of Salmonella-specific serum killing. 
e) To determine whether maternal breast milk kills Salmonella ex vivo. 
 
4.2  PARTICIPANT RECRUITMENT AND METHODS 
The participant recruitment and methods for this chapter have been described in Chapter 
2 section 2.2. In brief, 60 healthy children and their mothers were recruited from 
Zingwangwa Health Centre (ZHC) at 6 months of age and followed for 1 year. ZHC 
provides primary health care to persons living in Soche Ward (SW) of Blantyre city. SW 
is one of the densely populated wards in Blantyre, with the population of 60,000 (MCI, 
2012). Child participants were sampled stool and oropharynx swab at monthly intervals 
and were also sampled serum at 3 months intervals. Mothers of each child participant 
were sampled serum at study entry only and also sampled breast milk at 6 months 
intervals. To determine the pattern of Salmonella exposure, stool and oropharynx swabs 
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were examined for Salmonella using standard culture or PCR. Serum from children 
exposed to Salmonella or not was quantitatively examined for serum bactericidal activity 
to S. Typhimurium strain D23580, S. Typhimurium 037v4 and Salmonella species 049v3. 
Maternal breast milk was also quantitatively examined for breast milk bactericidal 
activity to S. Typhimurium strain D23580. At monthly intervals children were clinically 
examined (MUAC, Temperature, and malaria rapid test) and clinical history (diarrhoea, 
cough, antimalarial and antibiotics usage) was taken by the research nurse. Research 
nurse also administered a questionnaire to mothers to explore child feeding practices 
including breast feeding, water source and water treatment. Global Positioning System 
(GPS) coordinates for each child place of residence were captured by the research field 
worker.  
 
4.3  STATISTICAL ANALYSES 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad 
Software, USA) and Stata SE® version 12.1 (StataCorp, USA) statistical analysis 
packages. End-point response variables (SBA) were examined for normality of 
distribution. Normally distributed immune variables were analysed using paired t test to 
compared groups at different time points. Two-tailed nonparametric, Mann-Whitney tests 
were used to compare immune variables at different time points. Kaplan-Meier survival 
function test was used to demonstrate the trend of Salmonella exposure events and 
feeding practices with age. Odd ratios were used to describe the relationship between 
Salmonella exposure events and clinical presentation, Salmonella exposure events and 
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feeding practices and Salmonella exposure events and serum bactericidal activity. Global 
Positioning System (GPS) visualizer (www.gpsvisualizer.com) was used to draw maps 
for the study participant’s places of residence. Logistic regression analyses were used to 
describe the relationship between location absolute altitudes and Salmonella exposure 
events. 95% confidence intervals or interquartile range (IQR) were reported and p value 
of <0.05 or confidence intervals not crossing 1 were considered statistically significant.  
 
4.4  RESULTS 
4.4.1 Incidence of first Salmonella exposure within the GIT in a cohort of healthy 
Malawian children 
A total of 60 healthy children were recruited (25 were male [42%]) at 6 months of age 
between August 2013 and December 2013, and these were followed until December 2014 
for study specific procedures described in Chapter 2 section 2.2. A total of 630 stool 
samples from 60 children were examined for Salmonella (stool culture or rt-PCR) in this 
cohort. Kaplan–Meier survival analysis was used to describe the pattern of Salmonella 
exposure events. A total of 630 stool samples were examined for Salmonella (stool 
culture or rt-PCR) in this cohort, there were 105 observations beginning on or after the 
first exposure event within the GIT (stool samples). There were 525 observations 
remaining, from 60 children and 22 children were positive for Salmonella at least once 
during the follow up period. Mean number of visits per child was 9 (ranging from visit 1 
to 13) and by the 13
th 
study visit (18 months of age) 21.6% (13/60) of children, were lost 
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to follow up. These children (13/60) voluntarily withdrew from the study because their 
parents (father) or guardians (uncle/grandparent) were not willing for their child to 
participate in the study. Over the period of observation from 6 months to 18 months of 
age, 46.8% (22/47) of children were exposed to Salmonella (detected using culture and 
RT-PCR) within the GIT on at least one occasion (Figure 4.1).   
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Figure 4. 1: Incidence of first Salmonella exposure within the GIT in a cohort of 
healthy Malawian children 
Incidence of first Salmonella exposure within the GIT in a cohort of children recruited at 
6 months of age, examined for Salmonella exposure at monthly intervals and exiting the 
study at 18 months. Using Kaplan-Meier survival function test, this figure shows the 
proportion of children remaining unexposed over time (Figure 4.1).  
 
All stool samples (630) were examined by culture and from this total, 198 samples (these 
samples were of varying ages and were selected consecutively) were also examined by 
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real time PCR. Not all stool samples were tested using PCR because the test was 
developed when the study had already started and there was limited funding to test all 
samples. A total of 29 Salmonella exposure events were detected in stool by culture or 
real time PCR thus representing 4.6% (29/630) of the stool samples obtained and when 
Salmonella was detected in stool is shown  (Figure 4.2A). Salmonella exposure events 
among female and male children were similar, 18/368 (4.8%) and 11/251 (4.2%) 
respectively. Out of these 29 exposure events, 6 were detected by rt-PCR only and none 
were detected by culture only. The remaining 23 were serotyped using standard 
procedures as described in Chapter 2 section 2.2.8.7. Among stool samples that tested 
culture or PCR positive, salmonellae isolates were principally S. Typhimurium 51.7% 
(15/29), followed by non-defined serovars 31% (9/29), S. Typhi 10.3% (3/29)  and S. 
Enteritidis 7% (2/29) (Figure 4.2B).  Among samples analysed by both culture and PCR, 
there were 7/29 (24%) children exposed to Salmonella at least twice during whole study 
period (5/7 [71%] were 1 month apart and 2/7 [28.5%] were 3 months apart) and none 
was exposed more than twice. Among children that were exposed twice to Salmonella 
within the GIT; 5/7 (71%) to S. Typhimurium, 1/7 (14.2%) to S. Typhimurium and S. 
Enteritidis and 1/7 (14.2%) to S. Typhi and non-defined Salmonella serovars. A total of 
269 oropharynx swabs were tested for Salmonella by standard culture only and all 
samples tested negative for Salmonella. 
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Figure 4. 2:  Frequency of Salmonella exposure within the GIT in Malawian children 
Salmonella detected in stool samples by either culture (n=630) or rt-PCR (n-198) were 
plotted against varying ages as indicated (Figure 4.2A). Distribution of Salmonella 
serovars detected by culture or rt-PCR are shown (n=29) (Figure 4.2.B). 
 
 
4.4.2 Clinical features of Salmonella exposure  
Young children may have a relatively high background rate of intercurrent 
gastrointestinal symptoms  including diarrhoea, fever and vomiting  (Uhnoo, et al., 
1986). To explore whether or not children exposed to Salmonella were more likely than 
unexposed children to be symptomatic, clinical history in relation to Salmonella exposure 
events were reviewed.   
During the follow-up visits, there were a total of 54/563 (9.6%) current diarrhoea 
(defined as  3 loose stools per day) events recorded. There were 3/23 (13%) diarrhoea 
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events in children with Salmonella in their stool while 51/540 (9.4%) were found in stool 
negative children, OR 1.43 95% CI (0.41, 5.0) (Table 4-A). In the month prior to the 
follow-up visits, a total of 99/563 (17.6%) diarrhoea events were reported. 6/23 (26%) 
were reported in children that were exposed to Salmonella while 93/540 (17.2%) 
diarrhoea events were reported in non-exposed children, OR 1.69, 95% CI (0.65, 4.4) 
(Table 4-B). These findings showed that although there was a trend for children who had 
Salmonella detected in their stool to have diarrhoea or to have had a diarrhoea episode in 
the last month, this did not reach statistical significance.  Rotavirus is important causative 
agent of diarrhoea in Malawi (Cunliffe, et al., 2010). Recently the government of Malawi 
introduced rota virus vaccination (Madsen, et al., 2014). Coverage of rota virus 
vaccination in this cohort was 100% (60/60) at 6 months of age (study entry). To what 
extent the frequency of diarrhoea in this cohort was influenced by the recently rolled-out 
rotavirus vaccination in Malawi is not clear, but since coverage was so high, there is 
unlikely to be a difference between those who did or did not experience exposure to 
Salmonella.  
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Table 4- A: Clinical presentation among children at current visit  
 
Total 
(%) 
(N=563) 
Exposed 
(%) 
(N=23) 
Non-exposed (%) 
(N=540) 
 
Exposed vs non-
exposed 
OR (95% CI) 
 
Diarrhoea 54 (9.6) 3 (13) 51 (9.4) 1.43 (0.41, 5.0) 
Vomit 21 (3.7) 2 (8.7) 19 (3.5) 2.6 (0.57, 11.9) 
Cough 110 (19.5) 7 (30.4) 103 (19) 1.8 (0.74, 4.6) 
Temp >37.8
o
C 11(1.9) 2 (8.7) 9 (1.7) 5.6 (1.14, 27.6) 
Malaria 5 (0.9) 0 (0) 5 (0.92) ND 
MUAC 11-12.5cm
a 15 (2.6) 1 (4.3) 14 (2.6) 1.7 (0.21, 13.2) 
MUAC 12.5-13.5 cm
b 35 (6.2) 2 (8.6) 33 (6.1) 1.46(0.33, 6.4) 
MUAC 11-13.5 cm
c 50 (8.8) 3 (13) 47 (8.7) 1.57(0.45, 5.4) 
ND refers to not done  
a 
Moderate acute malnutrition (MAM) 
b 
At risk of acute malnutrition
 
 
c 
Combination of MAM and those at risk of malnutrition  
 
Table 4- B: Clinical history over the previous month among children 
 
Total 
(%) 
(N=563) 
Exposed (%) 
(N=23) 
Non-exposed (%) 
(N=540) 
Exposed vs non-
exposed 
OR (95% CI) 
Diarrhoea 99 (17.6) 6 (26) 93 (17.2) 1.69 (0.65, 4.4) 
Vomit 30 (5.3) 1 (4.3) 29 (5.4) 0.8 (0.104, 6.15) 
Cough 
127 
(22.5) 
5 (21.7) 122 (22.6) 0.95 (0.34, 2.6) 
Antibiotic 
139 
(25.9) 
7 (30.4) 132 (18.5) 1.35 (0.54, 3.35) 
Antimalarial 8 (1.4) 1 (4.3) 7 (1.3) 3.4 (0.4, 29) 
 
Malnutrition is commonly associated with NTS bacteraemia in children from SSA 
(Graham, et al., 2000, Babirekere-Iriso, et al., 2006). In this cohort, children Mid-Upper 
Arm Circumference (MUAC) ranging 11.5-19cm were recorded and the mean was 15cm. 
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MUAC measurements were grouped or defined as follows; <11cm severe acute 
malnutrition (SAM), 11-12.5cm moderate acute malnutrition (MAM), 12.5-13.5cm at 
risk of acute malnutrition and above 13.5cm well nourished. A total of 50/563 (8.8%) 
children had MUAC ranging 11-13.5cm and amongst these children 3/23 (13%) had 
Salmonella detected in theirs stool and 47/540 (8.7%) had no Salmonella detected in their 
stool (OR 1.57, 95% CI [0.45, 5.4]). Although not statistically significant, these findings 
suggested that malnutrition may be associated with a predisposition to Salmonella 
exposure in the gut. Similarly, there was a no significant difference for children to 
experience either cough (at current visit OR 1.8, 95% CI [0.74, 4.6]) or vomiting (at 
current visit OR, 2.6, 95% CI [0.57, 11.9] at the time when children stool was positive for 
Salmonella compared to when children stool was negative (Table 4-A).  
 
A total of 11/563 (1.9%) fever events (Temp >37.8
o
C) were recorded in this cohort at 
current visit, 2/23 (8.7%) were detected in children exposed to Salmonella while 9/540 
(1.7%) were detected in non-exposed children, OR 5.6, 95% CI (1.14, 27.6) (Table 4-A).  
These findings suggest that children whose stool culture was positive for Salmonella 
were 5.6 times more likely to have a current fever than children without a positive stool 
culture for Salmonella. Clinical features including fever, cough, vomiting and diarrhoea 
in which stool culture was positive for Salmonella may have resulted in non-specific 
symptomatic febrile illness. 
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Recent or current malaria infections are an important comorbidity of NTS bacteraemia in 
children from SSA (Graham, et al., 2000, Brent, et al., 2006, Bronzan, et al., 2007, 
Biggs, et al., 2014). The burden of malaria is considerably high in Malawi, particularly, 
in under-five children (Mathanga, et al., 2012), with asymptomatic parasitaemia rates 
ranging between 11.2-18.5% (Roca-Feltrer, et al., 2012). In Blantyre, the Plasmodium 
falciparum parasite rate for children 2-<10 years is the lowest in Malawi (26%) (Bennett, 
et al., 2013). It was therefore somewhat surprising that even for these very young urban 
dwelling children, at the current visit, only  0.9% (5/563) malaria events were recorded, 
none was among children that had Salmonella detected in their stool. Furthermore, during 
the previous month a total of 8/563 (1.4%) antimalarial usage events were recorded, 1/23 
(4.3%) were recorded in children exposed to Salmonella and 7/540 (1.3%) were recorded 
in non-exposed children, OR 3.4, 95% CI (0.4, 29). This difference was not significant, 
but the trend would be in keeping with literature suggesting that recent (rather than 
current) malaria is a risk factor for Salmonella disease (Brent, et al., 2006). It is also 
possible that antimalarial drugs were taken by children as syndromic management rather 
than a confirmed disease. These findings would need to be further explored in a much 
larger cohort. 
 
During the previous month a total of 139/563 (25.9%) antibiotic usage events were 
reported, 30.4% (7/23) antibiotic usage events were reported in children who were 
exposed to Salmonella and 24.4% (132/540) were reported in non-exposed children, OR 
1.35, 95% CI (0.54, 3.4). This difference was not statistically significant, but it is known 
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that administration of antibiotics may be a risk factor for more prolonged carriage of 
Salmonella (Miller, et al., 1954), or may alternatively be a proxy marker for recent febrile 
illness caused by carriage or indeed malaria. Taken together these findings suggest that 
some Salmonella episodes (ranging 8.7% to 30.4%) detected were associated with non-
specific symptomatic febrile illness. In keeping with the literature, recent malaria and 
prior antibiotic usage might be risk factors for Salmonella exposure in the GIT.  
 
 
4.4.3 Child feeding practices and Salmonella exposure  
Salmonella infection follows ingestion of contaminated food, water or contact with 
contaminated fomites (Kariuki, et al., 2006). Most Malawian babies are exclusively 
breast fed and introduced to supplementary food after 3 months of age (Kalanda, et al., 
2006); milk formula feeding is rare, particularly in the demographic sampled. Chapter 3 
demonstrates that T cell immunity to S. Typhimurium is detected early in life (peaking at 
14 months of age) suggesting early exposure to Salmonella serovars or cross-reactive 
enteric bacteria. From this background, child feeding practices in this cohort were 
retrospectively explored. In this cohort, all children were being breast fed at 6 months 
(study entry). Supplementary feeding had been gradually introduced: 9% by the first 3 
months of life; 29% by 4 months of age; 63% by 5 months of age and 91% by 6 months 
of age (Figure 4.3). At 18 months (study exit age), 8/47 (17%) of those children 
remaining in the study had discontinued breast feeding.  
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Figure 4. 3: Introduction of supplementary food in Malawian children  
Mothers were asked, at the study entry point (6 months of age) when they introduced 
supplementary food to their babies. Using Kaplan-Meier survival function test, 
percentage of children exclusively breast fed during the first 6 months of life are shown 
(Figure 4.3).  
 
Sources of water used by study participants at their homes were documented. A majority 
of families, 82.7% (466/563) were using tap water (Table 4-C). Among children that 
were exposed to Salmonella, 82.6% (19/23) were using tap water and among non-
exposed children, 82.7% (447/540) were using tap water, OR 0.99, 95% CI (0.32, 2.97). 
Among children that were exposed to Salmonella, 26% (6/23) were using boiled water 
for drinking and among non-exposed children, 35.1% (190/540) were using boiled water, 
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OR 0.65, 95% CI (0.25, 1.67). This non-significant trend showed that boiling water for 
drinking might have reduced Salmonella exposure or transmission.   
 
Table 4- C: Water source and Salmonella exposure 
 
Total (%) 
(N=563) 
Exposed (%) 
(N=23) 
Non-exposed (%) 
(N=540) 
Exposed vs 
non-exposed 
OR (95% CI) 
Tap 
466 (82.7) 19 (82.6) 447 (82.7) 0.99 (0.32, 2.97) 
Borehole 
64 (11.3) 1 (4.3) 63 (11.6) ND
a 
River 
23 (4) 3(13) 20 (3.7) 3.9 (1.07, 14.2) 
Bottle 10 (1.7) 0 (0) 10 (1.8) ND
a 
a
ND refers to not done  
 
Furthermore, a total of 64/563 (11.3%) observations were made on use of borehole water. 
Among children that were exposed to Salmonella, 4.3% (1/23) were using borehole water 
and among the non-exposed children, 11.6% (63/540) were using borehole water. While 
using water from the borehole appeared to have reduced Salmonella transmission, this 
was not statistically significant. A total of only 23/563 (4%) children were using river 
water for drinking. Among Salmonella exposed children, 13% (3/23) were using river 
water and among non-exposed children, 3.7% (20/540) were using river water, and this 
finding was statistically significant, albeit with wide confidence intervals because of the 
small numbers; OR 3.9, 95% CI (1.07, 14.2).  Together these findings suggest that 
Salmonella exposure occurred in these children following the introduction of 
supplementary food in nearly all children. Furthermore, using water from the river may 
be a risk factor for Salmonella exposure and although not statistically significant, use of 
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borehole or boiled water may be associated with reduced Salmonella transmission or 
exposure. A larger study would be needed to establish this definitively.  
 
4.4.4 Living adjacent to a river or water stream may be a risk factor for 
Salmonella exposure in children 
Both poor sanitary environment and food hygiene are important risk factors for the 
transmission of Salmonella (Crump & Mintz, 2010, Breiman, et al., 2012). In this cohort, 
geographical locations of these children’s homes (by protocol design coming from within 
5 kilometres radius from ZHC) were explored. Using GPS co-ordinates study 
participant’s homes locations were mapped by GPS visualizer (Figure 4.4A-B). Initially 
it appeared that children that were exposed to Salmonella appeared to reside in close 
proximity to the river or water streams. It is possible that families living nearer the river 
or water stream use contaminated water for household chores and also drinking. Children 
living at lower altitude relative to rivers might experience more “washout” surface water 
from contaminated sources or from contaminated standing groundwater near the river 
during rainy season when the water table is higher. However, when this was explored 
systematically using logistic regression analysis, the analysis did not show any statistical 
significant difference between the distribution of absolute altitude GPS locations of the 
homes of Salmonella-exposed and the non-exposed groups, OR 0.99, 95% CI (0.98, 1.0).  
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AA Salmonella exposed children 
 
BB Unexposed children 
 
Figure 4. 4: GPS mapping of the homes of Salmonella-exposed and unexposed 
children 
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A Google terrain map showing the GPS location of homes of children that were 
Salmonella-exposed (Figure 4.4A) and homes of children that were never exposed to 
Salmonella (Figure 4.4.B) 
 
Further more complex geospatial modelling analysis of absolute altitude, altitude above 
rivers, and distance from rivers is therefore planned, but is beyond the scope of this 
thesis, and further studies are required to understand the geospatial factors that are 
important in the transmission of Salmonella in this population. 
 
4.4.5 Maternal breast milk lacks Salmonella-specific bactericidal activity  
Maternal breast milk has a role in protecting children from a wide range of pathogens, 
including enteric pathogens (Hanson, et al., 1990). Previously it was demonstrated that 
breast fed children had 5 fold reduced risk of  Salmonella  gastroenteritis infection 
compared to non-breast fed children (Borgnolo, et al., 1996). Whether breast milk was 
able to kill or control the growth of Salmonella was investigated in this cohort. Chapter 2 
section 2.2.8.5, describes the development of the milk bactericidal activity assay. 
Unexpectedly, breast milk did not inhibit the growth S. Typhimurium strain D23580 by a 
least -1 log10 change cfu/ml, while maternal serum from the same mothers used as a 
control, robustly inhibited growth of  S. Typhimurium strain D23580 (p=<0.001, Mann-
Whitney test) (Figure 4.5).   
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Figure 4. 5: Maternal breast milk lack invasive Salmonella-specific bactericidal 
activity 
Log10 change in S. Typhimurium strain D23580 cfu/ml from the baseline condition in 
maternal serum and breast milk. PBS and heat inactivated milk were used as the baseline 
condition for maternal serum and breast milk respectively as describe in chapter 2 section 
2.2.8.5.  The red bars represents the mean (n=51).  
 
These findings suggest that breast milk itself lacks bactericidal activity against S. 
Typhimurium strain D23580. However, it is possible that breast-feeding might limit 
Salmonella colonisation within the GIT by other mechanisms apart from direct 
bactericidal activity, such as inhibition of colonisation or mucosal adherence, or by 
altering the infant’s gut microbiota (Weening, et al., 2005, Roger, et al., 2010, Mantis, et 
al., 2011, Stecher & Hardt, 2011). 
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4.4.6 Relationship between Salmonella exposure and serum bactericidal activity in 
children 
Chapter 3 describes that SBA to S. Typhimurium strain D23580 is acquired with age and 
peaks at 36 months of age in Malawian children, while T cell immunity to S. 
Typhimurium is acquired early in life, peaking at 14 months of age. Whether or not this 
antibody and T cell immunity development is facilitated by mucosal Salmonella exposure 
is a key question. In this cohort, two stool Salmonella isolates (S. Typhimurium ID 037v4 
and Salmonella spp. ID 049v3 isolated from children 9 months and 8 months old 
respectively)  were selected  to be used in SBA experiments in parallel with S. 
Typhimurium  strain D23580 (a sequenced and well-characterised blood isolate 
(Kingsley, et al., 2009)). Using serum from 6 month-old children, D23580 and 037v4 
resistance to serum killing was similar while 049v3 was significantly more sensitive to 
serum  killing  compared to D23580 and 037v4 (Mean;  D23580 -0.09, 95% CI[-0.44, 
0.24]  vs  049v3  -2.52, 95% CI[-2.82, -2.22]), (Mean; 037v3 0.001, 95% CI[-0.40, 0.40]  
vs 049v3 -2.52, 95% CI[-2.82, -2.22]) (Figure 4.6A). Whether S. Typhimurium D23580 
and S. Typhimurium 037v4 are genetically similar will be addressed by whole genome 
sequencing in future studies. In relation to SBA, there was positive correlation between 
SBA to D23580 and SBA to 037v4, using serum from children aged 6 to 18 months 
(r=0.64, 95% CI [0.56, 0.71], p=<0.0001) (Figure 4.6B). In our later SBA experiments 
D23580 and 037v4 were used in parallel because it was assumed that serum from older 
children (> 6months) would nearly all be competent to kill Salmonella 049v3. 
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Figure 4. 6: Serum bactericidal activity to various Salmonella serovars 
Log10 change in Salmonella serovars as indicated from baseline condition in serum from 
children at study entry (6 months) Figure 4.6A. The red bars represent the mean. 
Correlation of SBA to S. Typhimurium strain D23580 and 037v4 at 6 months to 18 
months (Figure 4.6B). r represents Pearson correlation coefficient.   
 
In keeping with previously presented data (chapter 3), serum bactericidal activity to both 
S. Typhimurium  strain D2380 and S. Typhimurium  ID 037v4 increased with age from 6 
months to 18 months (Figure 4.7A-B). SBA to D23580 was significantly more inhibitory 
in children at 9 months, 12 months and 18 months compared to 6 months (Mean; 9 
months  -0.96, 95% CI[-1.43, -0.50 ] vs 6 months -0.09, 95% CI[-0.44, 0.24], p=0.003), 
(Mean; 12 months -2.02, 95% CI[-2.41, -1.62] vs 6 months -0.09, 95% CI[-0.44, 0.24], 
p=<0.0001), (Mean; 15 months  -1.76, 95% CI[-2.04, -1.47] vs 6 months -0.09, 95% CI[-
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0.44, 0.24], p=<0.0001), (Mean; 18 months  -1.64, 95% CI[-1.86, -1.41] vs 6 months -
0.09, 95% CI[-0.44, 0.24], p=<0.0001) (Figure 4.7A).   
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Figure 4. 7: Development of Serum bactericidal activity to Salmonella serovars 
Log10 change in S. Typhimurium strain D23580 and 037v4 as indicated from baseline 
condition in serum from children at varying ages in months (Figure 4.7A-B). The red bars 
represent the mean.   
 
SBA to D23580 was also significantly more inhibitory in children at 12 months 
compared to at 9 months (Mean; 12 months -2.02, 95% CI [-2.41, -1.62] vs 9 months -
0.96, 95% CI[-1.43, -0.50 ], p=0.003). Similarly SBA to 037v4 was significantly more 
inhibitory in children at 12 months and 15 months compared to 6 months (Mean; 9 
months  -0.39, 95% CI[-0.89, 0.11] vs 6 months 0.001, 95% CI[-0.40, 0.40], p=0.41), 
(Mean; 12 months  -1.42, 95% CI[-1.93, -0.92] vs 6 months 0.001, 95% CI[-0.40, 0.40], 
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p=0.006) and (Mean; 15 months  -1.91, 95% CI[-2.2, -1.55] vs 6 months 0.001, 95% CI[-
0.40, 0.40], p=<0.001)  (Figure 4.7B). SBA to 037v4 was also significantly more 
inhibitory in children at 12, 15 and 18 months compared to 9 months (Mean; 12 months  -
1.42, 95% CI[-1.93, -0.92] vs 9 months -0.39, 95% CI[-0.89, 0.11] p=0.006),   (Mean; 15 
months -2.12, 95% CI[-2.4, -1.8] vs 9 months -0.39, 95% CI[-0.89, 0.11], p=<0.0001) 
and (Mean; 18 months -2.27, 95% CI[-2.49, -2.0] vs 9 months -0.39, 95% CI[-0.89, 
0.11], p=<0.0001). 
To explore whether SBA to Salmonella is facilitated by natural Salmonella exposure, 
SBA to D23580 and SBA to 037v4 in children exposed to Salmonella were quantitatively 
compared to non-exposed children at 9, 12, 15 and 18 months. SBA to D23580 among 
Salmonella exposed and non-exposed children were similar at 9 months (Median; 
exposed  -0.61, IQR [-3- 1.28] vs non-exposed -1.3, IQR [-2.51- 0.43], p=0.839), 12 
months (Median; exposed  -1.96, IQR [-3.46- 1.1] vs non-exposed -2.1, IQR [-2.51- -
1.52], p=0.81), 15 months of age (Median; exposed  -1.57, IQR [-2.5- -1.3] vs non-
exposed -1.69, IQR [-2.1- -1.3], p=0.61) and 18 months of age (Median; exposed  -1.87, 
IQR [-2.15- -1.36] vs non-exposed -1.74, IQR [-2.2- -1.08], p= 0.61) (Figure 4.8A).  
Similarly, SBA to 037v4 among Salmonella exposed and non-exposed children was also 
similar at 9 months (Median; exposed  0.18, IQR [-1.71- -3.2] vs non-exposed -0.69, IQR 
[-2.07- -0.43], p=0.156), 12 months (Median; exposed  -2.13, IQR [-2.8- 0.8] vs non-
exposed -2.0, IQR [-2.5- 0], p=0.91), 15 months of age (Median; exposed  -2.52, IQR [-3- 
-2.3] vs non-exposed -2.36, IQR [-2.5- -1.25], p=0.126)  and 18 months of age (Median; 
exposed  -2.3, IQR [-2.8- -2.2] vs non-exposed -2.31, IQR [-2.73- -2.04], p=0.66) (Figure 
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4.8B). SBA was observed to vary with age, as some children that had SBA of -1 log10 
change in Salmonella cfu/ml at younger age had lower  SBA  at older age, suggesting 
intra-individual variability of this measurement over time (Figure 4.8C-D). This needs to 
be explored in future.  
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Figure 4. 8: Relationship between Salmonella exposure and serum bactericidal 
activity in children 
Salmonella exposure and development of specific immunity  
 
172 
 
Children serum killing capacity to S. Typhimurium strain D23580 or 037v4 are shown. 
Log10 change in S. Typhimurium strain D23580 or 037v4 cfu/ml from the control 
condition were plotted against varying  ages as indicated  (Figure 4.8A-D), grouped as 
exposed and non-exposed (Figure 4.8A-D), and individual SBA liked with age (Figure 
4.6C-D). The bars represent the median. Child serum that attained of ≥ -1 Log10 change 
in Salmonella cfu/ml was considered ‘protected’. 
 
The relationship between SBA and S. Typhimurium and Salmonella exposure in children 
was further analysed by Chi squared analysis. SBA of ≥ -1 log10 change in Salmonella 
cfu/ml (considered as a surrogate of protective immunity) was used as a cut off. A total of 
229 observations of  SBA to S. Typhimurium  D23580 or 037v4 were made (56 at 6 
months, 48 at 9 months, 36 at 12 months, 43 at  15 months and 46 at 18 months) (Table 
4-D and 4-E). Comparing SBA to both S. Typhimurium D2350 and 037v4  by specific 
age groups (between 6 and 18 months), there was a  trend at 15 months that Salmonella 
exposure is associated with acquisition of potentially protective SBA but this did not 
reach statistical significance  OR 3.04, 95% (0.32, 28.8)
 
(Table 4-D and 4-E). 
Interestingly, acquisition of potentially protective SBA to S. Typhimurium D23580, when 
all observations over the period of 1 year (6-18 months)  were considered, was 3.65 times 
more likely to occur in children who  had  Salmonella detected in stool than  in children 
who had no Salmonella detected, OR 3.65, 95%  CI(1.54, 8.65). Similarly, acquisition of 
potentially protective SBA to S. Typhimurium  037v4 for all observations over the period 
of 1 year  was 4.25 times more likely to occur in children who  had  Salmonella detected 
Salmonella exposure and development of specific immunity  
 
173 
 
in stool than  in children who had no Salmonella detected OR 4.25, 95% CI (1.79, 10). 
Taken together, these findings support the study hypothesis that Salmonella exposure 
within the GIT may facilitate the acquisition of potentially protective SBA to Salmonella 
in children.  
 
Table 4- D: Relationship between SBA to S. Typhimurium strain D23580 and 
Salmonella exposure 
Age  
 
 All 
SBA ≥ -1 
log10 
[%] 
SBA ≥ -1 
log10 
Exposed 
[%] 
SBA ≥ -1 
log10 
Non 
exposed 
[%] 
Exposed vs 
non-exposed 
OR (95% CI) 
6 months 
 
Total 
N=56 
(n/N) 
14 (14/56) 
[25] 
0 (0/0) 
[0] 
14 (14/56) 
 [25] 
ND 
9 months 
 
Total 
N=48 
(n/N) 
25 (25/48) 
[52] 
2 (2/5) 
[40] 
23 (23/43)  
[53] 
0.57 (0.87, 3.82)
 
12 months 
 
Total 
36 (n/N) 
30 (30/36) 
[83] 
5  (5/6) 
[83] 
25 (25/30)  
[83] 
ND
a 
15 months 
 
Total 
  43 (n/N) 
37 (37/43) 
 [86] 
14 (14/15) 
[93] 
23 (23/28) 
 [82] 
3.04 (0.32, 28.8)
 
18 months 
 
Total 
N=46 
(n/N) 
37 (37/46) 
 [80] 
14 (14/16) 
[87] 
23 (23/30) 
[76] 
2.13 (0.38, 11.7)
 
6-18  
months 
 
Total 
N=229 
(n/N) 
143 (143/229) 
[62.4] 
35 (35/42) 
[83.3] 
108 (108/187) 
[57.7] 
3.65 (1.54, 8.65)
 
a
ND refers to not done  
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Table 4- E: Relationship between SBA to S. Typhimurium strain 037v4 and 
Salmonella exposure 
Age  
 
         All 
SBA ≥ -1 log10 
         [%] 
SBA ≥ -1 
log10 
Exposed 
[%] 
SBA ≥ -1 
log10 
Non exposed 
[%] 
Exposed vs 
non-exposed 
OR (95% 
CI) 
6 months 
 
Total 
N=56 
(n/N) 
13 (13/56)  
[23] 
0 (0/0)  
[0] 
13 (13/56) 
[23] 
  ND
a
 
9 months 
 
Total 
N=48 
(n/N) 
17 (17/48)  
[35.4] 
2 (2/5)  
[40] 
15 (15/43) 
[34.8] 
  
1.24 (1.24, 8.2)
 
12 months 
 
Total 
  N=36 
(n/N) 
25 (30/36)  
[69.4] 
4 (4/6)  
[66.6] 
12 (31/30) 
[70] 
  0.85 (0.13, 5.55)
 
15 months 
 
Total 
  43 (n/N) 
37 (37/43)  
[86] 
14 (14/15) [93] 23 (23/28) 
[82] 
  3.04 (0.32,  
28.8)
 
18 months 
 
Total 
N=46 
(n/N) 
44 (44/46)  
[95.6] 
16 (16/16) 
[100] 
28 (28/30) 
[93] 
  ND
a 
6-18  
months 
 
Total 
N=229 
(n/N) 
136 (136/229) 
[59] 
35 (35/42) 
[83.3] 
101 
(101/187) 
[54.7] 
4.25 (1.79, 10)
 
a
ND refers to not done  
 
4.5 DISCUSSION  
This cohort study extends the findings in Chapter 3 that SBA (peaking at 36 months) and 
T cell immunity (peaking at 14 months) to S. Typhimurium are naturally acquired in 
Malawian children. This cohort study has demonstrated that Salmonella exposure within 
the GIT occurs in the first 18 months of life, re-affirming our earlier hypothesis that the 
early acquisition of T cells immunity to Salmonella could be driven, at least in part, by 
exposure to S. Typhimurium. Salmonella exposure within the GIT was associated with 
acquisition of potentially protective SBA to S. Typhimurium in children aged between 6 
and 18 months. However, there were many children who developed serum bactericidal 
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killing without detection of Salmonella exposure, and the time course of SBA acquisition 
in non-exposed children was not different from children who were exposed. It is 
anticipated that there were episodes of Salmonella exposure that were not detected, or 
that other exposures to cross-reacting bacteria also occurred which we did not detect.  
 
In this cohort, 46.8% Salmonella exposure within the GIT of children aged ≤18 months 
was demonstrated, after children were prospectively followed for a period of 12 months 
(from 6 to 18 months of age). These findings are in keeping with a previous report from 
Mexican children that found that were 40% of children were exposed to Salmonella in the 
first year of life (Cravioto, et al., 1990). Enteric pathogens exposure in that study was, 
however, examined at 2 weeks intervals. It is likely that higher than 46.8% Salmonella 
exposure might have been detected in our cohort if shorter time intervals to observe 
Salmonella exposure events were adopted because in some children shedding of 
Salmonella might be of shorter duration (< 4 weeks) than what was anticipated. It was, 
however, previously demonstrated that under-five year-old children, on average, shed 
Salmonella in their stools for as long as 7 weeks (Buchwald & Blaser, 1984). Cross-
sectionally, Salmonella was detected in 4.6% (29/630) of stools tested in Malawian 
children aged 6-18 months. Importantly, among the Salmonella serovars isolated, S. 
Typhimurium was the predominant serovar (52%), followed by non-defined Salmonella 
serovars (31%), S. Typhi (10%) and S. Enteritidis (7%). A cross-sectional  study in 
Blantyre, Malawi found asymptomatic Salmonella carriage in 2.4% (6/251) of children 
aged 0-2 years and 0.8% (1/131)  of  children aged 2-5 years from Ndirande community 
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(Msefula, 2009). This was lower than 4.6% detected in this cohort. The difference in 
magnitude of Salmonella detected in these studies might arise from differences in age 
distribution, from seasonal differences particularly during the wet season when the level 
of enteric pathogens including Salmonella has been reported to be high (Kariuki, et al., 
2006, Gordon, et al., 2008, Morpeth, et al., 2009) and also from methodological 
differences; in this study culture and PCR were used, while culture only was used in 
previous studies.    
 
Salmonella infection occurs through the oral route following ingestion of contaminated 
food, water or contact with contaminated fomites (Kariuki, et al., 2006) and it is possible 
that colonisation of the oropharynx could be immunizing. In this cohort throat swabs 
were examined for Salmonella to describe the pattern of Salmonella exposure within the 
oropharynx. Oropharynx swabs did not yield positive result for Salmonella, even in 
children that had stool culture Salmonella positive result. This was in keeping with a 
previous report that only detected Salmonella in throat swabs of children with acute 
bacteraemia and not asymptomatic children and adults from the communities (Msefula, 
2009). These differences may arise from secondary infection in oral cavity in children 
with Salmonella bacteraemia (Sirsat, 2013) and which could be unlikely in children 
asymptomatically carrying Salmonella within the GIT. This study, however, did not use 
molecular methods to increase the sensitivity of detection from throat swabs. Further 
studies are required to investigate variations in colonization pattern of Salmonella in 
different tissues. 
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Although this cohort of Salmonella exposed children was intended to be a survey of 
asymptomatic children, at the point of the stool being positive for Salmonella (positive 
stool culture), children were more likely to have fever (>37.8º C), and there was a trend 
for them to have a range of non-specific symptoms such as diarrhoea, vomiting or cough, 
at the time of positive stool sample. As previously reported (Bar-Meir, et al., 2005), it is 
possible that these febrile children may have had sub-clinical blood-stream infections, 
which were not detected. Incidence of bacteraemia among children with gastroenteritis 
caused by NTS may range from 3-41% (Meadow, et al., 1985, Bar-Meir, et al., 2005). 
This might suggest that transient or low-level blood stream infection with NTS may be 
common outside of hospital admissions, and this might be important in relation to the 
development immunity.   
 
Among children that had Salmonella in their stool there was a non-statistically significant 
trend that diarrhoea was more likely occur than in children with no Salmonella in their 
stool. Diarrhoea episodes (13% and 26% at current visit and during previous month 
respectively) amongst Salmonella in this cohort may be explained by NTS strains ability 
to trigger pro-inflammatory diarrhoea (Zeng, et al., 2003).  
 
Current or recent malaria infection is commonly associated with S. Typhimurium 
bacteraemia in children from SSA (Graham, et al., 2000, Bronzan, et al., 2007, Biggs, et 
al., 2014). Surprisingly, in this cohort only a few children were diagnosed with malaria 
infection (<1%). Among children that had Salmonella in their stool, there was a non-
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statistically significant trend that they had taken anti-malarial drugs in the previous 
month. However, it is also possible that some children had taken antimalarial drugs as 
syndromic management rather than a confirmed disease. Malaria infection is thought to 
impair phagocyte effector functions and this favours S. Typhimurium to break mucosal 
host immunity and cause bacteraemia (MacLennan, 2012). World Health Organisation 
(WHO) already recommend the prescription of antibiotics, to treat possible non-
diagnosed bacterial blood stream infections [BSI] in children presenting to hospital with 
severe malaria infection (Church & Maitland, 2014). Further studies into malaria and 
Salmonella co-infection are required to understand the biology and provide possible 
immunological or clinical management interventions.  
 
Importantly, in this cohort usage of antibiotics was high (25.9%) compared usage of 
antimalarial drugs (1.4%). Antibiotics are thought to disturb the GIT microbial 
communities and potentially favour Salmonella colonisation as normal flora resistance is 
compromised (Lolekha, 1986, Pavia, et al., 1990, Gradel, et al., 2008, Endt, et al., 2010, 
Kaiser, et al., 2012). Although statistically non-significant, there was a trend that having 
taken recent antibiotics had a higher risk of having Salmonella in stool. Coughing was 
commonly reported clinical presentation in this cohort (22.5%), so it is possible that 
children took these antibiotics to treat cough, a common childhood symptom. Cough is 
known to be a nonspecific symptom of invasive NTS disease among children, and is also 
common in typhoid fever (Graham, et al., 2000, Gordon, et al., 2002, Feasey, et al., 
2012). Alternatively, antibiotic-usage may be an indirect proxy marker for fever from 
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previous malaria, which is also known to be a risk factor for Salmonella disease. Sadly, 
high usage of antibiotics is thought to drive antimicrobial resistance (Lolekha, 1986) and 
could have huge implications in management of bacterial infections using antibiotics, 
particularly in SSA where  resources are also limited.  
 
There have been few studies into factors (i.e. food and water intake, environmental) that 
contribute to Salmonella transmission in this population. As shown before (Kalanda, et 
al., 2006), Malawian babies in this cohort were introduced to supplementary food 
gradually from around 9% at 3 months to 91% by 6 months. A minority of children were 
exclusively being breast fed at 6 months of age (9%). Un-expectedly, maternal breast 
milk lacked bactericidal effect to S. Typhimurium strain D23580 while maternal serum 
robustly inhibited growth of S. Typhimurium strain D23580. Previous reports recognised 
‘protective’ role of breast milk in breast fed children to pathogenic infections including 
Salmonella gastroenteritis (France, et al., 1980, Borgnolo, et al., 1996). In this study, 
levels of antibodies in maternal milk were not quantified and the contribution of 
antibodies to maternal milk bactericidal activity was also not explored. The contribution 
of IgA to complement fixing has been controversial and it is generally agreed that it does 
not efficiently fix complement which is required for killing of invasive S. Typhimurium 
strain D23580 (Michetti, et al., 1992, Roos, et al., 2001, Woof & Kerr, 2006). The level 
of IgG and IgA antibodies specific for Salmonella in maternal milk is not known and this 
needs to be investigated in future. Human breast milk exhibit specific IgG and IgA 
antibodies to pathogens including Haemophilus influenza, Campylobacter jejuni, 
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Helicobacter pylori and Streptococcus pneumoniae (Shapiro, et al., 2007). Human breast 
milk also contains complement (Ogundele, 2001) and has been demonstrated to opsonise 
serum sensitive E. coli strain (Ogundele, 1999, Ogundele, 2000), indicating that it could 
be activated in vivo. Together these findings indicates that breast milk may lack direct 
bactericidal activity against S. Typhimurium strain D23580 and suggest that breast-
feeding might limit Salmonella colonization within the GIT by other mechanisms  such 
as contribution to normal flora colonization resistance by promoting growth of bacteria 
that resist Salmonella invasion and prevention of  Salmonella adherence  to intestinal 
epithelial cells through opsonisation or blocking of Salmonella fimbriae or pili (Weening, 
et al., 2005, Mantis, et al., 2011, Stecher & Hardt, 2011). 
 
Normally water intake begins very early after birth in Malawian children. In this cohort 
most families had access to tap-water (82.7%) but a majority of them were taking non-
boiled water (64.8%). Importantly, among children that had Salmonella in their stool, 
there was a non-statistically significant trend that using non-boiled water contributed to 
being exposed to Salmonella while use of boiled water appeared to prevent Salmonella 
transmission and colonisation. A minority of families were using water from the river 
(4%) or a borehole (11.3%). Using water from the river had 3.9 times higher risk of being 
exposed to Salmonella among children. Borehole and boiled water appeared to reduce or 
prevent Salmonella transmission, but these were not statistically significant. Taken 
together these findings suggest that Salmonella exposure occurred in these children, 
following the introduction of supplementary food, and water sources including tap 
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water(particularly when used non-boiled) or river water might have an important role in 
transmission of Salmonella infection. In the developed world, typhoid cases have 
considerably reduced (Clark, et al., 2010), while in sub-Saharan Africa, Asia and the 
Indian sub-continent typhoid fever remain endemic mainly due to limited access to clean 
water, poor sanitation and poor food hygiene (Crump & Mintz, 2010, Breiman, et al., 
2012) which hugely contribute to Salmonella transmission. Improvements in water, 
sanitation and hygiene could reduce transmission of Salmonella and other enteric 
pathogens these populations.  
 
Observations made on geographical locations of exposed and non-exposed children 
residences seem to suggest that living in close proximity to the river or water stream 
contributed to Salmonella transmission. There was no evidence of statistical difference in 
absolute altitude position of the homes of those exposed to Salmonella and compared to 
those who were non-exposed. It is possible that families living near the river or water 
stream use this water for household chores or also drinking. It has previously been 
demonstrated that residents in lower grounds (low latitudes) are at risk of Salmonella 
infection (Baker, et al., 2011). Waste disposal in Blantyre is fairly good in the 
commercial area and low density areas, but poor in high density areas and among low 
income earners (including Soche Ward) (Kumwenda, et al., 2012, MCI, 2012). In 
Blantyre city, Soche Ward, water taps frequently run dry coupled with high water bills 
(MCI, 2012), some families resort to use of river and stream water. It is not clear whether 
living in close proximity (either by distance or altitude) to the river or water stream might 
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be a risk factor for contracting Salmonella infection. Further investigations including 
more complex, geospatial analyses studies are required, to generate hypotheses 
stimulating future studies aimed at understanding the role of environmental factors 
(including water sources) in the transmission of Salmonella infection in this population.  
 
The ultimate objective of this project was to provide an answer as to whether or not 
Salmonella exposure within the GIT facilitates development of serum immunity. For the 
first time in this population, this cohort study demonstrated 46.8% overall Salmonella 
exposure in Malawian children that were prospectively examined at 1 month intervals 
from 6 to 18 months of age. In keeping with findings in a cross sectional study (chapter 
3), SBA increased with age from 6 months to 18 months. In keeping with the study 
hypothesis, acquisition of potentially protective SBA to S. Typhimurium D23580 and 
037v4 from 6-18 months was 3.65 and 4.25 times more likely to occur in children who 
had Salmonella detected in stool than in children who had no Salmonella detected 
suggesting that Salmonella exposure within the GIT facilitates the acquisition of 
potentially protective SBA to Salmonella in children. However, observations were made 
that children that had no Salmonella detected in their stool also developed SBA to S. 
Typhimurium D23580 and 037v4. This might have arised from suboptimal sensitivity to 
detect all Salmonella exposures, because other exposures to cross-reactive species also 
contribute to protection. Multiple Salmonella exposure events might be required to 
develop potentially protective SBA. This cohort described 24% (7/29) of children that 
were at least exposed twice to Salmonella. A majority of these were exposed twice to S. 
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Typhimurium 71% (5/7). Whether development of potentially protective SBA varies 
following single or multiple exposure events to the same serovar or different serovar is 
the key question to be explored in future. The effect of Salmonella exposure in this study 
was also hindered by the unanticipated and intra-individual variation in SBA at different 
time points and further studies might address this issue.   
 
Summary 
This cohort study revealed that the magnitude of Salmonella exposure within the GIT in 
Malawian children is high in early life (< 18 months of age) when the potentially 
protective SBA is not fully mature. True to this study hypothesis, Salmonella exposure 
within the GIT is associated with acquisition of SBA. Maternal breast milk lacks direct 
bactericidal effect to S. Typhimurium strain D23580. Non-specific clinical features 
including fever, and possibly diarrhoea, vomiting and cough are associated with 
Salmonella exposure events in a small proportion of episodes. Further studies are 
required to determine whether previous administration of antibiotic and recent malaria 
infection and feeding practices including taking river and non-boiled water are possible 
risk factors of Salmonella exposure. These findings underlie the need for a better 
understanding of the relationship between Salmonella exposure within the GIT and the 
development of protective immunity and also Salmonella exposure within the GIT and 
spread into systemic tissues. Public health interventions including improvements in 
sanitary environments, food hygiene and access to clean and safe water are required in 
addition to administration of  a cross protective Salmonella  vaccine in this population.  
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CHAPTER 5: DEVELOPMENT OF T CELL AND ANTIBODY MEDIATED 
IMMUNITY IN RESPONSE TO INVASIVE SALMONELLA INFECTION 
5.1 INTRODUCTION 
Nontyphoidal Salmonella (NTS), principally S. Typhimurium and S. Enteritidis, 
frequently causes bacteraemia in children under 2 years and HIV infected individuals in 
sub-Saharan Africa (SSA)(Graham, et al., 2000, Graham, et al., 2000, Bahwere, et al., 
2001, Berkley, et al., 2005, Gordon & Graham, 2008, Bassat, et al., 2009, Graham, 2010, 
Feasey, et al., 2012). In contrast, S. Typhi typically causes bacteraemia in children older 
than 2 years and adults in Malawi and elsewhere in SSA (Feasey, et al., 2010, Breiman, 
et al., 2012, Lutterloh, et al., 2012). As described in Chapter 1, both NTS and S. Typhi 
isolates from blood are frequently multi-drug resistant in SSA (Kariuki, et al., 2010, 
Lutterloh, et al., 2012). To effectively control Salmonella bacteraemia, a comprehensive 
approach is required, including vaccination and improvements in sanitation and food 
hygiene to prevent new infections and transmission. The rational design of protective 
vaccines requires better understanding of the targets and determinants of naturally 
acquired immunity. 
 
Although its remains poorly defined, humoral immunity appears to constitute a key 
component of protective immunity to both NTS and S. Typhi bacteraemia in children 
from endemic countries (MacLennan, et al., 2008, Pulickal, et al., 2009). CD4+ T helper 
1 (Th1) immunity constitutes another important component of protective immunity 
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against Salmonella (Mastroeni, et al., 1993, MacLennan, et al., 2004). In Chapter 3, we 
show that the development of both CD4+ T cell and SBA immunity to Salmonella in 
healthy children coincides with the decline in cases of NTS bacteraemia, suggesting 
establishment of high level of resistance. 
 
As discussed in Chapter 1, currently they are a number of research groups working on the 
development of an effective vaccine for Salmonella bacteraemia. Pre-clinical work has 
demonstrated that both LPS-O;4,5 (O antigen specific for S. Typhimurium) (Grimont PA. 
D and Weill, Cited 2007) and  LPS-O;9 (O antigens shared by S.Enteritidis and S. Typhi) 
(Grimont PA. D and Weill, Cited 2007) antigens have considerable potential as vaccine 
targets (Colwell, et al., 1984). Pure polysaccharide vaccines induces the generation of 
antibodies which are short-lived (Simon, et al., 2011, MacLennan, 2013), in contrast 
polysaccharide conjugated vaccines induce the generation of  antibodies that are T cell-
dependent and are long-lived (Simon, et al., 2011, MacLennan, 2013). Pre-clinical work 
has also demonstrated that immunisation with outer membrane proteins (OMP) and 
flagellin protein FliC derived from Salmonella induces both T cell and antibody immune 
responses (Udhayakumar & Muthukkaruppan, 1987, Cunningham, et al., 2004, Gil-Cruz, 
et al., 2009, Bobat, et al., 2011). Whether or not these protein vaccine candidates can 
confer superior protection separately (Gil-Cruz, et al., 2009) or covalently linked to O-
antigen as glyco-conjugates (Simon & Levine, 2012) is not clear and is currently being 
investigated. Recently, MacLennan and colleagues adopted a previous described 
Generalised Modules for Membrane Antigens (GMMA) platform for Shigella (Berlanda 
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Scorza, et al., 2012), to generate GMMA from Salmonella (MacLennan, 2013). GMMA 
are outer membrane particles naturally released by Salmonella during growth, and  
contain high amounts of periplasmic and outer membrane protein (MacLennan, 2013). 
This is achieved through the disruption of the Tol-Pal system which leads to an increase 
in rate of GMMA natural release enabling exploitation of GMMA as vaccine candidate 
(Berlanda Scorza, et al., 2012). Generation of GMMA with O antigen (GMMA O+) and 
lacking O antigen (GMMA O-)  involves ultracentrifugation of culture supernatants from 
tolR- and tolR-wabaP-mutants of Salmonella serovar of choice (Berlanda Scorza, et al., 
2012). GMMA have been shown to be highly immunogenic in mice  (MacLennan, 2013) 
but their importance in humans as vaccine candidate has not been evaluated. 
 
It is thought that natural Salmonella bloodstream infection results in  the acquisition of 
effector and memory B and T cells (Mittrucker & Kaufmann, 2000) and Chapter 4 
demonstrates that Salmonella exposure within the GIT facilitate development of 
‘protective’ serum bactericidal activity to invasive NTS strain D23580  in children (6 to 
18 months). In this study, a cohort of children with Salmonella bacteraemia was 
evaluated for immune response to Salmonella specific antigens during the acute phase of 
infection and at 1 month in convalescence. In addition, healthy family members from the 
index cases’ households were recruited for similar immunological investigations. 
Immunity was evaluated ex vivo, using immunological assays including the intracellular-
cytokine staining assay (for detection of Salmonella-specific CD4+ T cells producing 
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IFN-γ) and the B cell ELISpot assay (for detection of Salmonella-specific IgG or IgA 
antibody secreting cells [ASC]).  
 
Hypothesis: Invasive Salmonella infection induces the development of Salmonella 
specific B cell and CD4+ T cell immunity. 
 
Study objectives: 
1. To determine the immunological importance of Salmonella derived proteins; FliC, 
OMP, GMMA O+ and GMMA O- and polysaccharide antigens; LPS O; 4,5 and LPS 
O; 9 as inducers of  B cell and T cell immunity.  
2. To determine whether or not Salmonella bacteraemia primes the development of  
memory CD4+ T cell immunity. 
 
End points:  
1. Measure and compare Salmonella-specific CD4+IFN-γ+ T cells, induced by ex vivo 
stimulation of T cells with Salmonella derived proteins; FliC, OMP, GMMA O+ and 
GMMA O, in a cohort of children with Salmonella bacteraemia at acute phase, 
convalescent  phase (at 1 month) and in healthy family members.  
2. Measure and compare Salmonella-specific IgG and IgA-secreting cells, targeting 
Salmonella derived proteins; FliC, OMP, GMMA O+ and GMMA O-  and 
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polysaccharide antigens; LPS O;4,5 and LPS O;9, in children with Salmonella 
bacteraemia at acute phase and in healthy family members. 
 
5.2 PARTCIPANTS RECRUITMENT AND METHODS 
The methods for this chapter have been described in chapter 2, section 2.4. 
Study participants: Children admitted and diagnosed with Salmonella bacteraemia were 
termed index cases. This project aimed at recruiting equal numbers of children presenting 
with NTS and S. Typhi bacteraemia. Unexpectedly only children with S. Typhi 
bacteraemia were recruited as cases of NTS bacteraemia were rare during the recruitment 
period. Children (aged below 15 years) with Salmonella bacteraemia were recruited 
sequentially.  These children were presenting to QECH with a Gram negative 
bacteraemia which was then confirmed as Salmonella by routine identification as 
described in Chapter 2, section 2.15. These index cases were recruited and blood samples 
drawn within 72 hours of diagnosis for immunological investigations, typically 1-2 days 
after treatment with recommended antibiotics (ceftriaxone and ciprofloxacin) had been 
commenced. From each index case, a convalescent blood sample was collected at 1 
month. Healthy family members (both children and adults) living in the same household 
as index cases were also recruited into the study and blood samples were collected at 
entry. Healthy family members were not age matched with index cases. 
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Antigens used for immunological investigations: All antigens used in this study have 
considerable potential to be used a vaccines and are currently being investigated in pre-
clinical studies. Outer membrane protein (OMP) was generated from S. Typhimurium as 
a rough preparation as previously described (Gil-Cruz, et al., 2009). These OMP are 
thought to cross-react with S. Typhi due to conservation of the OmpC and F dominant 
proteins (Maclennan, et al., 2014). Flagellin protein FliC was generated from S. 
Typhimurium. S. Typhimurium flagellin reacts to anti-Hi antibodies whiles S. Typhi 
reacts to anti-Hd antibodies according to the Kauffman-White scheme (Grimont PA. D 
and Weill, Cited 2007). To what extent S. Typhi and S. Typhimurium FliC cross-react is 
not clear. GMMA O- were generated from mutant S. Typhimurium strain D23580 
(wabaP-mutants) while GMMA O+ was generated from wild type S. Typhimurium strain 
D23580 (MacLennan, et al., 2008). GMMA proteins derived from S. Typhimurium cross-
react with S. Typhi. LPS-O; 4,5 and LPS-O;9 were commercial S. Typhimurium LPS and 
S. Enteritidis LPS respectively (ALEXIS, Biochemicals). In addition S. Enteritidis  LPS-
O;9  cross-reacts with S. Typhi LPS as these share LPS O; 9 antigen (Grimont PA. D and 
Weill, Cited 2007). 
 
5.3 STATISTICAL ANALYSES 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad 
Software, USA). Percentages of CD4+IFN-γ+ T cells and absolute counts of IgG or IgA 
ASCs were examined for normality of distribution using D’Agostino and Pearson 
omnibus normality test. Non-normally distributed immune responses (T cells and ASCs), 
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groups were compared using Wilcoxon matched paired t test. End point immune response 
for each group, or interquartile range (IQR) were reported, and p value of less than 0.05 
was considered statistically significant. 
 
5.4 RESULTS 
5.4.1 Study participant’s demographics and clinical presentation 
In this cohort study, a total of 20 children were recruited, less than <15 years of age 
(Median; 8 years range [0.8-13.9]) presenting to QECH with S.Typhi bacteraemia. 
Among these index cases, 10/20 (50%) were female. A total of 21 healthy family 
members of index cases (Median; 30 years, range [12-40 years]) were also recruited into 
the study (Table 5-A). Among these healthy family members 20/21 (95.2%) were female. 
About one third (35%) of index cases had diarrhoea at the acute phase (Table 5-A). A 
majority of index cases were vomiting (75%) while coughing was rare (10%) at the acute 
phase. As expected, the family members to index cases were generally asymptomatic 
(Table 5-A). 
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Table 5- A: Study participant’s demographic and clinical characteristics 
 Description Index 
a
 (%) 
n=20
 
Family (%) 
n=21 
Sex Male  10 (50) Male (4.7) 
Median age in years (range) 8 (0.8-13.9) 30 (12-40) 
Median PCV (range) 34 (21-45) ND 
c 
Diarrhoea  7/20 (35) 0/21 (0) 
Vomit  15/20 (75) 2/21 (9.5) 
Cough  2/20 (10) 1/21 (5) 
HIV status 1/20 (5) 4/21 (19) 
MUAC 1 15 (10-23) ND 
Currently breastfeeding 2(10) ND 
Median breast feeding discontinued (range)   24 (11-36) ND 
a
All the 20 index cases recruited had blood culture confirmed S. Typhi result 
  ND refers to not done 
 
5.4.2 High percentage of FliC- and OMP-specific-CD4+IFN-γ+ T cells in  healthy 
family members  
Both FliC and OMP have previously been demonstrated to induce protective immunity in 
mice (Udhayakumar & Muthukkaruppan, 1987, McSorley, et al., 2000, Cunningham, et 
al., 2004) but their importance in humans as markers of antigen-specific memory T cells 
has received limited attention. 
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Figure 5. 1: High percentage of specific- CD4+IFN-γ+ T cells in healthy family 
members 
Percentage of CD4+IFN-γ+ T cells in the peripheral blood among children with 
Salmonella bacteraemia; index cases at acute phase (n=12), at 1 month into recovery 
phase (n=12) and in healthy family members (n=12). Antigen-specific CD4+IFN-γ+ T 
cells were examined using ICS assay, stimulated with Salmonella protein antigens; FliC 
and OMP as indicated (Figure 5.1A-B) and described in Chapter 2. The bars represent the 
median. Groups were compared using Wilcoxon matched paired t test and considered 
significant with p value<0.05. 
 
CD4+ T cells producing IFN-γ were quantified in index cases at the acute phase and 1 
month in recovery phase and also in healthy family members. There was no statistical 
difference between FliC-specific CD4+IFN-γ+ T cells  in index at acute phase cases and  
recovery phase (Median acute 0.021, IQR[0-0.046] vs recovery 0, IQR [0-0.026], 
p=0.078), (Figure 5.1A). OMP-specific CD4+IFN-γ+ T cells were significantly higher in 
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index cases at acute phase compared to recovery phase (Median 0.025, IQR [0.013-
0.039] vs 0, IQR [0-0.012], p=0.006)(Figure 5.1B). 
 
There was no statistical difference in percentage of both FliC-specific and OMP-specific 
CD4+IFN-γ+ T cells between healthy family members and index cases at acute phase;  
FliC (Median family 0.048, IQR [0-0.12] vs acute 0.021, IQR [0-0.046], p=0.46) (Figure 
5.1A), OMP (Median family 0.07, IQR [0.023-0.15] vs acute 0.025, IQR [0.013-0.039], 
p=0.092) (Figure 5.1B). The percentage of both FliC-specific and OMP-specific 
CD4+IFN-γ+ T cells were significantly higher in healthy family members compared to 
index cases at recovery phase, FliC (Median family 0.048, IQR [0-0.12] vs recovery  0, 
IQR [0-0.026], p=0.016) (Figure 5.1A), OMP (Median family 0.07, IQR [0.023-0.15] vs 
recovery 0, IQR [0-0.012], p=0.005) (Figure 5.1B). 
 
5.4.3 LPS-O antigen expression on GMMA elicits robust Salmonella-specific 
CD4+IFN-γ+ T cells 
Generalised Modules for Membrane Antigens (GMMA) are thought to be highly 
immunogenic in mice (MacLennan, 2013). Salmonella derived GMMA antigens are 
generated with or without LPS O antigens. It is not known whether GMMAO+ and 
GMMA O- would elicit different antigen-specific memory T cell responses ex vivo. 
Firstly, GMMA O- specific CD4+IFN-γ+ T cells were quantified in cohort of index cases 
and healthy family members. The percentage of GMMA O- specific CD4+IFN-γ+ T cells 
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were higher during acute phase compared to recovery phase and healthy family members, 
but these did not reach statistical difference (Median acute 0.05, IQR [0.01-0.10] vs 
recovery 0.002, IQR [0-0.07], p=0.51), (Median acute 0.05, IQR [0.01-0.10] vs family 
0.003, IQR [0-0.08], p=0.62) (Figure 5.2A).   
 
Secondly, GMMA O+ specific CD4+IFN-γ+ T cells were quantified in the same cohort 
of index cases and healthy family members. GMMA O+ specific CD4+IFN-γ+ T cells 
were significantly higher in index cases during  acute phase compared to recovery phase 
(Median acute 0.09, IQR [0.03-0.27] vs recovery 0.03, IQR [0-0.12], p=0.018) (Figure 
5.2B). Furthermore, it was observed that healthy family members had higher percentage 
of CD4+IFN-γ+ T cells in GMMA O+ condition compared to GMMA O- condition 
(Figure 5.2A-B), suggesting that LPS O antigen  augmented this T cell immune response. 
Consequently, there was no statistical difference in percentage of  GMMA O+ specific 
CD4+IFN-γ+ T cells between index cases at acute phase and healthy family members 
(Median acute 0.09, IQR [0.03-0.27] vs family 0.14, IQR [0.03-0.31], p=0.7) (Figure 
5.2B).  
Immune response to invasive Salmonella infection  
 
195 
 
A B GMMA O+
Acute Recovery Family
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.6
1.2
p=0.018
p=0.06
Index
      p=0.70
C
D
4
+
IF
N
g
+
%
GMMA  O-
Acute Recovery Family
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.6
1.2
p=0.51
p=0.57
Index
p=0.62
C
D
4
+
IF
N
g
+
%
 
Figure 5. 2: LPS-O antigen expression on GMMA induces highest magnitude of 
antigen CD4+IFN-γ+ cells 
Percentage of CD4+IFN-γ+ T cells in the peripheral blood among children with 
Salmonella bacteraemia; index cases at acute phase (n=12), at 1 month into recovery 
phase (n=12) and in healthy family members (n=12). Antigen-specific CD4+IFN-γ+ T 
cells were examined using ICS assay, stimulated with Salmonella protein antigens 
GMMA O- and GMMA O+ as indicated (Figure 5.2A-B) and described in Chapter 2. 
The bars represent the median. Groups were compared using Wilcoxon matched paired t 
test and considered significant with p value <0.05. 
  
 
5.4.4 IgG and IgA ASC targeting  Salmonella derived proteins and LPS O antigens  
are elevated  during acute phase of Salmonella bacteraemia  
Specific B cells are generated following Salmonella infection (Kantele, et al., 2012). B 
cell immune responses to specific antigen are commonly evaluated using ELISpot assay 
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(which measures antibody secreting cells i.e. effector B cells [plasma blast] or memory B 
cells) and ELISA (measure antibodies secreted in plasma or serum) (House, et al., 2008, 
Kantele, et al., 2012). In this study, Salmonella-specific IgG and IgA antibody secreting 
cells (ASCs) were quantified in the peripheral blood circulation using a B cell ELISpot 
assay described in Chapter 2, section 2.3.6.4. This study, aimed at measuring transient 
effector B cells in the peripheral blood without ex vivo stimulation and IgA and IgG 
ASCs only at acute phase and in healthy family members were examined.  There was no 
statistical difference in absolute counts of IgA-ASC targeting; FliC, OMP, GMMA O- 
and GMMA O+ among index cases were higher  compared to healthy family members; 
FliC (Median  index   44, IQR [7-62.5] vs family  13.5, IQR [1.87-37], p=0.62), OMP 
(Median  index   36, IQR [8.5-38] vs family  14.7, IQR [1.62-35.2], p=0.43), GMMA O- 
(Median  index    30.5, IQR [22-39] vs family  10, IQR [1.12-31.2], p=0.58), GMMA O+ 
(Median  index    34.6, IQR [8-51.5] vs family  8.5, IQR [0.37-19.8], p=0.18) (Figure 
5.3A). In contrast to IgA absolute counts, absolute counts  of IgG-ASC targeting all 
proteins examined (FliC, OMP, GMMA O-  and GMMA O+) were all significantly 
higher in index cases compared to healthy family members;  FliC (Median index 51.5, 
IQR [24.3-105.8] vs family 10.5, IQR [2.68-17.3], p=0.007), OMP (Median index 32, 
IQR [14.6-59.1]  vs family 8.1, IQR [1.37-20], p=0.015), GMMA O- (Median index 55, 
IQR [14.5-104.9] vs 5.5, IQR [1.87-26], p=0.015), and GMMA O+ (Median index 47.4, 
IQR [30.3-111] vs 10, IQR [2.75-17], p=0.007) (Figure 5.3B).  
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Figure 5. 3: IgG and IgA ASC targeting Salmonella derived proteins and LPS O 
antigens are elevated during acute phase of Salmonella bacteraemia   
Number of antigen specific antibody secreting cells (ASC) secreting IgA and IgG among 
children with Salmonella bacteraemia (Index IgA [n=7], IgG [n=8]) and family members 
(IgA [n=6], IgG [n=8]) as indicated (Figure 5.3 A-B). B cell ELISpot plates were coated 
with Salmonella antigens as indicated and described in Chapter 2 (Figure 5.3A-B). The 
bars represent the median. Groups were compared using Wilcoxon matched paired t test 
and considered significant with p value <0.05. 
 
There was no statistical difference in  absolute counts of  IgA-ASC targeting LPS O;9 
and  LPS O;4,5, detected  in index cases compared to  healthy family members; LPS O;9 
(Median index 24, IQR [14-72.5] vs  family 16, IQR [6-81.7], p=0.62), LPS O;4,5 
(Median index 24, IQR [14-73] vs  family 21.2, IQR [5.2-56.3], p=0.62) (Figure 5.3A). 
In contrast to IgA-ASC specific absolute counts, absolute counts of IgG-ASC targeting 
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LPS-O;4,5 and IgG-ASC targeting  LPS O;9 were significantly higher in index cases at 
acute phase compared to healthy family members; LPS O;9 (Median index 58.5, IQR 
[13.2-75.5] vs family 9.8, IQR [4.5-13.3], p=0.015), LPS O; 4,5 (Median index 77.8, IQR 
[21.6-231] vs family 16.6, IQR [3.87-30.5], p=0.007) (Figure 5.3B).  
 
In this project, only children with S. Typhi bacteraemia were recruited. Unexpectedly, the 
absolute counts of IgA-ASC and IgG-ASC targeting LPS-O;4,5 (derived from S. 
Typhimurium) and IgA and IgG-ASC targeting  LPS-O; 9 (derived from S. Enteritidis, 
O9 shared with S. Typhi) were similar in index cases (Figure 5.3 A-B). To explore this 
further, absolute counts of both IgA and IgG ASC targeting LPS O; 9 and LPS O; 4,5 
were linked (Figure 5.4A-B) and found that individual responses were similar (Figure 
5.4A-B). Furthermore, these absolutes counts correlated strongly; IgA ASC targeting 
LPS O; 9 and O; 4, 5 (r=0.76, p=0.03) and IgG-ASC targeting LPS O; 9 and O; 4,5 
(r=0.86, p=0.01). These findings suggest cross-reactivity occurs in antibody responses to 
S. Typhi and S. Typhimurium during infection.  
Taken together, these findings show that IgG-ASC targeting Salmonella derived LPS O 
antigens and proteins are highly elevated during acute phase of Salmonella bacteraemia 
compared to IgA-ASC targeting Salmonella derived LPS O antigens and proteins. IgG-
ASC targeting LPS O antigens specific for S. Typhi and S. Enteritidis appear to cross-
react with S. Typhimurium LPS O antigen, suggesting these might have a broader role in 
controlling Salmonella infection caused by various Salmonella serovars. 
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Figure 5. 4: LPS-O antigen-specific ASC in typhoid patient’s cross-react with O4-
LPS  
Number of antigen specific antibody secreting cells (ASC) secreting IgA and IgG among 
children with Salmonella bacteraemia (Index) (Index IgA [n=7], IgG [n=8]) and healthy 
family members (IgA [n=6], IgG [n=8]). B cell ELISpot plates were coated with 
Salmonella antigens as indicated. Absolute counts were linked (Figure 5.4A-B). 
Correlation of IgA and IgG targeting LPS O;9 and LPS O; 4,5 are shown (Figure 5.4C-
D). r value representing spearman correlation coefficient is shown. 
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5.5 DISCUSSION 
The burden of Salmonella bacteraemia caused by NTS and S. Typhi is considerably high 
in SSA (Reddy, et al., 2010, Agnandji, et al., 2011, Breiman, et al., 2012). This requires 
public health interventions including the development of an effective Salmonella vaccine. 
Previous studies in mice, have demonstrated that immunization with Salmonella derived 
proteins such as flagellin and outer membrane protein and polysaccharides such as S. 
Typhimurium LPS O antigen confers protection to virulent Salmonella infection 
(Udhayakumar & Muthukkaruppan, 1987, Simon, et al., 2011). 
 
This study extend these pre-clinical observations in mice by evaluating the importance of  
Salmonella derived FliC, OMP, GMMA O+ and GMMA O-  and LPS O antigens as 
targets of effector B cell immune response and markers of memory CD4+ T cell 
immunity. This study evaluated the importance of these vaccine candidates ex vivo by 
quantifying Salmonella-specific IgG and IgA ASCs and CD4+IFN-γ+ T cells in a cohort 
of children with S. Typhi bacteraemia at acute phase and convalescent phase and in 
healthy family members. Serum IgG antibody immunity constitutes a key component that 
controls Salmonella bacteraemia in humans (MacLennan, et al., 2008, Pulickal, et al., 
2009). Opsonic IgG antibodies targeting LPS O antigen fixes complement to effect serum 
bactericidal activity to NTS and S. Typhi (MacLennan, et al., 2008, Pulickal, et al., 
2009). Although, IgG antibodies targeting LPS O antigen are considered to correlate with 
protection to invasive NTS and S. Typhi bacteraemia, correlates of invasive Salmonella 
protection and the targets of protective antibodies are poorly defined. This  study, show 
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that absolute counts of IgG-ASC targeting FliC, OMP, GMMA O- and GMMA O+ were 
significantly higher in index cases compared to healthy family members. In contrast 
absolute counts of IgA-ASC targeting FliC, OMP, GMMA O- and GMMA O+ were 
higher in index cases compared to healthy family members, but this did not reach 
statistical difference. Previous studies in Bangladesh demonstrated that secretory IgA 
targeting crude membrane proteins (MP) are elevated at acute phase of S. Typhi infected 
patients compared to healthy controls (Sheikh, et al., 2009, Khanam, et al., 2013). It is 
possible that the results from this current study and the Bangladesh studies differ due to 
methods employed (Bangladesh studies measured MP-specific IgA antibodies secreted 
by B cell lymphocytes in supernatants using the ELISA as the readout while the current 
study measured IgA expressed by the ASC using direct ELISpot). Even though both the 
Bangladesh studies and this current study aimed at examining transient B cell responses 
and ex vivo stimulation was not required, it is possible that measuring antibodies in 
lymphocytes supernatants technique is more sensitive compared to direct ELISpot.  
 
These findings may also reflect minimal contribution of IgA immunity in response to S. 
Typhi infection in the peripheral blood compared to IgG immunity. Lee and colleagues 
previously showed that immunized mice lacking IgA or the polymeric Ig receptor 
acquired robust protection against Salmonella infection, suggesting that systemic, rather 
than mucosal, B-cell responses are important for protective immunity to virulent 
Salmonella (Lee, et al.). This is also consistent with previous observations that IgA 
antibodies play a crucial role in primary defence (within the gut mucosa) against enteric 
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pathogens including Salmonella (Griffin & McSorley, 2011) while IgG antibodies are 
crucial for controlling  Salmonella infection in systemic organs (MacLennan, et al., 
2008). Compartmentalisation of IgA ASCs and IgG ASCs following varying routes of 
immunisation including oral and systemic have been reported before (Quiding-Jarbrink, 
et al., 1997), whether this might have important implications in vaccine design and 
administration (oral or parental vaccine) targeting Salmonella is the key question. It 
remains possible that IgA ASCs are important but not detectable peripherally.  
Furthermore, Salmonella-specific IgG are required to fix complement in immune serum, 
and this enables killing of  complement resistant invasive Salmonella strains including S. 
Typhimurium strain D23580 (MacLennan, et al., 2008), while  IgA antibodies  capacity 
to activate complement is poor and the role of IgA in complement mediated killing or  
opsonophagocytosis has been controversial (Michetti, et al., 1992, Roos, et al., 2001, 
Woof & Kerr, 2006).  
 
Despite the fact that this study only examined children with S. Typhi bacteraemia, 
absolute counts of IgG ASC and IgA ASC targeting LPS-O;4,5 (specific for S. 
Typhimurium) and LPS-O; 9 (Shared by S. Enteritidis and S. Typhi) were similar in 
index cases. Furthermore, only absolute counts of IgG ASC targeting LPS-O;4,5 and 
LPS-O; 9 were significantly higher in index cases compared to healthy family members. 
Importantly, these findings suggest that secreted IgG antibodies targeting LPS O; 9 
induced by S. Typhi infection, cross-reacts with S. Typhimurium LPS O: 4, 5 antigen in 
vivo. These findings are in agreement with a previous report (Kantele, et al., 2012). They 
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demonstrated that Ty21a vaccinees and patients with enteric fever had a strong gut-
directed cross-reactive plasma blast response against Salmonella serovars sharing the two 
O-antigens (LPS O; 9, 12) (shared by S. Typhi and S. Enteritidis). They also 
demonstrated a weaker gut-directed cross-reactive plasma blast response against 
Salmonella serovars sharing one (LPS O;12)  with S. Typhi including Typhimurium 
(Kantele, et al., 2012). Whether this cross-reactivity observed ex vivo in our currently and 
the previous study (Kantele, et al., 2012), results in cross-protection to multiple 
Salmonella serovars in vaccinated or naturally infected individuals is the key question.   
For instance, is it possible that oral Ty21a vaccination for typhoid fever can confer 
protection to S. Typhimurium and S. Enteritidis infection? It has  previously been shown  
that attenuated S. Typhi vaccines including Ty21a and CVD 909 induces 
opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A 
and S. Paratyphi B (Wahid, et al., 2014). These observations need further studies to 
determine whether or not already licenced vaccines such as oral Ty21a could confer 
protection to NTS and be used in endemic countries. In SSA, Salmonella serovars 
principally; S. Typhi, S. Typhimurium and S. Enteritidis frequently causes bacteraemia in 
children and adults (Reddy, et al., 2010, Agnandji, et al., 2011, Breiman, et al., 2012). A 
vaccine that confers protection to multiple Salmonella serovars would be highly 
desirable.  
 
In recent years protein array and proteomic technology, has been used to determine 
antibody targets and potential diagnostic markers during invasive Salmonella infections 
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in both mice and humans (Lee, et al., Charles, et al., 2010). Current diagnostic tools 
including blood culture and Widal test for Salmonella bacteraemia have had considerable 
setbacks (Khanam, et al., 2013). The significant increase in absolute counts of  IgG ASCs 
targeting  Salmonella derived antigens; FliC, OMP, LPS O;4,5 and LPS O;9 in index 
cases compared to healthy family members suggests that secreted serum IgG antibodies 
targeting these antigens might be valuable as diagnostic marker for S. Typhi infection  in 
endemic countries. But antigens examined in this current study lack specificity between 
NTS and S. Typhi (For instance antibodies targeting LPS O;9 cross-reacts with LPS 
O;4,5, crude preparation of OMP derive from S. Typhimurim cross-reacts with S. 
Typhimurium). Further studies using both protein array and proteomic technology in a 
natural infection study design, are required to determine unique antigens for exploration 
as diagnostic tools. 
 
Both during the early and secondary phases of Salmonella infection, CD4+ T cells 
provide help to monocytes and macrophages to efficiently kill Salmonella through the 
generation of pro-inflammatory cytokines such as IFN-γ and TNF-α (Mastroeni, et al., 
1992, Mastroeni, 2002). A study on Vietnamese typhoid patients showed that S. Typhi 
infection induces a molecular signature that is mainly pro-inflammatory in nature during 
the acute phase (Thompson, et al., 2009). A study on Bangladesh  typhoid patients 
showed that S. Typhi specific-CD4+ T cell immune responses as evidenced by IFN-γ 
production (detected by ELISpot and ICS) and proliferation are increased at acute phase 
and convalescence phase (14-28 days)(Sheikh, et al., 2011). In this cohort of index cases, 
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the proportion of Salmonella-specific CD4+IFN-γ+ T cells was higher during acute phase 
and declined at 1 month in convalescence. This decrease in Salmonella-specific 
CD4+IFN-γ+ T cells observed, contradicts previous reports in typhoid patients, which 
showed that CD4+ T cell immune responses specific S. Typhi proteins expressed in vivo 
during human infection, including StaF, StbB, CsgF, and CsgD, OppA, STY2195, and 
PagC were generally  sustained at convalescent  phase (14-28 days) (Sheikh, et al., 2011, 
Bhuiyan, et al., 2014). The important differences observed between this study and the 
two Bangladesh studies; protein antigens (Bangladesh study panel of purified proteins 
expressed during S. Typhi infection versus proteins express on the surface of S. 
Typhimurium) used to stimulate T cells and the timing for blood sampling particularly 
during the convalescence phase (Bangladesh study 14-28 days versus current study at 1 
month). Whether this decline in specific CD4+ T cells observed a month into the 
recovery period reflects changes in memory CD4+ T cells in systemic circulation or lack 
of establishment of memory CD4+ T cell immunity is not clear. 
 
Perhaps this reduction in specific CD4+ T cell immune responses might result from the 
decrease in effector memory T cells in the systemic circulation as they differentiate into 
central memory T cells and migrate to the secondary lymphoid tissues. In this study 
immunological tool that were used, essentially measures effector CD4+ T cells producing 
IFN-γ specific for Salmonella. A short-term (6 hours stimulation plus CD28/49d co-
stimulation) intracellular cytokine staining assay was used. It may have been possible to 
detect sustained Salmonella-specific CD4+ T cells immune response in the recovery 
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period, if immunological tools that typically measures the central memory CD4+ T cells 
such as proliferations assay were employed (Lundin, et al., 2002, Salerno-Goncalves, et 
al., 2002). Several factors including taking antibiotics and Salmonella mediated immune 
modulation might have a role in the decline of specific CD4+ T cells at 1 month into 
recovery phase. Administration of antibiotics is thought to compromise the development 
of specific memory CD4+ T cell immunity (Griffin, et al., 2009) through a mechanism 
that is not very clear. Through the SPI2 T3SS, Salmonella has the capacity to escape host 
defence by compromising the priming of naïve CD4+ T cells in natural infection. 
Salmonella is thought to exploit development of immune memory by reducing its antigen 
availability, avoiding phagosome-lysosome fusion and down-regulation of T cell receptor 
(Matsui, 1996, Tobar, et al., 2006, Bueno, et al., 2007, Srinivasan & McSorley, 2007).  
It was observed that in healthy family members, the majority of whom  were mothers, the 
percentage of Salmonella specific-CD4+IFN-γ+ T cells were generally higher (in ex vivo 
stimulated T cells with FliC, OMP, GMMA O+) compared to index cases at acute phase. 
These Salmonella-specific CD4+IFN-γ+ T cells reflect presence of memory CD4+ T cell 
mediated immunity in adults in this population. These memory T cells most likely are 
developed as a result of previous Salmonella exposure.  
 
Generalised Modules for Membrane Antigens (GMMA) are thought to be highly 
immunogenic in mice (MacLennan, 2013, Koeberling, et al., 2014). Interestingly, this 
study demonstrated that T cells stimulation with GMMA O- resulted in generation of 
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higher percentage of CD4+IFN-γ+ T cells in index cases during acute phase compared to 
healthy family members. Furthermore, in healthy family members, T cell stimulation 
with GMMA O- resulted in generation of lower percentage of CD4+IFN-γ+ T cells 
compared to T cells stimulation with GMMA O+. The lower percentage of CD4+IFN-γ+ 
T cells in GMMA O- condition among healthy family members can be attributed to lack 
of LPS O antigen. Natural LPS antigen has a profound effect on CD4+ T cell immune 
responses although this has been explored more intensively in mouse models than in 
humans (McAleer & Vella, 2008, Chilton, et al., 2013). LPS stimulates CD4+ T cell 
immune responses through toll like receptor 4 (TLR4). This TLR4 signalling  cause 
APCs to  up-regulate antigen bearing MHC class II chains and co-stimulatory molecules, 
both of which push T cell clonal expansion and  mount specific effector functions in mice 
(McAleer & Vella, 2008). How LPS O antigen in GMMA O+ augments generation of 
Salmonella-specific CD4+IFN-γ+ T cell immune responses needs to be explored in 
humans. 
 
Limitations  
The major limitation of this study was that only children with S. Typhi bloodstream 
infection were recruited although it was planned to recruit children presenting with S. 
Typhi and those presenting with NTS. Recruitment of one group of children suffering 
from NTS and another group presenting with S. Typhi bacteraemia would have offered us 
the opportunity to compare the nature of immunity induced by exposure to either one of 
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these invasive Salmonella serovars. Furthermore, healthy family members that were used 
as healthy controls were mainly adults as compared to the index cases who were children.  
It is very likely that immune responses to Salmonella differ in different age groups. A 
group of age-matched children as controls would have been ideal. All proteins antigens 
used in this study were derived from both wild type and tolR-wabaP mutant (lack LPS O 
antigen) S. Typhimurium strain D23580. All protein antigen preparations (FliC, OMP, 
GMMA O- and GMMA O+) were derived from S. Typhimurium. Some proteins antigens 
derived from S. Typhi would have allowed appropriate comparison. 
 
Summary 
In children with S. Typhi bacteraemia, IgG antibodies targeting S. Typhi LPS O; 9 
antigens were high during  acute infection and appeared to cross-react with S. 
Typhimurium LPS O; 4, 5, suggesting pre-existing S. Typhi  IgG antibodies specific for 
LPS O;9 might have a wider role in controlling S. Typhimurium infections. Further 
studies are required to explore the potential of already licensed vaccines in providing 
protection against nontyphoidal Salmonella serovars including S. Typhimurium and S. 
Enteritidis. Salmonella specific effector memory CD4+ T cells were elevated during the 
acute phase which decreased one month in convalescence. This might have resulted from 
effector CD4+ T cell differentiation to central memory CD4+ T cell and subsequently 
migrate to  secondary lymphoid tissues. In contrast to GMMA O-, LPS O antigen on 
expression GMMA O+ appears to act as an adjuvant and augments the generation of 
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Salmonella-specific CD4+IFN-γ T cells. Clinical studies are required to study the 
immunogenicity induced by Salmonella derived GMMA O+ and GMMA O- as vaccines. 
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CHAPTER 6: Ty21a ORAL TYPHOID VACCINE INDUCED IMMUNITY IN 
THE PERIPHERAL BLOOD AND GUT MUCOSA OF HEALTHY ADULTS 
6.1  INTRODUCTION 
About 21.7 million people worldwide contract typhoid fever annually (Crump, et al., 
2004, Crump & Mintz, 2010). In the developed world, typhoid cases have considerably 
reduced (Clark, et al., 2010), while in sub-Saharan Africa, Asia and the Indian sub-
continent typhoid fever remain endemic mainly due to limited access to clean water, poor 
sanitation and poor food hygiene (Crump & Mintz, 2010, Breiman, et al., 2012). Clinical 
management of typhoid fever is problematic in endemic countries, due to the emergence 
of multi drug resistant (MDR) S. Typhi (Rowe, et al., 1997, Crump & Mintz, 2010, 
Kariuki, et al., 2010, Aggarwal, et al., 2011, Zaki & Karande, 2011). Besides other public 
health interventions such as improvements in sanitation and food hygiene, vaccination for 
typhoid was recommended by world health organization (WHO) as a means to control S. 
Typhi infections since 2008 (WHO, 2008).   
 
As described in Chapter 1, oral Ty21a is a vaccine for  typhoid fever and was generated 
in the 1970s following chemical mutagenesis of the wild type strain S. Typhi Ty2 and 
does not express the Vi polysaccharide and galE gene (Germanier & Fuer, 1975, 
Guzman, et al., 2006). Ty21a (Vivotif) contains attenuated S. Typhi Ty2 in lyophised 
form, and each capsule contains no less than 2x10
9
  viable cells (Guzman, et al., 2006). 
Oral Ty21a vaccine is one of the two currently licensed vaccines for typhoid fever, the 
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other being the Vi polysaccharide (VCP) parenteral vaccine (Germanier & Fuer, 1975, 
Guzman, et al., 2006, Khan, et al., 2010). Both are used mainly by travellers from 
developed world when they visit endemic areas, but may also be used for disease control 
within endemic areas. As discussed in Chapter 1, clinical trials demonstrated that oral 
Ty21a vaccine is extremely safe and well tolerated (Olanratmanee, et al., 1992, Guzman, 
et al., 2006). A meta-analysis of randomised controlled trials demonstrated that Ty21a 
vaccination has three years cumulative protective efficacy of 51% (Fraser, et al., 2007). 
Ty21a vaccine induces both antibody and T cell immune responses (Pasetti, et al., 2011). 
However, the nature of oral Ty21a vaccine-induced antibody and T cell immune 
responses within the gut mucosa has not been directly examined and neither has this 
immune response within the gut mucosa been compared to peripheral blood immune 
responses.  
 
Oral vaccines or enteric pathogens induce immune response within the gut associated 
lymphoid tissues (GALTs) (Pasetti, et al., 2011). Naïve T cells are primed when they 
encounter peptide antigen through local dendritic cells (DC) and imprinted within the 
regional mesenteric lymphoid tissues to express gut mucosa specific trafficking 
molecules including α4β7 and CCR9. Vitamin A (retinol) metabolite retinoic acid (RA) 
has been implicated in imprinting gut mucosa homing molecules such as α4β7 and CCR9 
on T cells (Johansson-Lindbom, et al., 2003, Iwata, et al., 2004). B cells and T cells 
expressing integrin α4β7 interacts with mucosal vascular address in cell adhesion 
molecule 1 (MAdCAM1), which is constitutively expressed on endothelial venules in 
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intestinal lamina propria (LP) and Peyer’s patches (PP) (Berlin, et al., 1993). B cells and 
T cells express chemokine receptor CCR9 and interact with the gut-associated chemokine 
ligand CCL25/TECK (Kunkel, et al., 2000, Iwata, et al., 2004). CCL25 has been 
implicated in trafficking blood lymphocytes into the mucosal epithelial tissues of the gut, 
respiratory and urogenital tracts (Kunkel, et al., 2003). CCR9+ T cells are not found 
within the colon, perhaps due to lack of CCL25 expression in the colon. In contrast, 
CCL28 is expressed by colonic epithelial cells and interacts with CCR10 (Kunkel, et al., 
2003). It is therefore thought that CCR9 promotes B cells and T cells homing within the 
small bowel while CCR10 promotes these lymphocytes homing within the large bowel. 
CD62L is mainly expressed on naïve lymphocytes and facilitates trafficking into the 
secondary lymph nodes (SLN) via high endothelial venules (HEV). Homing to the SLN 
is directed by T cell expression of CD62L which interacts with Gly-CAM-1, CD34 and 
SGL-1 expressed by endothelial cells, and expression of CCR7, which interacts with 
CCL19, CCL21 expressed by the lymph nodes (Streeter, et al., 1988). A majority of 
central memory (CM) T cells express high CD62L and this permits CM T cells to  reside 
within the lymphoid tissues, in contrast effector memory (EM) T cells express low 
CD62L, and  permits these cells to migrate to  infected tissues for antigen-specific 
effector functions (Sallusto, et al., 1999). It has previously been shown, that oral Ty21a 
vaccination induces a peripheral S. Typhi-specific CD4+ and CD8+ T cell immune 
responses and a majority of these peripheral cells express gut homing markers including 
α4β7 and CCR9 (Lundin, et al., 2002, Salerno-Goncalves, et al., 2002). However, what 
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happens at the site of immune induction (the gut mucosa) in humans has not previously 
been addressed. 
This study aimed at modelling natural Salmonella infection induced immune responses 
using oral Ty21a vaccination. A model for natural Salmonella infection and immune 
responses occurring within the gut mucosa and peripheral blood will help to understand 
natural immunizing events that occurs in young children exposed to gut localised NTS 
and invasive NTS disease in SSA. Currently, there is no licenced vaccine for NTS, 
understanding the immunizing events that occur in this model will help to inform the 
design of future NTS vaccine candidates. This model will also help refine the design of 
immunological investigations and tools needed to investigate natural Salmonella 
infection and related immunizing events. Thus to model natural Salmonella infection 
induced immune responses, an interventional study was carried out in healthy adults 
comprising of vaccinated group (received 3 doses of oral Ty21a vaccine) and a control 
group (unvaccinated) and examined T cell immune responses within the peripheral blood 
(at 11 days and 18 days) and gut mucosa (at day 18 only) post-vaccine administration.  
 
Hypothesis: Salmonella infection through the oral route induces the generation of 
specific immune responses within the gut mucosa and by using gut mucosa specific 
homing markers, antigen-specific T cells reflecting mucosal responses can effectively be 
examined non-invasively in the peripheral blood. 
 
Study objectives: 
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1. To examine and compare oral Ty21a vaccine induced T cell immune responses in the 
peripheral blood and gut mucosa. 
2. To examine the usefulness of gut mucosa homing markers in evaluating these 
antigen-specific immune responses. 
 
Endpoints: 
1. Measure Ty21a specific CD4+ and CD8+ T cells producing IFN-γ, TNF-α and IL-2 
in peripheral blood and gut mucosa of vaccinated and unvaccinated subjects. 
2. Measure Ty21a-specific CD4+ and CD8+ T cells co-expressing gut homing markers 
(β7 and CCR9) producing IFN-γ, TNF-α and IL-2 in peripheral blood of vaccinated 
and unvaccinated subjects. 
 
6.2 PARTICPANTS, MATERIALS AND METHODS  
The methods for this chapter have been described in Chapter 2: study designs, materials, 
and methods, section 2.4. 
Briefly, in this prospective interventional study, a total of 17 healthy adults (Median age 
21 years and range [18-30]) from the UK were recruited. The participants were randomly 
assigned to vaccine and control groups. There were a total of 9 vaccinated (female 55% 
[5/9]) and 8 unvaccinated participants (female 25% [2/8]). Vaccinees were given three 
oral doses of the vaccine. Ty21a (Vivotif) contains attenuated S. Typhi Ty2 in lyophised 
form, and each capsule contains no less than 2x10
9
 viable cells. One capsule was taken 
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on each of days 0, 2 and 4, approximately one hour before a meal, with a cold or 
lukewarm drink, as recommended by the manufacturer and as licensed for use in the UK.  
Blood samples were collected at day 0 (before vaccine administration), day 11 and day 
18 while mucosal specimens were collected only at day 18, at gastroscopy. Salmonella 
specific peripheral and gut mucosal T cell cytokine responses; IFN-γ, IL-2, TNF-α were 
quantified by the intracellular cytokine staining assay. In these experiments peripheral 
blood mononuclear cells and gut mucosal mononuclear cells were stimulated with heat-
inactivated Ty21a at 0.0632µg/ml (Berna Biotech, Switzerland) and influenza (Influenza 
virus vaccine) at 0.225µg/ml (Solvay Biologicals B.V., Netherlands) and SEB at 
100µg/ml (Sigma Aldrich, USA) were used as control stimulants. Peripheral blood 
memory T cell subsets (naïve, central and effector) were quantified by immuno-
phenotyping using CD45RA, and CCR7 markers and T cells homing were quantified by 
immuno-phenotyping using β7, CCR9, and CD62L markers.  
 
6.3 STATISTICAL ANALYSES 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad 
Software, Inc., USA). Percentages of T cells producing cytokines were examined for 
normality of distribution using D’Agostino and Pearson omnibus normality test. In case 
of normally distributed immune responses, paired groups were compared using two-tailed 
parametric t test. While non-normally distributed immune responses, paired groups were 
compared using Wilcoxon signed ranked test, and non-paired groups were compared 
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using two tailed nonparametric Mann Whitney test. Mean or median and 95% confidence 
intervals (CI) or interquartile range (IQR) for each group immune response were 
reported. A p value of less than 0.05 was considered statistically significant. 
 
6.4 RESULTS 
6.4.1 Peripheral blood Ty21a-specific CD4+/CD8+Cytokine+ T cell responses 
remain un-changed following Ty21a vaccination at day 11 and 18 
In this intervention study, Salmonella-specific CD4+ and CD8+ T cells producing a 
combination of cytokines (addition of cells producing single, double and triple 
combinations of cytokines IFN-γ, TNF-α and IL-2, here termed as Cytokine+) in the 
peripheral blood were quantified  using the intracellular-cytokine staining (ICS) assay as 
described in Chapter 2. CD4+ T cells producing cytokines, for instance IFN-γ, were gated 
as shown in figure 6.1.  
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Figure 6. 1 Gating strategy for detection of CD4+ T cells producing cytokines 
From the CD4+ T cells gate shown (Figure 6.1 top), CD4+ T cells producing IFN-γ were 
defined as CD4+IFN-γ+ (Figure 6.1 top and bottom plots). Representative plots of un-
stimulated condition and Ty21a and SEB stimulated conditions are shown (Figure 6.1 
bottom plots). 
 
There was no evidence of statistical difference in the percentages of Ty21a-specific T cell 
immune responses at day 0 (baseline) comparing the vaccinated and unvaccinated 
subjects (CD4+Cytokine+ T cells, median; 0.062%, IQR [0.015-0.077]  vs 0.02%, IQR 
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[0.016-0.029 ], p=0.31) and (CD8+Cytokine+ T cells, median; 0.05%, IQR [0.002-0.13] 
vs 0.04%, IQR [0-0.11], p=0.8) (Figure 6.2A and 6.3A). 
There was no evidence of statistical difference in the percentages of Ty21a-specific 
CD4+Cytokine+ T cells  and CD8+Cytokine+ T cells  at day 11 and 18 in comparison 
with day 0  in vaccinated subjects (CD4+Cytokine+ T cells, median; 0.062%, IQR 
[0.015-0.077]  at day 0 vs 0.023%, IQR [ 0.019-0.075] at day 11, p=0.87 and 0.02%, IQR 
[0.010-0.058] at day 18, p=0.68) and (CD8+Cytokine+ T cells, median; 0.05%, IQR 
[0.002-0.13] at day 0 vs 0.03%, IQR [0.004-0.065] at day 11, p=0.25 and 0.04%, IQR 
[0.01-0.098] at day 18, p=0.34)  (Figure 6.2A and 6.3A). 
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Figure 6. 2: Percentage of Ty21a-specific CD4+Cytokine+ T cells remain unchanged 
in  
Ty21a vaccinated subjects at day 11 and 18 
Percentage of CD4+ T cells producing a combination of cytokines (addition of single, 
double and triple cytokine producers [IFN-γ, TNF-α and IL-2], here termed as 
Cytokine+) in the peripheral blood among control (unvaccinated) and vaccinated subjects 
as indicated (6.2A-C). Blood was collected from study participants on day 0, 11 and 18 
and PBMCs were stimulated with heat killed Ty21a, Influenza (control) and SEB 
(control) as indicated. Vaccinated subjects at day 0 (n=7), 11 (n=6), and 18 (n=9). 
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Unvaccinated subjects at day 0 (n=7), 11 (n=5) and 18 (n=7). The bars represent the 
median. Group immune responses were compared using Wilcoxon signed ranked test. 
 
There was no statistical difference in the percentages of  Ty21a-specific CD4+Cytokine+ 
T cells  and CD8+Cytokine+ T cells  at day 11 and 18 in comparison with day 0 in 
control (unvaccinated) subjects (CD4+Cytokine+ T cells, median; 0.02%, IQR [0.016-
0.029 ] at day 0 vs  0.02%, IQR [0.010-0.039] at day 11, p=1.0 and 0.01% , IQR [ 0.004-
0.026 ] at day 18, p=0.31) and (CD8+Cytokine+ T cells, median; 0.04%, IQR [0-0.11] at 
day 0 vs 0.03% , IQR [0.023-0.078] at day 11 , p=0.87 and 0.03%, IQR [0.014-0.04] at 
day 18 , p=1.0) respectively  (Figure 6.2A and 6.3A).  
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Figure 6. 3: Percentage of Ty21a-specific CD8+Cytokine+ T cells remain unchanged 
in Ty21a vaccinated subjects at day 11 and 18 
Percentage of CD8+ T cells producing a combination of cytokines (addition of single, 
double and triple cytokine producers [IFN-γ, TNF-α and IL-2], here termed as 
Cytokine+) in the peripheral blood among control and vaccinated subjects as indicated 
(6.3A-C). Blood was collected from study participants on day 0, 11 and 18 and PBMCs 
were stimulated with heat killed Ty21a, Influenza (control) and SEB (control) as 
indicated. Vaccinated subjects at day 0 (n=7), 11 (n=6), and 18 (n=9). Unvaccinated 
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subjects at day 0 (n=7), 11 (n=5) and 18 (n=7). The bars represent the median. Group 
immune responses were compared using Wilcoxon signed ranked test.  
 
In all T cell-stimulated control conditions (influenza and SEB) there was no evidence of 
statistical difference in percentage of CD4+Cytokine+ and CD8+Cytokine+ T cells at day 
11 and 18 in comparison with day 0 in vaccinated subjects; Influenza stimulated 
condition (CD4+Cytokine+, median; 0.19%, IQR [0.11-0.48] at day 0 vs 0.20%, IQR 
[0.10-0.28], at day 11, p=0.87 and 0.19%, IQR [0.087- 0.34] at day 18, p=0.93) and SEB 
stimulated condition (CD4+Cytokine+, median; 4.28%, IQR [2.39-6.14] at day 0 vs 
2.44%, IQR [1.48-4.89] at day 11, p=0.62 and 3.49%, IQR [2.97-5.34] at day 18, 
p=0.81)(Figure 6.2B-C). Influenza stimulated condition (CD8+Cytokine+, median; 
0.05%, IQR [0-0.13] at day 0 vs 0.12%, IQR [0.02-0.24], at day 11, p=0.12 and  0.12%, 
IQR [0.01-0.45] at day 18, p=0.29) and SEB stimulated condition (CD8+Cytokine+, 
median; 2.14%, IQR [1.77-4.02] at day 0 vs 1.96%, IQR [0.73-3.5] at day 11, p=1.0 and 
2.9%, IQR [1.72-4.8] at day 18, p=0.29) (Figure 6.3B-C).   
There was no evidence of statistical difference in percentage of CD4+Cytokine+ and 
CD8+Cytokine+  T cells at day 11 and 18 in comparison with day 0 in control 
(unvaccinated) subjects; Influenza stimulated condition (CD4+Cytokine+, median; 
0.19%, IQR [0.15-0.31] at day 0 vs 0.11%, IQR [0.09-0.18], at day 11, p=0.10  and 
0.20%, IQR [0.13-0.28]at day 18, p= 0.21) and in SEB stimulated condition 
(CD4+Cytokine+, median; 3.79%, IQR [1.52-6.99] at day 0 vs  2.89%, IQR [1.61- 6.99] 
at day 11 p=0.37 and 3.89%, IQR [2.27-4.79] at day 18, p=0.84) (Figure 6.2B-C). In 
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Influenza stimulated condition (CD8+Cytokine+, median; 0.10%, IQR [0.002-0.20] at 
day 0 vs 0.002%, IQR [0-0.04], at day 11, p=0.25  and 0.05%, IQR [0-0.11] at day 18, p= 
0.68) and in SEB stimulated condition (CD8+Cytokine+, median; 4.07%, 95% Cl [3.65-
9.55] at day 0 vs  2.49%, IQR [1.47-3.48] at day 11 p=0.61  and 2.69%, 95% Cl [1.49-
10.12] at day 18, p=0.31) (Figure 6.3B-C). Taken together these findings show that oral 
Ty21a vaccination did not induce an increase in peripheral CD4+ or CD8+ T cell 
immune responses to S. Typhi, detectable at 11 and 18 days post-vaccination. 
 
6.4.2 Effector memory T cells highly express gut mucosal homing marker β7+ and 
CCR9+  
Recently primed T cells within the gut associated lymphoid tissues (GALTs) migrate to 
sites of infection for antigen-specific effector functions, and migrate back to the gut 
mucosa through imprinted homing signature (Kantele, et al., 1999). To investigate this in 
context of Ty21a vaccination, we quantified T cell subsets expressing gut mucosa 
homing markers (β7 and CCR9) and peripheral lymph nodes (PLN) homing marker 
(CD62L) using immunophenotying as described in Chapter 2 and figure 6.4 shows the 
representative gating strategy. 
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Figure 6. 4: Memory CD4+ T cells and homing marker gating strategy 
From the CD4+ T cell gate (Figure 6.4 top left), memory CD4+ T cells were detected by 
the expression of CD45RA and CCR7. We defined me naïve CD4+ T cells as 
CD45RA+CCR7+, central memory CD4+ T cell as CD45RA-CCR7+ and effector 
memory CD4+ T cells as CD45RA-CCR7- (Figure 6.4 top right). CD4+ T cell subsets 
trafficking properties were characterized by expression of gut homing markers (β7 and 
CCR9) and peripheral lymphoid tissues homing marker CD62L (Figure 6.4 histogram 
plots). To determine the positive population FMO (fluorochrome Minus One) condition 
(FMO condition was stained with the same cocktail of  fluorochrome antibodies as the 
test condition minus the antibody to the  homing marker of interest i.e. anti-CCR9 PerCP 
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Cy 5.5) was used to set up the cut off line (represented by the black line) for the test 
condition. 
 
There was a higher proportion of total CD8+ T cells expressing β7+ compared to CD4+ T 
cells (Median; CD4+β7+ 51%, IQR [45-57] vs CD8+β7+ 70%, IQR [57.5-77.5]) (Figure 
6.5A). The  proportion of  CD4+ and CD8 T cells expressing CCR9 and CD62L were 
similar (Median; CD4+CCR9+ 28%, IQR [23-31] vs CD8+CCR9+ 32%, IQR [24.5-
34.5]) and (Median; CD4+62L+ 30%, IQR [20.5-63.5] vs CD8+CD62L+ 29%, IQR [20-
44.5]) respectively (Figure 6.5A).  
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Figure 6. 5: Proportion of T cell subsets expressing homing markers   
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Percentage of total CD4+ and CD8+T cells in the peripheral blood imprinted for homing 
to the gut mucosa; CD4+β7+ and CCR9+, and the peripheral lymphoid tissues; CD62L+. 
(Figure 6.5A). Percentage of the total CD4 or CD8 population that were central memory 
(CM) CD4+ or CD8+ T cells (defined as CD45RA-CCR7+), effector memory (EM) 
CD4+ or CD8+ T cells (defined as CD45RA-CCR7-) and naïve CD4+ or CD8+ T cells 
(defined as CD45RA+CCR7+) (Figure 6.5B). Percentage of naïve (Figure 65.C), EM 
(Figure 6.5D), CM (Figure 6.5E) CD4+ or EM CD8 T cells in the peripheral blood 
imprinted for homing to the gut mucosa; CD4+β7+ and CCR9+, and the peripheral 
lymphoid tissues; CD62L+ (Figure 6.5C-E). Figure 6.5A-E, n=9. The bars represent the 
median. 
 
Vaccination or pathogen exposure induces the generation of memory T cells and these 
can ably be distinguished phenotypically (Mackay, et al., 1990, Bunce & Bell, 1997).  
There was a lower percentage of CM CD8+ T cells compared to CM CD4+ T cells 
(Median; CM CD4+ 68%, IQR [51-76] vs CM CD8+ 4%, IQR [3.1-44]) (Figure 6.5B).  
There was a higher percentage of naïve CD8+ T cells compared to  naïve CD4+ T cells 
(Median; Naïve CD4+  16%, IQR [8.1-23] vs naïve CD8+  31%, IQR [16.5-39.5])  while 
the percentage of EM were similar (Median; EM CD4+  16% , IQR [6.3-36.5] vs EM 
CD8+  12%, IQR [9.25-25.5]) (Figure 6.5B).  
 
There were variations in proportions of memory T cells subsets expressing β7+, more 
naïve CD4+ T cells were expressing β7+ (Median; 77% , IQR [74.5-80.5]) followed by 
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EM CD4+ (Median; 72% , IQR [57-86])  and less CM CD4+ T cells were expressing β7+ 
(Median; 37%, IQR [34.5-43]) (Figure 6.5C-E). The proportion of naïve and effector 
memory CD8+ T cells expressing β7+ were similar (naïve CD8+ median; 67%, IQR [61-
73]) and (EM CD8+ median; 69%, IQR [64-82]) and less proportion of CM CD8+ T cells 
were expressing β7+ (Median; 55%, IQR [46-67]). However, the fluorescent intensity of 
β7+ was highest in EM CD4+ T cells followed by CM CD4+ T cells and least expressed 
in naïve CD4+ T cells (Figure 6.6A). The proportion of CD4+ and CD8+ T cells 
expressing CCR9+ was similar in all CD4+ and CD8 T cell subsets examined (Naïve, 
EM and CM) (Figure 6.5C-E). The fluorescent intensity of CCR9+ was highest in EM 
CD4+ T cells while it was similar in CM and naïve CD4+ T cells (Figure 6.6B). As 
expected, the proportion of  CD4+ and CD8+ T cells expression of CD62L was highest in 
naïve T cells (median; naïve CD4+CD62L+88%, IQR [82-97] and naïve 
CD8+CD62L+64%, IQR [37-73]) followed by CM T cells (median; CM 
CD4+CD62L+22%, IQR [17-49] and CM CD8+CD62L+38%, IQR [33-47.5])  and  less 
proportion of  EM T cells were expressing CD62L (median; EM CD4+CD62L+ 7.6%, 
IQR [3.9-21] and EM CD8+CD62L+17%, IQR [9.9-31.5]). The fluorescent intensity of 
CD62L expression was highest in naïve CD4+ T cells, followed by CM CD4+ T cells 
and least expressed by EM CD4+ T cells (Figure 6.6C). Taken together these findings 
indicate that in the peripheral blood, some  EM T cells are imprinted within the gut 
mucosa to  highly express gut homing markers β7+ and CCR9+ and this permits these 
cells to  migrate back  to the  gut mucosal tissues for mounting of effector functions.  
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Figure 6. 6: Heterogeneous expression of homing markers on T cell subsets  
Representative diagram showing expression fluorescent intensity of homing markers 
(β7+ CCR9+ and CD62L) on  CD4+ T cells subsets (naïve, EM, CM). 
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6.4.3 Peripheral blood cytokine producing CD4+β7+ and CD8+β7+ T cells remain 
unaltered following oral Ty21a vaccination   
An approach was then taken, thought to be more sensitive in detecting oral vaccine 
induced T cell immune responses, by quantifying Ty21a-specific T cells expressing gut 
homing markers (Lundin, et al., 2002). There was no statistical difference in percentage 
of Ty21a-specific CD4+β7+Cytokine+ and CD8+β7+Cytokine+  T cells in the peripheral 
blood at day 11, and 18 compared to day 0 in vaccinated subjects (CD4+β7+Cytokine+, 
median; 0.035%, IQR [0.020-0.08] at day 0 vs 0.031%, IQR [0.021-0.092] at day 11, 
p=0.75 and 0.032%, IQR [0.001-0.10] at day 18, p=0.56) and (CD8+β7+Cytokine, 
median; 0.05%, IQR [0.03-0.06] at day 0 vs 0.036%, IQR [0-0.069] at day 11, p=0.25 
and 0.055%, IQR [0.02-0.09] at day 18, p=0.68)(Figure 6.7A and B). 
 
Similarly, there was no statistical difference in percentage of Ty21a-specific 
CD4+CCR9+Cytokine+ and CD8+CCR9+Cytokine+  T cells in the peripheral blood at 
day 11, and 18 compared to day 0 in vaccinated subjects (CD4+CCR9+Cytokine+, 
median; 0.022%, IQR [0.06-0.32] at day 0 vs 0.081%, IQR [0.01-0.23] at day 11, p=1.0 
and 0.045%, IQR [0.01-0.34] at day 18, p=0.84) and (CD8+CCR9+Cytokine+, median; 
0.055%, IQR [0-0.12] at day 0 vs 0.0% , IQR [0-0.04] at day 11, p=0.25  and 0.045%, 
IQR [0-0.13] at day 18, p=0.62) (Figure 6.7C and D). Taken together these findings show 
that oral Ty21a vaccination did not induce an increase in  gut homing CD4+ and CD8+ T 
cell immune responses to S. Typhi, detectable at 11 and 18 days post-vaccination. 
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Figure 6. 7: Peripheral blood cytokine producing CD4+β7+ and CD8+β7+ T cells 
remain unaltered following oral Ty21a vaccination   
Percentage of CD4+β7+ and CD8+ β7+  T cells (Figure 6.7A-B) andCD4+CCR9+ and 
CD8+CCR9+  T cells (Figure 6.7C-D) producing combination of cytokines (addition of 
single, double and triple cytokine producers[IFN-γ, TNF-α and IL-2], here termed as 
Cytokine+) in the peripheral blood among  vaccinated  and unvaccinated subjects as 
indicated. Blood was collected from study participants on day 0, 11 and 18 and PBMCs 
were stimulated with heat killed Ty21a. Vaccinated subjects at day 0 (n=7), 11 (n=5), and 
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18 (n=8). Unvaccinated subjects at day 0 (n=7), 11 (n=5) and 18 (n=7). The bars 
represent the median. Groups were compared using Wilcoxon signed ranked test. 
 
6.4.4 Gut mucosa Ty21a-specific CD4+Cytokine+ and CD8+Cytokine+ T cells 
remain unaltered following oral Ty21a vaccination  at day 18 
Evaluation of oral Ty21a vaccine induced T cell and antibody immune response has 
mainly relied on peripheral blood immunological measurements. Direct measurement of 
oral Ty21a induced immune responses in the gut-mucosa tissue has not previously been 
undertaken. It was hypothesised that direct measurement of oral Ty21a induced immune 
responses within the gut mucosal tissue and might provide more insight than peripheral 
blood measurements because it is possible that some immunizing events occurring within 
the gut mucosa could be missed by using peripheral blood measurements only. Day 18 
was chosen in order to allow time for priming and re-homing events to have occurred. 
Twelve to 15, D2-D3 duodenal single-bite cold biopsies at 20-25cm insertion were 
collected using Boston Scientific large capacity ‘jumbo’ forceps (Boston Scientific, 
USA) which passed through a standard 2.8mm endoscopic biopsy channel. Gut mucosal 
biopsies were collected from all study subjects on day 18 post vaccination. As described 
in chapter 2, mucosal mononuclear cells (MMNCs) isolated were examined for Ty21a 
specific T cell cytokine immune responses. Cytokine responses were examined on viable 
MMMCs using Vivid dye and no less than 90% lymphocytes viability was achieved. 
Contrary to this study hypothesis, there was no statistical difference in percentage of 
Ty21a-specific CD4+Cytokine+ and CD8+Cytokine+ T cells in vaccinated and 
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unvaccinated subjects in the gut mucosa at day 18 (CD4+Cytokine+, median; control 
0.14%, IQR [0-0.41] vs  vaccine 0.08% , IQR [0.002-0.18], p=0.44) and 
(CD8+Cytokine+, median; control 0.039% , IQR [0.02-0.21] vs vaccine 0.022%, IQR [0-
0.08], p=0.39)(Figure 6.8A). It was observed that both influenza and SEB stimulated 
conditions in the gut mucosal performed as expected and immune responses were similar 
in vaccinated and unvaccinated subjects (Figure 6.8B-C). 
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Figure 6. 8:  Gut mucosa cytokine producing CD4+ and CD8+ T cells remain 
unaltered following oral Ty21a vaccination   
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Percentage of CD8+ T cells producing a combination of cytokines (addition of single, 
double and triple cytokine producers [IFN-γ, TNF-α and IL-2], here termed as 
Cytokine+) in the duodenum (gut mucosa) among control (represented by C) and 
vaccinated (represented by V) subjects as indicated (6.8A-C). Gut mucosa biopsy was 
collected from study participants on day 18 after vaccination, and MMNCs were 
stimulated with heat killed Ty21a, Influenza (control) and SEB (control) as indicated. 
Vaccinated subjects CD4+Cytokine+ Ty21a (n=8), Influenza (n=7), and SEB (n=8). 
Vaccinated subjects CD8+Cytokine+ Ty21a (n=8), Influenza (n=8), and SEB (n=8). 
Unvaccinated subjects CD4+Cytokine+ Ty21a (n=5), Influenza (n=6), and SEB (n=6). 
Unvaccinated subjects CD8+Cytokine+ Ty21a (n=6), Influenza (n=6), and SEB (n=6).  
The bars represent the median. Groups were compared using two-tailed nonparametric 
Mann Whitney test. 
 
Taken together these findings suggest that oral Ty21a vaccination does not induce an 
increase in CD4+ and CD8+ T cell immune responses to S. Typhi detectable in the gut 
mucosa and peripheral blood compartments among vaccinated subjects at day 18. 
 
6.5  DISCUSSION 
Currently, assessment of T cell and antibody immune responses induced by oral vaccines 
such as Ty21a or natural Salmonella infection relies on indirect measurements of immune 
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responses, mainly within the peripheral blood. Commonly used immunological tools for 
measurement of T cell immune responses include; intracellular-cytokine staining, 
proliferation, ELISpot (Lundin, et al., 2002, Salerno-Goncalves, et al., 2002) while 
commonly used tools for measurement of antibody production include ELISA and 
ELISpot (Toapanta, et al., 2014). Peripheral blood assessment of antigen-specific 
immune responses induced by oral vaccination or natural Salmonella infection might lead 
to under-appreciation of immunological events, particularly immunizing events occurring 
within the gut mucosa. In this interventional study comprising Ty21a vaccinees and 
unvaccinated subjects natural Salmonella infection was modelled and directly quantified 
Ty21a-specific CD4+Cytokine+ and CD8+Cytokine+ T cells within the gut mucosa and 
indirectly quantified similar T cells in the peripheral blood simultaneously. 
Unexpectedly, in the vaccinated group, peripheral blood Ty21a-specific CD4+Cytokine+ 
and CD8+Cytokine+ T cells were not statistically different at day 11 and day 18 post-
vaccination compared to day 0. This study findings are not in keeping with previous 
reports (Salerno-Goncalves, et al., 2002, Salerno-Goncalves, et al., 2005). 
 
In this study, the proportion of memory T cell subsets were characterised and showed that 
a effector memory CD4+ and CD8+ T cells highly express gut homing marker β7+ and 
CCR9. Observations were made that large proportion of naïve T cells also express gut 
homing markers β7+ and CCR9 and this was in keeping with previously studies (Cose, 
2007). Furthermore, the fluorescent intensity of β7+ and CCR9+ expression of naïve T 
cells was lower compared to EM T cells. This may not mean that naïve and memory  T 
Vaccine induced immune responses 
 
236 
 
cells have the same migration pathways to the non-lymphoid tissues (sites of infection) 
since migration is dictated by the density of homing receptor, in this case memory T cells 
are likely to preferentially home to gut mucosal tissue over the naïve T cells (Cose, 
2007).  Previously, it has been demonstrated that a majority of Ty21a-specific CD4+ and 
CD8+ T cells are imprinted for gut mucosa homing, as evidenced by the expression of β7 
(Lundin, et al., 2002), suggesting that evaluation of gut homing T cells might improve the 
sensitivity of detecting antigen-specific T cells. Unexpectedly, using the gut homing 
marker β7 to identify Ty21a-specific cytokine-producing T cells, did not help to delineate 
immunological changes that might have occurred in vaccinated compared to non-
vaccinated subjects. There were no statistical differences in percentage of Ty21a specific-
CD4+β7+Cytokine+ and CD8+β7+Cytokine+ T cells at day 11 and day 18 compared to 
day 0 in vaccinated group. These findings are not consistent with previous reports 
(Lundin, et al., 2002). There were also no statistical differences in percentage of Ty21a 
specific-CD4+CCR9+Cytokine+ and CD8+CCR9+Cytokine+ T cells at day 11 and day 
18 compared to day 0 in the vaccinated group. Furthermore, even with direct assessment 
of gut mucosa immunological measurements, there was no evidence that oral Ty21a 
vaccination induced an increase in  Ty21a-specific CD4+Cytokine+ and CD8+Cytokine+ 
T cell responses in vaccinated subjects compared to non-vaccinated subjects at day 18 
post-vaccination. Why this study found no evidence of increased T cell responses 
following vaccination with Ty21a as previously described elsewhere (Salerno-Goncalves, 
et al., 2002, Salerno-Goncalves, et al., 2005) is the key question. The control stimulated 
condition’s (Influenza and SEB) induced CD4+Cytokine+ and CD8+Cytokine+ T cells 
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responses performed as expected, so there was no evidence that cell isolation and culture 
conditions compromised the ability of cells to produce cytokine responses.  In this study 
heat-inactivated whole-bacterial Ty21a stimulant was used in ICS experiments, it is 
possible that our stimulant could not induce robust stimulation comparable to live 
stimulants used by other groups (Thatte, et al., 1993). It has been demonstrated before 
that whole-cell killed bacteria are less efficient stimulant compared to live whole cell 
bacteria (Thatte, et al., 1993, Nyirenda, et al., 2010). In this study, co-stimulatory 
antibody such as CD28/49d were not used as before (Nyirenda, et al., 2010), and this 
might have increased the ability to detect different responses. Previous studies have 
shown that T cell responses to oral vaccination vary as to when they are evaluated in the 
peripheral blood. Antigen-specific T cell responses such as  CD4+ T helper 1 cytokines 
and proliferation peaks around 7 to 14 days (Lundin, et al., 2002). In this study, timing 
for assessment of antigen-specific responses at day 11 post-vaccination in our 
intervention study was in keeping previous work. Whether assessment at 18 day post-
vaccination might have been late to detect immune response is not clear. Taken together 
these findings and previous reports, it is inconclusive whether or not Ty21a vaccination  
does induce the generation of  Ty21a specific CD4+ and CD8+ T cells both within the 
gut mucosa and peripheral blood. To effectively trouble shoot this lack of T cell immune 
responses following Ty21a vaccination in future investigations a panel of antigen specific 
stimulants will be evaluated to identify the strong stimulant. These experiments will 
include, evaluation of antibody responses S. Typhi using ELISA on existing serum 
samples from this cohort,   comparing live versus heat killed specific antigen, purified 
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antigens versus crude preparations and also determining the optimum stimulation 
concentration of these antigens. A number of immunological tools for assessment of 
antigen specific T cell immune responses will be compared including ICS short term 
stimulation versus long terms stimulation, ICS versus ELISpot and also proliferation 
assays. Optimum time for assessment of T cells responses following Ty21a vaccination 
will also be evaluated in time course experiments, whereby blood specimens from 
vaccinees collected at varying days following vaccination will be compared. Only one 
vaccine batch will be used and the vaccine concentration of live attenuated S. Typhi will 
be verified.   
 
Currently, there is no human vaccine for NTS bacteraemia which is an important public 
health problem in SSA. Young children and HIV infected individuals are more 
susceptible to NTS bacteraemia and non-invasive techniques are required to evaluate 
immunity following natural or vaccine exposure. This model is important for 
understanding immunizing events that occur within the gut following natural NTS 
infection and evaluates immunological tools that could be used to assess immunity 
occurring within the gut and peripheral blood. Gut homing makers including CCR9 and 
β7 can potentially be used non-invasively to evaluate T cell immune responses in 
children and HIV infected individuals naturally infected with NTS. Better understanding 
of natural Salmonella immunizing events within the gut will help in designing an 
effective vaccine for NTS that is urgently required.  
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Summary 
This study has demonstrated that in the peripheral blood, effector memory T cells highly 
express β7, suggesting these T cells migrates back to the gut mucosal for induction of 
antigen-specific immunity. In this study, using gut mucosal measurements and peripheral 
blood measurements including use of gut homing markers, failed to detect a significant 
increase in the percentage of Ty21a specific CD4+Cytokine+ and CD8+Cytokine+ T cell 
immune responses in blood at day 11 and 18 in vaccinees, and Ty21a specific 
CD4+Cytokine+ and CD8+Cytokine+ T cell immune responses at day 18 in gut mucosa 
in vaccinees compared to control subjects. Better immunological methods and 
appropriate study design could help to answer the question whether or not orally induced 
antibody and T cell immune responses occurring within the gut mucosa can be measured 
directly and also whether these responses can be evaluated non-invasively in the 
peripheral blood. Both young children and HIV infected individuals, who are more 
susceptible invasive NTS infection in SSA, will require use of non-invasive 
immunological techniques such as gut homing markers (CCR9 and β7) to evaluate 
immunizing events occurring within the gut mucosa.  
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CHAPTER 7: GENERAL DISCUSSION 
7.1 Introduction 
The research studies presented in this thesis were designed to investigate natural 
acquisition of antibody and T cell immunity to Salmonella in healthy and Salmonella-
infected Malawian children. In healthy adults, in the UK, acquisition of live oral typhoid 
vaccine-induced T cell immunity was investigated to model immunizing events occurring 
with the gut mucosa following natural Salmonella infection. A range of immunological 
tools were used in these investigations including the intra-cellular cytokine staining assay 
(ICS), serum bactericidal activity (SBA) assay, ELISA and ELISpot. Microbiological 
tools including standard stool culture and real-time PCR for detection of Salmonella were 
also used.  
These tools were implemented in several cross-sectional and longitudinal studies. Firstly, 
the development of antibody and T cell immune responses to S. Typhimurium in healthy 
Malawian children aged 0-60 months from Blantyre urban were investigated in a cross-
sectional study. Secondly, the relationship between Salmonella exposure events within 
the gastrointestinal tract (GIT) or oropharynx and development of Salmonella-specific 
serum immunity in healthy Malawian children aged 6-18 months from Blantyre urban 
was investigated in a longitudinal study. Thirdly, the immunological importance of 
vaccine candidates for Salmonella disease were investigated in a cohort of children below 
15 years, presenting to hospital with Salmonella bacteraemia at acute and convalescent 
phases and healthy family members. These vaccine candidates are, currently in pre-
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clinical phase, including Salmonella derived-surface proteins (FliC, OMP and GMMA) 
and lipopolysaccharide (LPS) O antigens. Lastly, antibody and T cell immune responses 
induced by oral Ty21a typhoid vaccination were investigated within the gut mucosa and 
peripheral blood compartments in vaccinated and unvaccinated healthy adults from the 
UK to prospectively model immunizing events occurring with the gut mucosa following 
natural Salmonella infection. 
This discussion focusses on lessons learnt and the implications of the research findings. 
Special emphasis is given to the development of antibody and T cell immunity to 
Salmonella resulting from natural Salmonella infection. Future investigations originating 
from this PhD study are then discussed. 
  
7.2  Review of important findings from thesis 
7.2.1 Development of adaptive immunity to nontyphoidal  Salmonella in Malawian 
children 
The first research study was aimed at characterizing the development of antibody and T 
cell immunity to S. Typhimurium in healthy Malawian children aged 0-60 months. At the 
time this research study idea was conceived, it was known that complement-fixing IgG 
and IgM antibodies to Salmonella play an important role in controlling S. Typhimurium 
bacteraemia. Both IgG and IgM antibody immunity to S. Typhimurium develops with age 
(MacLennan, et al., 2008). How CD4+ T cell immunity to S. Typhimurium develops in 
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Malawian children was not known. It was hypothesized that CD4+ T cell immunity to S. 
Typhimurium develops in parallel with antibody immunity in the first 2 years of life.  
Chapter 3 demonstrates that S. Typhimurium-specific CD4+ T cell immunity is detected 
early in life and reaches a peak at 14 months of age, suggesting early exposure to S. 
Typhimurium or cross-reactive bacteria antigens. In early life (≤ 14 months) S. 
Typhimurium-specific cytokine producing CD4+ T cells correlated positively with the 
anti-S. Typhimurium OMP and FliC IgG antibody titres, thus re-affirming that early 
exposure to Salmonella might be a requirement in the development of this immunity. 
Salmonella infection primarily results from the ingestion of contaminated food, water and 
fomites (Kariuki, et al., 2006). The pattern of Salmonella exposure events within the 
gastrointestinal tract (GIT) in Malawian children had not been investigated.  Salmonella 
exposure within the GIT is thought to be driven by several factors such as breast feeding 
and supplementary feeding practices in childhood, environmental sanitation, food 
hygiene, dosage of the infecting Salmonella bacteria and the frequency of Salmonella 
exposure events (France, et al., 1980, Kariuki, et al., 2006, Bollaerts, et al., 2008, 
Farooqui, et al., 2009). These factors have not been investigated in Malawian children, in 
relation to natural Salmonella. Chapter 3 also demonstrates that S. Typhimurium specific-
CD4+ T cells were lower in older children (24-60 months) in contrast to the younger age 
group (≤ 14 months) suggesting that Salmonella exposure events were low in the older 
children. Furthermore the decline in Salmonella exposure events might indicate 
differentiation of circulating specific-effector memory CD4+ T cells to central memory 
CD4+ T cells which are less readily detectable in the systemic circulation.    
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In agreement with what had previously been shown in Malawian children (MacLennan, 
et al., 2008), Chapter 3 demonstrates that acquisition of serum bactericidal activity (SBA) 
to S. Typhimurium occurs with age. Development of the child’s SBA to S. Typhimurium 
is delayed, and appears to start developing after the decline (in the first 8 months of life) 
of passively acquired maternal SBA. SBA to S. Typhimurium gradually develops from 8 
months of age and peaks at 36 months of age in children aged 0-60 months. Importantly, 
S. Typhimurium-specific SBA correlated with specific IgG antibody titres targeting LPS 
O;4,5 antigen suggesting the importance of this antigen to the development of this 
immunity compared to other protein antigens, including S. Typhimurium derived OMP 
and FliC which were also examined in this study. In contrast to the observation made in 
an earlier study where serum from HIV infected adults had impaired SBA to S. 
Typhimurium (MacLennan, et al., 2010), Chapter 3, shows that older children had robust 
SBA to S. Typhimurium. Lack of SBA to S. Typhimurium in HIV infected individuals 
has been attributed to high concentration of IgG antibodies targeting S. Typhimurium 
LPS O antigen and these appear to block bactericidal antibodies targeting S. 
Typhimurium OMP antigen (MacLennan, et al., 2010, Trebicka, et al., 2013). 
The variation in T cell and SBA immunity to S. Typhimurium, in relation to frequency of 
S. Typhimurium bacteraemia in the same population and age group were evaluated. As 
demonstrated before (MacLennan, et al., 2008), Chapter 3 demonstrates that S. 
Typhimurium bacteraemia in under-five children most frequently occurs in the first 2 
years of life (80%) and the median age was 13 months. Observations were made that 
even though S. Typhimurium-specific CD4+Cytokine+ T cells were acquired early in  
General discussion 
 
244 
 
life, T cells alone appeared not to sufficiently control S. Typhimurium bacteraemia but 
sequential acquisition of SBA to S. Typhimurium was associated with a decline of 
bacteraemia cases. These findings are in agreement with the proposed hypothesis on how 
mice control systemic salmonellosis (Mastroeni, 2002), which suggests that high level of 
immune resistance to Salmonella infection is established in a step-wise fashion and 
involves both innate and adaptive immunity. 
 
It is likely that the early development of T cell mediated response specific for S. 
Typhimurium protein antigens, and subsequent cognate interactions with B cells, promote 
antibody production against S. Typhimurium antigens, class-switching, affinity 
maturation and memory formation (Mohr, et al., 2010). In view of the potentially 
complex nature of Salmonella antigen presentation during natural infection, it is possible 
that CD4+ T cells promote B cell immunity through a bystander (hapten-carrier) effect to 
B cells specific for S. Typhimurium-LPS. LPS alone is a T cell independent type 2 
antigen, but when taken up by antigen presenting cells (APC) in combination with S. 
Typhimurium proteins, it has the potential to elicit  the same response that 
polysaccharide-conjugate vaccines trigger and generate isotype-switched memory B-cell 
immunity (Mitchison, 1971). 
Given the burden of invasive NTS disease in SSA (Reddy, et al., 2010, Agnandji, et al., 
2011), a vaccine is urgently required. S. Typhimurium LPS O-antigen has considerable 
potential as a vaccine target and there are currently several groups developing conjugate 
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vaccines for this purpose to overcome the short-lived T-independent antibody response 
generated by polysaccharide alone (MacLennan, 2013). Immunization with S. 
Typhimurium-OMP and Typhimurium-FliC induce both T cells and antibodies in mice, 
and are therefore also being investigated as vaccine candidates, either separately (Gil-
Cruz, et al., 2009) or covalently linked to O-antigen as glycoconjugates (Simon & 
Levine, 2012).  
Key immunological questions arising from this component of the thesis:  
 When is the appropriate time for administration of a cross-protective Salmonella 
vaccine? 
 What are antibody targets for both gut localised and systemic Salmonella 
infection? 
 
7.2.2 Salmonella exposure and development of specific  immunity in Malawian 
children 
The second research study was aimed at characterizing the relationship between 
Salmonella exposure events within the GIT or oropharynx and development of 
Salmonella-specific serum immunity in Malawian children aged 6-18 months. At the time 
this study idea was conceived, observations were made (Chapter 3) that CD4+Cytokine+ 
T cells to S. Typhimurium in Malawian children were detected early in life peaking at 14 
months of age, suggesting that Malawian children are exposed to Salmonella or cross-
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reactive bacteria in early life. Furthermore the pattern of Salmonella exposure within the 
GIT in Malawian children was not known, when this study idea was conceived. It was 
hypothesized that Salmonella exposure within the GIT/or oropharynx facilitate the 
acquisition of Salmonella-specific serum immunity in Malawian children. In a cohort 
study, healthy Malawian children aged 6-18 months, were tested for Salmonella exposure 
within the GIT and oropharynx by standard culture and rt-PCR at 1 month intervals and 
also quantified serum immunity to S. Typhimurium at 3 months intervals. 
Chapter 4 demonstrates that a total of 29 Salmonella positive stool out of 630 stool 
specimens, representing 4.6% were made. Furthermore, in this cohort, 46.8% (22/47) of 
children had at least one Salmonella exposure event within the GIT over a period of 1 
year. A total of 29 Salmonella positive stools were detected by culture or PCR.  
Salmonellae isolates were principally S. Typhimurium 51.7% (15/29), followed by non-
defined serovars 31% (9/29), S. Typhi 10.3% (3/29) and S. Enteritidis 7% (2/29). Chapter 
4 demonstrates that some children had at least two Salmonella positive stool events by 
culture or PCR, 24% (7/29). 71% (5/7) of these were exposed to the same serovar S. 
Typhimurium. These findings indicate that Salmonella exposure events within the GIT in 
Malawian children are common and this underlines the need of public health 
interventions including improvements in sanitation, food hygiene and vaccination. 
 
Observations were made that S. Typhimurium was the most commonly isolated 
Salmonella serovar from stool. S. Typhimurium is among the most frequent causes of 
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blood stream infection (BSI) in children <2 years of age (Chapter 3). S. Typhimurium 
isolates from blood in SSA are distinct from those isolated in the developed countries and 
are typically multi sequences locus type (MSLT) ST313 (Kingsley, et al., 2009). They 
are multi-drug resistant (MDR), possess a degraded genome, and initial speculation 
suggested they might be human host restricted (Kingsley, et al., 2009). Recently, 
however, another study demonstrated that ST313 can also cause severe and rapid 
invasive disease in chickens (Parsons, et al., 2013). The question as to whether 
transmission of ST313 S. Typhimurium strains occurs from human to human or animals 
to human remains unanswered. In murine  models, S. Typhimurium strain D23580 more  
efficiently spread to systemic organs from mesenteric lymph nodes compared to S. 
Typhimurium strain A130 (pre 2002 strain) (Msefula, 2009).  
Whether these S. Typhimurium isolates (isolated in this cohort) from stool are 
phenotypically and genetically similar to S. Typhimurium (ST313) isolates causing 
bacteraemia in SSA is the key question and will be addressed by whole genome 
sequencing and other studies in future investigations. Furthermore, the predominance of 
S. Typhimurium isolates in this cohort, is consistent with the hypothesis stated in Chapter 
3 that the early acquisition of CD4+ T cell immunity to S. Typhimurium might be driven 
by exposure to S. Typhimurium or cross-reactive bacteria within the GIT.  
 
Several factors might contribute to Salmonella exposure in Malawian children including 
feeding practices, food hygiene and sanitary environment. As previously demonstrated 
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(Kalanda, et al., 2006, Kerr, et al., 2007), and Chapter 4 shows that 9% of children were 
introduced to supplementary food (such as porridge) as early as <3 months of age, and 
91% were introduced to supplementary food by 6 months of age. At 6 months of age all 
children were being breastfed and only 9% were exclusively breastfeeding. Furthermore, 
only 17% of children had discontinued breast feeding by 18 months of age. Chapter 4 
also demonstrates that a majority of families (82.7%), had access to tap water (classified 
as protected source) but 64% of babies were drinking non-boiled water as reported by 
their parents/guardians. Observations were made that boiling water for drinking and using 
water from the borehole appeared to reduce transmission of Salmonella, although these 
findings did not reach statistical significance. Even though, a majority of families  had 
access to tap water, frequent water outages and high utility bills might be a barrier for this 
population access to tap water (MCI, 2012) and some might resort to using water from 
the nearby river or water stream for house hold chores.   
Rivers and water streams in Blantyre city have been shown to be highly polluted and also 
contaminated with potential pathogen   (Kumwenda, et al., 2012, MCI, 2012). Children 
that had Salmonella exposure detected in their stool, appeared to be living  in close 
proximity to the river or water streams (Chapter 4), suggesting that access to the river or 
water streams might contribute to transmission of  Salmonella in these children. The 
contribution of environmental factors in the transmission of Salmonella infection 
(including water sources) in this population is not known. Using water from the river was 
a significant risk factor for transmission of Salmonella in this cohort (Chapter 4). It has 
previously been demonstrated that residents in lower grounds (low altitudes) are at risk of 
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Salmonella infection (Baker, et al., 2011). In this cohort among children exposed to 
Salmonella and non-exposed, absolute altitude of location of residence did not reach 
statistical significance. Further investigations including more complex, geospatial 
analyses studies are required, to generate hypotheses stimulating future studies aimed at 
understanding the role of environmental factors (including water sources) in the 
transmission of Salmonella infection in this population. 
 
Malaria infection was uncommonly detected in this cohort at the current study specific 
visit 0.9% (5/563) and administration of antimalarial drugs in the previous months was 
only reported in 1.4% (8/563). This was surprising considering that Malawi is among the 
malaria endemic countries (Mathanga, et al., 2012), with asymptomatic parasitaemia 
rates ranging between 11.2-18.5% (Roca-Feltrer, et al., 2012). In Blantyre, the 
Plasmodium falciparum parasite rate for children 2-<10 years is the lowest in Malawi 
(26%) (Bennett, et al., 2013). Despite this observation, there was a trend that did not 
reach statistical significance that children that had taken antimalarial drugs were at higher 
risk of being exposed to Salmonella. Studies in mice models have demonstrated that 
malaria infection compromises neutrophil immunity and favours Salmonella to spread 
into the blood stream (Roux, et al., 2010, Cunnington, et al., 2012, Maclennan, 2014). 
Case fatality among children presenting to hospital with malaria and Salmonella BSI or 
any other BSI co-infection is higher compared to children that present with malaria 
infection alone (Bassat, et al., 2009). Most children with malaria and BSI co-infection are 
diagnosed and treated for malaria infection but BSI including Salmonella bacteraemia 
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remains non-diagnosed and un-treated. These critical observations in SSA, made WHO 
recommend that all children with severe malaria should be treated with antibiotics in 
addition to anti-malarial drugs (Brent, et al., 2006). There is need to study malaria and 
Salmonella co-infection in this population to inform the current clinical management 
guidelines. 
 
In keeping with the hypothesis made in Chapter 4, that Salmonella exposure within the 
gut facilitates acquisition of serum immunity in children, there was evidence that 
Salmonella exposure within the GIT associated with acquisition of ‘protective’ SBA to S. 
Typhimurium strain D23580 and 037v4 over a period of 1 year (6 to 18 months). As 
demonstrated by a previous study in Malawian children (MacLennan, et al., 2008), 
Chapter 4 also showed that serum bactericidal activity to S. Typhimurium strain D23580 
increased with age. It was further observed that serum bactericidal activity developed in 
children in whom Salmonella exposure was not detected, and this was in a similar pattern 
as the exposed counterparts. This study could not be certain if exposed and non-exposed 
children were appropriately grouped considering low sensitivity of Salmonella detection 
techniques employed and Salmonella exposure observations at 1 month interval, and it is 
also not clear whether cross-reactive enteric bacteria also facilitate serum bactericidal 
activity acquisition. Whether natural IgG antibodies (Michael, et al., 1962), which also 
develops with age, can fix-complement and facilitate serum bactericidal activity to S. 
Typhimurium strain D23580 is not clear. Taken together these findings suggest that there 
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is a relationship between Salmonella exposure events occurring within the GIT and 
development of SBA.  
 
Maternal breast milk capacity to kill S. Typhimurium strain D23580 ex vivo was also 
explored in Chapter 4. The hypothesis was made that maternal breast milk kills 
Salmonella ex vivo and might indicate that breast milk provides resistance to Salmonella 
colonisation within the gut lumen among breast fed children. Contrary to this hypothesis, 
maternal breast milk could not kill S. Typhimurium strain D23580 ex vivo. Whether or 
not lack of direct maternal breast milk bactericidal activity to S. Typhimurium strain 
D23580 ex vivo could also be true with other Salmonella serovars and other enteric 
pathogens is not clear. The general view is that breast feeding has considerable benefits 
to babies including protection to enteric pathogens such as Salmonella (France, et al., 
1980, Borgnolo, et al., 1996). It is possible that these findings do not necessary contradict 
these observation but this resistance to breast milk killing might be specific for S. 
Typhimurium strain D23580. S. Typhimurium strain D23580 is resistant to complement 
killing alone, and susceptible to IgG antibody fixed complement (MacLennan, et al., 
2008). Whether or not maternal breast milk antibodies (including IgG and IgA) fixes 
complement is not clear. Secretory IgA is more abundant in maternal breast milk and 
poorly activates complement (Michetti, et al., 1992, Roos, et al., 2001, Woof & Kerr, 
2006). A number of factors contribute to maternal breast milk bacterial resistance 
including complement, lysozymes and free fatty acid (Ogundele, 1999). But it appears all 
this did not make substantial contribution in maternal breast milk killing assay. Taken 
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together these findings suggest that in vivo maternal breast milk alone might not be 
sufficient to control S. Typhimurium colonisation within the GIT, in breast fed babies. 
Key immunological questions arising from this component of the thesis:  
 What is the relationship between natural Salmonella exposure within the gut and 
the development of protective immunity from gut localised and blood stream 
Salmonella infection? 
 What is the relationship between gut microbial flora changes and Salmonella 
exposure within the gut lumen?  
 How do malaria parasites predispose children to either or both gut and systemic 
Salmonella infection?
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7.2.3 Development of T cell and antibody immunity  in response to invasive 
Salmonella infection  
The third research study was aimed at determining the immunological importance of 
vaccine candidates, currently in pre-clinical phase, including Salmonella derived-surface 
proteins (FliC, OMP and GMMA) and LPS O antigens. The development of Salmonella-
specific antibody secreting cells (ASC) and T cells induced by invasive Salmonella 
infection (Salmonella bacteraemia) has not been investigated in Malawian children. It 
was hypothesized that invasive Salmonella infection facilitates the acquisition of ASCs 
and T cells. The frequency of IgG or IgA ASCs and T cells specific for Salmonella was 
evaluated in a cohort of children, presenting to hospital with Salmonella bacteraemia at 
acute and convalescent phases and healthy family members. 
 
Chapter 5 demonstrates that absolute IgG ASCs targeting Salmonella derived proteins 
(FliC, OMP, GMMA O+, GMMA O-) and polysaccharides (LPS O; 4,5 and LPS O; 9) 
were significantly increased in index cases compared to healthy family members. In 
contrast absolute IgA ASCs targeting Salmonella derived proteins (FliC, OMP, GMMA 
O+, GMMA O-) were higher in index cases compared to healthy family members 
although the difference did not reach statistically significance suggesting that IgG 
contribution to controlling Salmonella bacteraemia in the peripheral blood might be more 
compared to IgA. IgA antibodies constitute a key immune component that provides 
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primary immune defence to pathogens including Salmonella within the gut mucosa 
(Hapfelmeier, et al., 2010). 
Chapter 5 also showed that Salmonella-specific CD4+IFN-γ+ T cells were higher at acute 
phase compared to 1 month into recovery period. This decline in Salmonella specific 
CD4+ T cells might result from differentiation of effector CD4+ T cells into central 
memory CD4+ T cells which end up being recruited in the secondary lymphoid tissues 
(Sallusto, et al., 1999, Campbell, et al., 2001). This decline may also reflect 
compromised development of Salmonella specific T cell memory. A number of factors 
have been proposed to explain compromised development of Salmonella specific T cell 
memory, including administration of antibiotics and Salmonella immune escape 
mechanisms. Antibiotic administration has been implicated to compromise establishment 
of memory T cells (Griffin, et al., 2009, Endt, et al., 2012). In this study, children with S. 
Typhi bacteraemia were treated with ceftriaxone and ciprofloxacin. Whether or not this 
treatment regimen compromises development of memory T cells is not known. 
Salmonella has also the capacity to modulate immune responses and compromise 
development of memory T cells. For instance in mice, Salmonella compromise dendritic 
cells antigen presentation to T cells, down regulates T cell receptor expression, and 
Salmonella derived LPS and proteins are thought to be immune suppressive (Matsui, 
1996, Tobar, et al., 2006, Bueno, et al., 2007, Srinivasan & McSorley, 2007). In humans 
the mechanisms that Salmonella uses to compromise the acquisition of memory T cells 
have not been explicitly investigated particularly during the course of Salmonella 
bacteraemia disease.  
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T cells stimulation with Salmonella derived GMMA O+ induced robust CD4+IFN-γ+ T 
cells responses in index cases and family members compared to T cells stimulation with 
Salmonella derived GMMA O-. These findings suggested that expression of LPS O 
antigen on GMMA acted as adjunct and augmented the generation of Salmonella specific 
CD4+IFN-γ+ T cells. In mice LPS is thought to a have profound effect on CD4+ T cell 
responses through LPS interaction with APC toll like receptor 4, which results in up-
regulation of downstream signals including MHC-II expression (McAleer & Vella, 
2008). In pre-clinical phase it has been demonstrated that GMMA is highly immunogenic 
(MacLennan, 2013, Koeberling, et al., 2014). A clinical study is required to investigate 
the immunogenicity induced by Salmonella derived GMMA vaccination.  
Key immunological questions arising from this component of the thesis:  
 What immunological tests can be used to evaluate Ty21a vaccine induced 
protective immunity to nontyphoidal Salmonella serovars? 
 How can better serological tests be developed to study Salmonella epidemiology 
in sub Saharan Africa? 
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7.2.4 Ty21a oral typhoid vaccine induced  immunity in the gut mucosa and 
peripheral blood of healthy adults 
The fourth research study was aimed at evaluating antibody and T cell immune responses 
induced by Ty21a oral typhoid vaccine within the gut mucosa and the peripheral blood in 
healthy adults from the United Kingdom. This study aimed to model natural Salmonella 
immunizing events occurring within the gut mucosa compartment, by prospectively using 
a defined exposure. A model for natural Salmonella infection will help to understand 
natural immunizing events that occurs in young children exposed to gut localised NTS 
and invasive NTS disease in SSA. Currently, there is no licenced vaccine for NTS, 
understanding the immunizing events that occur in this model will help to inform the 
design of future NTS vaccine candidates. Oral Ty21a oral typhoid vaccine was licensed 
in the 1980s and yet immune responses induced by this vaccine have not been directly 
examined within the gut mucosa and compared to peripheral blood immune responses. 
Whether the current practice of measuring immunity induced by oral vaccines such as 
Ty21a within the peripheral blood alone sufficiently characterizes the immunizing events 
within the gut mucosa is not clear. It has been demonstrated previously that Ty21a 
vaccination  induces the generation of both T cell and antibody immunity and this  
vaccine is  safe, well tolerated and confers up to three years cumulative efficacy of 51% 
(Olanratmanee, et al., 1992, Fraser, et al., 2007, Pasetti, et al., 2011). 
T lymphocytes trafficking markers particularly those of the gut mucosa including β7 and 
CCR9 were used to extrapolate cellular immune responses occurring within the gut 
mucosa. A majority of effector memory T cells highly express the β7 and CCR9 
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compared to central memory CD4+ T cells and naïve T cells, suggesting Salmonella 
specific CD4+ T cells primed within the GALT migrate back to the gut mucosa for 
mounting of effector immune responses. A majority of central memory CD4+ T cells and 
naïve CD4+ T cells express CD62L. These are in keeping with previous reports (Sallusto, 
et al., 1999), expression of CD62L by  the central memory CD4+ T cells  allows them to 
reside within the secondary lymphoid tissues (SLT) while naïve CD4+ T cell are also 
able to home to SLT for antigen specific priming.  
Vaccination with Ty21a did not induce an increase in production of Ty21a specific-
CD4+Cytokine+ and CD8+Cytokine+T cells at day 11 and 18 post-vaccination in the 
peripheral blood. These findings are not consistent with previous reports (Salerno-
Goncalves, et al., 2002, Salerno-Goncalves, et al., 2005). Evaluation of gut mucosa 
induced immune responses by examining Ty21a-specific T cell immune responses co-
expressing gut homing markers β7 or CCR9 in the peripheral blood, also showed that 
vaccination with Ty21a did not induce an increase in production of Ty21a-specific 
CD4+β7+/CCR9+Cytokine+ and CD8+β7+/CCR9+Cytokine+T cells at day 11 and 18 
post-vaccination. Even with direct evaluation of  gut mucosa of immune responses,  
vaccination with Ty21a did not induce an increase in production of Ty21a-specific 
CD4+Cytokine+ and CD8+Cytokine+T cells at day 18 post-vaccination. The reason why 
this study did not detect differences in the magnitude of Ty21a-specific CD4+Cytokine+ 
and CD8+Cytokine T cells in peripheral blood and gut mucosa is the key question. A 
number of factors might have contributed to this outcome including poor antigen 
stimulation and inappropriate timing for blood and duodenum biopsy collection and not 
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ideal immunological tools. Due to lack of difference in magnitude of  CD4+ and CD8+ T 
cell immune responses in the gut mucosa and peripheral blood, this study failed to 
demonstrate relevance of using either direct (gut mucosa biopsy) or indirect (peripheral 
blood) assessment of oral Ty21a induced immune responses. Better methods and 
materials  including strong T cells stimulant, assessment of both effector and  central 
memory T cell responses and  appropriate timing for sampling and measurements will 
help to appropriately compare peripheral blood and gut mucosa immune responses 
induced by oral vaccination in future investigations. Gut homing makers including CCR9 
and β7 can potentially be used non-invasively evaluate T cell and B cell immune 
responses in children and HIV infected individuals infected with NTS. Better 
understanding of natural Salmonella immunizing events within the gut will help in 
designing an effective vaccine for NTS that is urgently required in SSA.  
Key immunological questions arising from this component of the thesis:  
 What is the relationship between gut mucosa and peripheral blood B cell and T 
cell immunity to Salmonella infection? 
 
General discussion 
 
259 
 
7.3  Future  investigations 
7.3.1 Development of adaptive immunity to nontyphoidal  Salmonella  in 
Malawian children 
In healthy Malawian children the development of antibodies and T cells to S. 
Typhimurium was somehow linked to age distribution or frequency of S. Typhimurium 
bacteraemia in under-five children. The study showed the age group as to when children 
are more vulnerable to S. Typhimurium bacteraemia. This was evidenced by lack of 
either CD4+ T cell or antibody immunity in a specific age group. Among under-five 
children, 80% of cases with S. Typhimurium bacteraemia cases occur in children under-
two and the median is 13 months. S. Typhimurium-specific CD4+ T cell immunity peaks 
at 1 year of life while specific antibody immunity peaks at 3 years of age. Essentially the 
study demonstrates the age group of children that require public health intervention in 
form of vaccine. Development of a vaccine for S. Typhimurium that can promote the 
generation of antibody and T cell immunity in children below 2 years is required in 
Malawian children and SSA. Currently, even the two licenced vaccines for typhoid fever, 
no vaccine is recommended for administration in children below 2 year of age 
(Germanier & Fuer, 1975, Guzman, et al., 2006, Khan, et al., 2010), indicating the need 
for Salmonella vaccine for both  S. Typhi and NTS in children below 2 years. As much as 
it is generally agreed that vaccination for NTS is required in under-two children, 
determining the appropriate time to administer a NTS vaccine is crucial. Children below 
6 months of age are at least protected by passively acquired maternal antibodies but are 
more vulnerable from 6 months to 36 months of age, as they are introduced to 
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supplementary food and passively acquired maternal antibodies continue to decline.  
Administration of NTS vaccine within the current immunization schedule would be 
pragmatic but would the timing be appropriate to elicit the desired immune response 
(antibody and T cell immunity). To effectively determine the time optimum time to 
administer a cross-protective vaccine; children of varying ages (1-24 months) will be 
investigated for immunogenicity elicited by the vaccine. Strong immune responses would 
signal appropriate age group to administer the vaccine but this would have to take into 
account when children are most vulnerable to invasive Salmonella bacteraemia to ensure 
that those most at risk are covered.   
 
The importance of S. Typhimurium derived FliC and OMP antigens were demonstrated 
in Chapter 3. These protein antigens positively correlated with age development of S. 
Typhimurium-specific CD4+Cytokine+ T cells. IgG antibody responses targeting S. 
Typhimurium derived LPS O;4,5  also  correlated with the development of  serum 
bactericidal activity to S. Typhimurium. Already these protein and polysaccharide 
antigens (FliC, OMP and LPS O;4,5) are being explored  in  pre-clinical phase as 
candidate vaccines (Udhayakumar & Muthukkaruppan, 1987, Cunningham, et al., 2004, 
Gil-Cruz, et al., 2009, Bobat, et al., 2011, Grimont PA. D and Weill, Cited 2007) either 
as conjugated polysaccharide vaccine or not. Further studies are required to evaluate 
vaccine candidates in pre-clinical phase now including FliC, OMP and LPS O antigen in 
humans, vaccines that confer cross-protection to Salmonella serovars causing substantial 
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burden in SSA and induce generation of memory B and T cell immunity should be 
prioritized.  
 
Antibody based vaccine for NTS is required as a means to control invasive NTS disease 
but moving forward with this would require determining key antibody targets that 
mediate SBA. During infection Salmonella does express a range of antigens or genes in 
various tissues for its survival (Lee, et al., Miller, et al., 1989, Ohl & Miller, 2001, 
Charles, et al., 2010). Therefore it is crucial to determine whether antibody target 
expressed by NTS are similar or not within the gut mucosa and systemic circulation. To 
effectively determine key antibody targets at various stage of infection or in various 
tissues; children infected with either or both gut localised and systemic Salmonella 
disease will be investigated during the acute and convalesces to determine antibody target 
profile using both immunological tools and molecular tools (proteomics, microarrays) as 
described before (Lee, et al., Charles, et al., 2010). This will help to inform the 
development of subunit vaccine for Salmonella.  
 
7.3.2 Salmonella exposure and development of specific-antibody  immunity in 
Malawian children 
Chapter 4 demonstrates that among children aged 6-18 months, 46.8% were exposed to 
Salmonella at least once within the GIT over a period of 1 year. Importantly, this 
demonstrates that Salmonella exposure within the GIT associated with the development 
General discussion 
 
262 
 
of ‘protective’ serum bactericidal activity (SBA) to S. Typhimurium D23580 in children. 
Whether or not natural Salmonella exposure within the gut confers protection to 
subsequent Salmonella infection within the gut and peripheral blood is a key question.  
Potentially protective SBA in this study was defined as SBA of at least -1 log10 change 
in Salmonella cfu/ml. Although acquisition of SBA or IgG antibodies to Salmonella 
correlates with the decline in bacteraemia cases of both NTS and S. Typhi in children 
(MacLennan, et al., 2008, Lindow, et al., 2011), correlates of protection for Salmonella 
bacteraemia are poorly defined. Recently, SBA assay has been proposed as key 
immunological tool for evaluation of Salmonella vaccines efficacy (Boyd, et al., 2014). 
To address this question a large cohort of healthy children (age 0-24 months) will be 
conducted. Children will be tested for Salmonella exposure within the GIT and blood by 
culture and PCR and this will be related with acquisition of potentially protective SBA as 
described in Chapter 4 and as before (MacLennan, et al., 2008, Boyd, et al., 2014). 
Children will be examined at scheduled visits and also whenever they experience 
gastrointestinal symptoms or bacteraemia symptoms. A total of 29 Salmonella positive 
stool were detected by culture or PCR. Salmonellae isolates were principally S. 
Typhimurium 51.7% (15/29), followed by non-defined serovars 31% (9/29), S. Typhi 
10.3% (3/29) and S. Enteritidis 7% (2/29). Chapter 4 demonstrates that some children had 
at least twice Salmonella positive stool by culture or PCR, 24% (7/29). Importantly, a 
majority of these 71% (5/7) were exposed to the same serovar S. Typhimurium. As 
hypothesised before, it is possible that protection develops following multiple Salmonella 
exposure events (Saul, et al., 2013, Pitzer, et al., 2014). Whether protection to Salmonella 
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is established following multiples exposure events will also be explored by comparing 
SBA amongst children exposed to Salmonella once and multiple times. Whether 
protection to Salmonella is established following exposure to a same Salmonella serovar 
or strain will also be investigated by comparing children SBA amongst those exposed to 
Salmonella serovar or strain and those exposed to multiple serovars or strains. Isolates 
from this cohort will be characterised phenotypically and also molecularly.   
 
Normal flora of the GIT contributes to resistance of enteric pathogens including 
Salmonella from colonizing the gut lumen (Endt, et al., 2010, Stecher & Hardt, 2011). 
The changes in microbial flora could result from a number of  factors including; breast 
feeding practices, administration of antibiotics and the virulence of the infecting pathogen 
(Lolekha, 1986, Pavia, et al., 1990, Bollaerts, et al., 2008, Gradel, et al., 2008, Endt, et 
al., 2010, Kaiser, et al., 2012). It has been demonstrated before that usage of antibiotics 
(particularly broad spectrum) disrupts the composition of gut microbial flora and 
Salmonella may take advantage of this to invade the gut lumen barrier (Lolekha, 1986, 
Pavia, et al., 1990, Gradel, et al., 2008, Endt, et al., 2010, Kaiser, et al., 2012). The 
variation of gut microbial flora composition in breast fed children and non-breast fed has 
been shown before (Gonzalez, et al., 2013). Chapter 4 demonstrates Salmonella exposure 
events within the period of 1 year (6 to 18 months). Whether or not microbial flora 
changes in the gut lumen predispose children to Salmonella colonisation is a key 
question. To investigate whether the Salmonella exposure events detected in this cohort 
are associated with the changes in normal flora, archive stool samples (Salmonella 
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exposed and non-exposed) collected in this cohort will be investigated for microbiome 
changes by shotgun sequencing as described before (Yatsunenko, et al., 2012) and this 
will be related to Salmonella exposure events. Antibiotic usage and breast feeding 
practices will also be investigated whether they contribute to changes in gut microbiome 
in relation to Salmonella exposure events in this cohort. Studying the microbiome 
changes by shotgun sequencing in relation to the Salmonella exposure events in this 
cohort will help to explain factors that render children susceptible to both gut localized 
and disseminated Salmonella infections. 
 
Malawi is among the malaria endemic countries (Mathanga, et al., 2012), with 
asymptomatic parasitaemia rates ranging between 11.2-18.5% (Roca-Feltrer, et al., 
2012). In Blantyre, the Plasmodium falciparum parasite rate for children 2-<10 years is 
the lowest in Malawi (26%) (Bennett, et al., 2013). Case fatality among children 
presenting to hospital with malaria and Salmonella BSI or any other BSI co-infection is 
higher compared to children that present with malaria infection alone (Bassat, et al., 
2009). In this cohort, there was a trend that did not reach statistical significance that 
children that had taken antimalarial drugs were at higher risk of being exposed to 
Salmonella. It has been shown in mice models that malaria infection compromises 
neutrophil immunity and favours Salmonella to spread into the blood stream (Roux, et 
al., 2010, Cunnington, et al., 2012, Maclennan, 2014). Neutrophils are key players in 
providing the primary immunity to rapidly dividing NTS within the gut mucosa and 
hence preventing the spread of NTS into the systemic organs (Tam, et al., 2008). 
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Correlates of protection for NTS bacteraemia have not been clearly defined in humans. 
IgG antibodies to Salmonella LPS are important for protection against NTS bacteraemia 
(Chapter 3) and also previously described (MacLennan, et al., 2008, Lindow, et al., 
2011). To investigate whether malaria parasites impairs neutrophils or monocytes  
effector function to Salmonella, it is not feasible to recruit children presenting with 
malaria and NTS co-infection, hence investigations will involve development of in-vitro 
malaria and NTS co-infection model to study bacterial growth kinetics during malaria 
infection. Malawian children aged (6-60 months) suffering from uncomplicated malaria 
will be investigated for impairment of neutrophil mediated immunity to NTS or 
Streptococcus pneumoniae (control) during acute and early convalescent phases. Briefly, 
whole blood or neutrophils plus red blood cells (RBCs) from subjects (malaria infected or 
healthy controls) will be challenged with NTS or Streptococcus pneumoniae (control) 
and examined for growth inhibition on LB agar plates. The contribution of antibody 
mediated neutrophil killing will be examined in anti-NTS-IgG antibody depleted and 
non-depleted plasma or serum as previously described (Trebicka, et al., 2013). 
Neutrophils will also be examined for respiratory burst as previously described (Gondwe, 
et al., 2010). Serum levels of IL-10 will be quantified by ELISA to explore the 
contribution of regulatory cytokines to this immunity. This study will therefore help to 
explain or define the immunological basis of immune impairment favouring bacterial BSI 
during malaria infection and associated poor health outcomes. These investigations 
would potentially provide rational basis for modifying the clinical management of 
malaria infection in children from SSA by revising the current management guidelines to 
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include routine provision of antibiotics to children suffering from malaria. It can further 
help to define those at greater risk and might require targeted antimicrobial treatment. 
 
7.3.3 Development of T cell and  antibody mediated immunity  in response to 
invasive Salmonella infection  
Among children that had S. Typhi bacteraemia, IgG ASCs targeting LPS O;4, 5 antigen 
and LPS O;9 correlated positively suggesting that  IgG antibodies targeting LPS O 
antigen induced by S. Typhi infection cross-react with S. Typhimurium LPS O (Chapter 
5). Already there is evidence that Ty21a and CVD 909 induce opsonophagocytic 
functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B 
(Wahid, et al., 2014). It is possible that currently licensed vaccines (for instance Ty21a) 
could confer cross protection to other Salmonella serovars in populations where the 
disease burden is considerable but there is no specific NTS vaccine available. To address 
the question of whether or not current licenced Salmonella vaccines for S. Typhi (Ty21a) 
confer cross-protection to NTS serovars in humans, a clinical study will be conducted to 
investigate the importance of cross-reactive antibodies in conferring protection. In a 
cohort of children older than 5 years vaccinated or not with Ty21a antibody immune 
responses to a range of Salmonella serovars (S. Typhimurium, S. Typhi and S. 
Enteritidis) derived antigens will be quantified by ELISA. Furthermore, SBA to a range 
of Salmonella serovars will be quantified to determine whether Ty21a vaccination 
facilitates development of cross-protective SBA. SBA will be examined as described in 
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Chapter 3 and before (MacLennan, et al., 2008, Boyd, et al., 2014). This study will 
inform the development of cross-protective vaccine for Salmonella and also provide the 
basis for use of currently licenced vaccines (such as Ty21a) in areas where NTS is an 
important public problem but there is no specific vaccine available.  
 
The burden of Salmonella in SSA is huge, and yet this is under appreciated partly due to 
lack of data on disease burden. Estimating the true burden of Salmonella has been 
challenging because data is patchy and confined largely to sentinel facility-based 
surveillance (Crump & Heyderman, 2014). The pattern of invasive NTS strains (S. 
Typhimurium and S. Enteritidis) transmission in SSA  is not clear and whether it is from 
human to human or from animals to human (Kariuki, et al., 2006) remains to be 
determined. Furthermore, the reservoirs for invasive NTS strains remain unknown. This 
is further hampered by lack for diagnostics for Salmonella. Whether immunological tools 
can help to understand the epidemiology of Salmonella in SSA is a key question.  
Chapter 5 demonstrates that the frequency of Salmonella-specific CD4+IFN-γ+ T cells 
was generally higher in healthy family members compared to index cases at both the 
acute phase and at 1 month into recovery period. These findings suggest that these 
healthy family members were previously exposed to Salmonella and further underlying 
the need for epidemiological study to understand the pattern of Salmonella disease 
transmission amongst cases and household contacts in this population. Children that had 
S. Typhi bacteraemia their IgG ASCs targeting FliC, OMP and LPS O antigens were 
significantly elevated compared to healthy family members suggesting that these 
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antibody targets can be explored for use as diagnostic markers (Chapter 5). But the 
challenge with the available diagnostic tools including Widal test for diagnosis of typhoid 
is the lack of specificity. Antibodies targeting LPS O;9 cross-react with LPS O;4,5 hence 
might not be ideal for development of diagnostic tools. Salmonella derived OMP (crude 
preparation) might also not be ideal for development of diagnostic tools due to cross-
reactivity between S. Typhimurium and S. Typhi.  
To effectively develop immunological tool for diagnosis of Salmonella and also for 
epidemiological studies (burden of disease), unique antibody targets for Salmonella in 
acute and convalescent patients will need to be determined using of advance technologies 
including proteomic and micro-array technologies (Lee, et al., Charles, et al., 2010). 
These unique targets for antibodies will then be investigated as diagnostic markers and be 
used to determine the burden of disease in cases and house hold contacts. Additional tests 
including blood and stool (culture and PCR) will be conducted to validate these tools.  
 
7.3.4 Ty21a oral typhoid vaccine induced immunity in the peripheral blood and 
gut mucosa of healthy adults 
The gut mucosa immunity mediated by both innate cell and adaptive cells has long been 
recognised to provide primary defence to enteric pathogens that potentially disseminate 
into the peripheral blood (Tam, et al., 2008, Hapfelmeier, et al., 2010). Little is known 
about the natural immunizing events occurring within the gut mucosa (GALTs) mainly 
due to anatomical barrier to obtain samples from the gut. Use of invasive methods to 
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evaluate immune response within is not recommended for other groups of interest like 
children and HIV infected individuals. There is evidence that oral vaccine induces both B 
cell and T cell immunity within the gut mucosa and antigen specific cells home back to 
the gut mucosa as dictated by expression of β7 and CCR9  as shown in  Chapter 6 and as 
shown before (Lundin, et al., 2002, Salerno-Goncalves, et al., 2002). There is evidence of 
compartmentalization of effector immune responses within the gut mucosa and the 
peripheral blood depending on the route of immunization for instance oral or  systemic 
vaccination (Quiding-Jarbrink, et al., 1997). Whether or not there is a relationship 
between B cell and T cell immune responses to Salmonella infection within the gut 
mucosa and peripheral blood is a key question. To answer this question, a clinical study 
will be conducted where Salmonella infected children with either gut localised or 
bacteraemia will be recruited. These children will be sampled blood to quantify 
Salmonella specific IgG or IgA ASC and memory T cells expressing gut homing markers 
including β7, CCR9 and CD62L. By comparing the nature of immune responses in 
children with gut localised Salmonella infection versus those with blood stream infection, 
the study will help to understand relationship between gut mucosa and peripheral blood 
immune responses. This will also help to inform vaccine design and also determine the 
suitable route of vaccination either oral or systemic.   
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Figure 7. 1: Natural acquisition of immunity to Salmonella in children  
Naïve children are more vulnerable to Salmonella infections as their immunity relies on 
innate arm of immunity to resist infections. Natural Salmonella exposure with the gut 
mucosa and peripheral blood facilitates the development of adaptive immunity 
(antibodies and T cells) within the gut associate lymphoid tissues (GALTs) and 
secondary lymphoid tissues (SLT). This permits establishment of high level of resistance 
to subsequent to Salmonella within the gut mucosa and peripheral blood compartments.   
 
7.4  Conclusion  
Many young Malawian children are naturally exposed to Salmonella. Salmonella 
exposure has previously been assumed to occur within the GIT, and may occasionally 
occur systemically beginning from young age. The studies included in this thesis suggest 
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that Salmonella exposure induces the sequential generation of T cells and antibodies 
directed against Salmonella that might provide protection to subsequent Salmonella 
infection. T cells might provide help for the generation of antibodies, and antibodies are 
crucial for serum bactericidal activity to Salmonella. These studies further show for the 
first time that natural exposure to Salmonella within the GIT is associated with the 
acquisition of potentially-protective serum bactericidal to invasive Salmonella strains in 
Malawian children. The acquisition of both antibody and T cell immunity is thought to 
control invasive Salmonella disease (see Figure 7.1). The studies also specifically explore 
the contribution of exposure to invasive Salmonella to responses to specific potential 
vaccine targets. Important risk factors for Salmonella infection include young age (< 2 
years) and this study provides preliminary data to suggest that environmental factors such 
as contaminated river or stream water are also important risk factors. Studies directly 
investigating the mucosal cellular response to Salmonella were inconclusive, and further 
work to understand the nature of mucosal immunology and responses to Salmonella is 
required. Public health interventions are urgently required in SSA including vaccination 
strategies that are effective in young children, improvements in sanitation, access to clean 
and safe water and food hygiene.   
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